Alere 10-Q 4 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 31, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	ALR
Entity Registrant Name	ALERE INC.
Entity Central Index Key	1,145,460
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		87,001,035

Consolidated Statements of Oper

Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Net product sales	$ 456,096	$ 472,128	$ 1,399,613	$ 1,447,515
Services revenue	123,778	128,341	364,296	378,825
Net product sales and services revenue	579,874	600,469	1,763,909	1,826,340
License and royalty revenue	2,480	3,299	7,742	13,691
Net revenue	582,354	603,768	1,771,651	1,840,031
Cost of net product sales	238,946	245,814	726,805	743,808
Cost of services revenue	76,639	79,851	228,033	232,277
Cost of net product sales and services revenue	315,585	325,665	954,838	976,085
Cost of license and royalty revenue	641	1,137	2,567	4,431
Cost of net revenue	316,226	326,802	957,405	980,516
Gross profit	266,128	276,966	814,246	859,515
Operating expenses:
Research and development	31,430	36,011	86,938	91,225
Sales and marketing	101,979	106,493	304,308	323,596
General and administrative	129,287	101,306	372,597	255,170
Impairment and (gain) loss on dispositions, net	0	2,074	(3,810)	42,408
Operating income (loss)	3,432	31,082	54,213	147,116
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(52,333)	(128,565)	(158,258)
Other income (expense), net	(14,312)	3,658	(29,773)	4,486
Loss from continuing operations before benefit for income taxes	(55,010)	(17,593)	(104,125)	(6,656)
Benefit for income taxes	(50,888)	(10,212)	(47,979)	(2,376)
Loss from continuing operations before equity earnings of unconsolidated entities, net of tax	(4,122)	(7,381)	(56,146)	(4,280)
Equity earnings of unconsolidated entities, net of tax	26,149	5,000	33,305	10,320
Income (loss) from continuing operations	22,027	(2,381)	(22,841)	6,040
Income from discontinued operations, net of tax	0	0	0	216,777
Net income (loss)	22,027	(2,381)	(22,841)	222,817
Less: Net income (loss) attributable to non-controlling interests	207	(61)	453	386
Net income (loss) attributable to Alere Inc. and Subsidiaries	21,820	(2,320)	(23,294)	222,431
Preferred stock dividends	(5,366)	(5,369)	(15,983)	(15,927)
Net income (loss) available to common stockholders	$ 16,454	$ (7,689)	$ (39,277)	$ 206,504
Basic net income (loss) per common share:
Income (loss) from continuing operations	$ 0.19	$ (0.10)	$ (0.45)	$ (0.13)
Income from discontinued operations	0	0	0	2.56
Net income (loss) per common share	0.19	(0.10)	(0.45)	2.43
Diluted net income (loss) per common share:
Income (loss) from continuing operations	0.19	(0.10)	(0.45)	(0.13)
Income from discontinuing operations	0	0	0	2.56
Net income (loss) per common share	$ 0.19	$ (0.10)	$ (0.45)	$ 2.43
Weighted-average shares - basic	86,753	85,895	86,708	85,141
Weighted-average shares - diluted	87,885	85,895	86,708	85,141

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 22,027	$ (2,381)	$ (22,841)	$ 222,817
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	8,727	(88,812)	(13,215)	(122,428)
Minimum pension liability adjustment	221	419	907	(1,337)
Other comprehensive income (loss), before tax	8,948	(88,393)	(12,308)	(123,765)
Other comprehensive income (loss), net of tax	8,948	(88,393)	(12,308)	(123,765)
Comprehensive income (loss)	30,975	(90,774)	(35,149)	99,052
Less: Comprehensive income (loss) attributable to non-controlling interests	207	(61)	453	386
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ 30,768	$ (90,713)	$ (35,602)	$ 98,666

Consolidated Balance Sheets (un

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 566,213	$ 502,200
Restricted cash	4,999	5,694
Marketable securities	75	164
Accounts receivable, net of allowances of $102,500 and $89,701 at September 30, 2016 and December 31, 2015, respectively	427,241	445,833
Inventories, net	348,845	347,001
Prepaid expenses and other current assets	163,833	152,233
Assets held for sale - current	0	4,165
Total current assets	1,511,206	1,457,290
Property, plant and equipment, net	446,313	446,039
Goodwill	2,805,682	2,836,915
Other intangible assets with indefinite lives	27,991	28,110
Finite-lived intangible assets, net	864,785	997,281
Restricted cash	42,438	43,228
Other non-current assets	16,219	18,078
Investments in unconsolidated entities	80,885	65,333
Deferred tax assets	56,638	13,993
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	0	13,337
Total assets	5,855,674	5,923,121
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	41,424	199,992
Current portion of capital lease obligations	3,713	3,962
Accounts payable	211,476	195,752
Accrued expenses and other current liabilities	449,897	324,465
Liabilities related to assets held for sale - current	0	363
Total current liabilities	706,510	724,534
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	2,905,067	2,831,166
Capital lease obligations, net of current portion	8,033	7,181
Deferred tax liabilities	52,513	147,618
Other long-term liabilities	133,182	154,193
Total long-term liabilities	3,098,795	3,140,158
Commitments and contingencies
STOCKHOLDERS' EQUITY:
Series B preferred stock, $0.001 par value (liquidation preference: $709,701 at September 30, 2016 and $709,763 at December 31, 2015); Authorized: 2,300 shares; Issued: 2,065 shares at September 30, 2016 and December 31, 2015; Outstanding: 1,774 shares at September 30, 2016 and December 31, 2015	606,406	606,468
Common stock, $0.001 par value; authorized: 200,000 shares; Issued: 94,613 shares at September 30, 2016 and 94,043 shares at December 31, 2015; Outstanding: 86,934 shares at September 30, 2016 and 86,364 shares at December 31, 2015	95	94
Additional paid-in capital	3,465,898	3,438,732
Accumulated deficit	(1,489,661)	(1,466,381)
Treasury stock, at cost, 7,679 shares at September 30, 2016 and December 31, 2015	(184,971)	(184,971)
Accumulated other comprehensive loss	(352,085)	(339,777)
Total stockholders' equity	2,045,682	2,054,165
Non-controlling interests	4,687	4,264
Total equity	2,050,369	2,058,429
Total liabilities and equity	$ 5,855,674	$ 5,923,121

Consolidated Balance Sheets (u5

Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 102,500	$ 89,701
Series B preferred stock, par value	$ 0.001	$ 0.001
Series B preferred stock, liquidation preference	$ 709,701	$ 709,763
Series B preferred stock, shares authorized	2,300,000	2,300,000
Series B preferred stock, shares issued	2,065,000	2,065,000
Series B preferred stock, shares outstanding	1,774,000	1,774,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	94,613,000	94,043,000
Common stock, shares outstanding	86,934,000	86,364,000
Treasury stock, shares	7,679,000	7,679,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash Flows from Operating Activities:
Net income (loss)	$ (22,841)	$ 222,817
Income from discontinued operations, net of tax	0	216,777
Income (loss) from continuing operations	(22,841)	6,040
Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities:
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs	9,305	10,627
Depreciation and amortization	214,187	233,651
Non-cash stock-based compensation expense	31,115	19,596
Impairment of inventory	915	201
Impairment of long-lived assets	634	378
Loss on disposition of fixed assets	5,492	3,273
Equity earnings of unconsolidated entities, net of tax	(33,305)	(10,320)
Deferred income taxes	(25,242)	(43,472)
(Gain) loss related to impairment and net loss on dispositions	(3,810)	42,323
Loss on extinguishment of debt	0	3,480
Other non-cash items	7,668	(4,785)
Non-cash change in fair value of contingent purchase price consideration	(16,290)	(51,911)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net	22,051	(3,161)
Inventories, net	(31,660)	(58,152)
Prepaid expenses and other current assets	(22,630)	(14,953)
Accounts payable	18,493	(16,000)
Accrued expenses and other current liabilities	110,683	34,972
Other non-current liabilities	(117,479)	(8,540)
Cash paid for contingent purchase price consideration	(324)	(6,315)
Net cash provided by (used in) continuing operations	146,962	136,932
Net cash provided by discontinued operations	0	318
Net cash provided by operating activities	146,962	137,250
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash	199	(438,765)
Purchases of property, plant and equipment	(49,995)	(67,947)
Proceeds from sale of property, plant and equipment	1,150	1,486
Cash received from dispositions, net of cash divested	21,470	586,625
Cash paid for business acquisitions, net of cash acquired	(5,958)	(60,135)
Cash received from sales of marketable securities	88	99
Cash received from equity method investments	3,357	14,297
Cash paid for equity investments	(184)	0
Proceeds from sale of equity investments	40,751	0
Decrease in other assets	460	881
Net cash provided by continuing operations	11,338	36,541
Net cash used in discontinued operations	0	(209)
Net cash provided by investing activities	11,338	36,332
Cash Flows from Financing Activities:
Cash paid for financing costs	(29,186)	(16,053)
Cash paid for contingent purchase price consideration	(575)	(14,079)
Cash paid for dividends	(15,969)	(15,970)
Proceeds from issuance of common stock, net of issuance costs	13,923	76,457
Proceeds from issuance of long-term debt	462	2,162,022
Payments on short-term debt	(1,722)	(25,584)
Payments on long-term debt	(187,817)	(2,129,165)
Net proceeds (payments) under revolving credit facilities	124,876	(126,603)
Excess tax benefits on exercised stock options	0	6,102
Principal payments on capital lease obligations	(3,103)	(4,339)
Net cash used in continuing operations	(99,111)	(87,212)
Net cash used in discontinued operations	0	(76)
Net cash used in financing activities	(99,111)	(87,288)
Foreign exchange effect on cash and cash equivalents	4,824	(8,674)
Net increase in cash and cash equivalents	64,013	77,620
Cash and cash equivalents, beginning of period - continuing operations	502,200	378,461
Cash and cash equivalents, beginning of period - discontinued operations	0	23,300
Cash and cash equivalents, end of period	566,213	479,381
Less: Cash and cash equivalents of discontinued operations, end of period	0	0
Cash and cash equivalents of continuing operations, end of period	$ 566,213	$ 479,381

Basis of Presentation of Financ

Basis of Presentation of Financial Information	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015. Certain amounts presented may not recalculate directly, due to rounding.

Revision of Previously Reported

Revision of Previously Reported Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Revision of Previously Reported Consolidated Financial Statements	(2) Revision of Previously Reported Consolidated Financial Statements In connection with the preparation of our consolidated financial statements for the fiscal year ended December 31, 2015, we determined that, in fiscal years 2013 and 2014, each of the interim periods of 2014 and the first three quarters of fiscal year 2015, we had incorrectly reported the timing of recognition of certain revenue transactions for such periods. As a result, we revised our consolidated financial statements as of December 31, 2014 and for the fiscal years ended December 31, 2014 and 2013, each of the interim periods in 2014 and the first three quarters of fiscal year 2015. Specifically, the errors in the application of U.S. GAAP rules regarding the timing of revenue recognition primarily related to: (i) transactions, principally in Africa, in which we recognized revenue when the product shipped to the distributor, but we contractually retained title in the products until the distributor paid for the products in full or the distributor was not obligated to pay us until the products were sold through to the end-user; (ii) “bill and hold” transactions, principally in China, which did not meet the criteria for revenue recognition under U.S. GAAP; and (iii) other transactions, in which we recognized revenue prior to full satisfaction of all contractual criteria for title and risk of loss passing to the customer. These errors required adjustments to the period in which certain revenues were recognized so that such revenues were recognized in the period in which: physical delivery occurred as defined by the contractual relationship; title and risk of loss had transferred to the buyer; or the buyer had the contractual obligation to pay the amounts invoiced, as required by U.S. GAAP revenue recognition rules and our accounting policy relating to revenue recognition. The impact of these adjustments was an increase in revenue of $1.7 million and $0.7 million for the three and nine months ended September 30, 2015, respectively. Additionally, we have reflected other out-of-period adjustments in the periods in which such adjustments originated. These adjustments were identified during the financial closing process in connection with the fiscal years ended December 31, 2014 and 2013 and the first three quarters of fiscal year 2015 but were not reflected in our prior filings because they were deemed immaterial. The financial statements included in this Quarterly Report on Form 10-Q have been adjusted to include the adjustments in the period in which these items originated. These out-of-period adjustments are treated as corrections to our prior period financial results. For the three months ended September 30, 2015 these adjustments include a $1.1 million decrease in other income and expense, net due to the measurement of a royalty obligation and a $9.2 million decrease in the income tax benefit related to tax return to provision adjustments and the release of income tax reserves on uncertain tax positions. For the nine months ended September 30, 2015 these adjustments include a $1.2 million increase in operating expenses related to a bonus accrual, a $3.3 million decrease in other income and expense, net due to the measurement of a royalty obligation, and an $8.6 million decrease in the income tax benefit related to tax return to provision adjustments and the release of income tax reserves on uncertain tax positions. Although management has determined that the errors, as well as the revenue recognition issues noted in the preceding paragraphs, individually and in the aggregate, were not material to prior periods, the financial statements for the three and nine months ended September 30, 2015, included herein, have been revised to correct for the impact of these items. Unless otherwise indicated, the consolidated financial information as of and for the three and nine months ended September 30, 2015 presented in this Quarterly Report on Form 10-Q reflects these revisions. The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts: Three Months Ended September 30, 2015 Revised Consolidated Statement of Operations (in thousands, As Previously Reported Adjustment As Revised Net product sales $ 470,404 $ 1,724 $ 472,128 Net product sales and services revenue $ 598,745 $ 1,724 $ 600,469 Net revenue $ 602,044 $ 1,724 $ 603,768 Cost of net product sales $ 246,055 $ (241 ) $ 245,814 Cost of service revenue $ 79,803 $ 48 $ 79,851 Cost of net product sales and services revenue $ 325,858 $ (193 ) $ 325,665 Cost of net revenue $ 326,995 $ (193 ) $ 326,802 Gross profit $ 275,049 $ 1,917 $ 276,966 Operating income $ 29,165 $ 1,917 $ 31,082 Other income (expense), net $ 4,745 $ (1,087 ) $ 3,658 Loss from continuing operations before provision for income taxes $ (18,423 ) $ 830 $ (17,593 ) Benefit for income taxes $ 18,924 $ (8,712 ) $ 10,212 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax $ 501 $ (7,882 ) $ (7,381 ) Income (loss) from continuing operations $ 5,501 $ (7,882 ) $ (2,381 ) Net income (loss) $ 5,501 $ (7,882 ) $ (2,381 ) Net income (loss) attributable to Alere Inc. and Subsidiaries $ 5,562 $ (7,882 ) $ (2,320 ) Net income (loss) available to common stockholders $ 193 $ (7,882 ) $ (7,689 ) Basic and diluted loss per common share: Income from continuing operations $ — $ (0.10 ) $ (0.10 ) Basic and diluted net loss per common share: Net loss per common share $ — $ (0.10 ) $ (0.10 ) Nine Months Ended September 30, 2015 Revised Consolidated Statement of Operations (in thousands, As Previously Reported Adjustment As Revised Net product sales $ 1,446,837 $ 678 $ 1,447,515 Net product sales and services revenue $ 1,825,662 $ 678 $ 1,826,340 Net revenue $ 1,839,353 $ 678 $ 1,840,031 Cost of net product sales $ 743,177 $ 631 $ 743,808 Cost of service revenue $ 232,137 $ 140 $ 232,277 Cost of net product sales and services revenue $ 975,314 $ 771 $ 976,085 Cost of net revenue $ 979,745 $ 771 $ 980,516 Gross profit $ 859,608 $ (93 ) $ 859,515 Sales and marketing $ 322,756 $ 840 $ 323,596 General and administrative $ 254,810 $ 360 $ 255,170 Operating income $ 148,409 $ (1,293 ) $ 147,116 Other income (expense), net $ 7,735 $ (3,249 ) $ 4,486 Loss from continuing operations before benefit for income $ (2,114 ) $ (4,542 ) $ (6,656 ) Benefit for income taxes $ 10,009 $ (7,633 ) $ 2,376 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax $ 7,895 $ (12,175 ) $ (4,280 ) Income from continuing operations $ 18,215 $ (12,175 ) $ 6,040 Net income $ 234,992 $ (12,175 ) $ 222,817 Net income attributable to Alere Inc. and Subsidiaries $ 234,606 $ (12,175 ) $ 222,431 Net income available to common stockholders $ 218,679 $ (12,175 ) $ 206,504 Basic and diluted income per common share: Income from continuing operations $ 2.57 $ (0.14 ) $ 2.43 Basic and diluted net income per common share: Net income per common share $ 2.57 $ (0.14 ) $ 2.43 Three Months Ended September 30, 2015 Revised Consolidated Statement of Comprehensive Loss (in thousands) As Previously Reported Adjustment As Revised Net income (loss) $ 5,501 $ (7,882 ) $ (2,381 ) Comprehensive loss $ (82,892 ) $ (7,882 ) $ (90,774 ) Comprehensive loss attributable to Alere Inc. and Subsidiaries $ (82,831 ) $ (7,882 ) $ (90,713 ) Nine Months Ended September 30, 2015 Revised Consolidated Statement of Comprehensive Income (in thousands) As Previously Reported Adjustment As Revised Net income $ 234,992 $ (12,175 ) $ 222,817 Comprehensive income $ 111,227 $ (12,175 ) $ 99,052 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 110,841 $ (12,175 ) $ 98,666 Nine Months Ended September 30, 2015 Revised Consolidated Statement of Cash Flows (in thousands) As Previously Reported Adjustment As Revised Net income $ 234,992 $ (12,175 ) $ 222,817 Income from continuing operations $ 18,215 $ (12,175 ) $ 6,040 Depreciation and amortization $ 233,511 $ 140 $ 233,651 Deferred income taxes $ (46,740 ) $ 3,268 $ (43,472 ) Accounts receivable, net $ (11,269 ) $ 8,108 $ (3,161 ) Inventories, net $ (58,781 ) $ 629 $ (58,152 ) Accrued expenses and other current liabilities $ 35,192 $ (220 ) $ 34,972 Other non-current liabilities $ (8,790 ) $ 250 $ (8,540 ) We have also reflected these corrections as applicable in our consolidated financial statements and our consolidating financial statements presented in Note 22 Guarantor Financial Information

Merger Agreement

Merger Agreement	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Merger Agreement	(3) Merger Agreement Merger Agreement with Abbott Laboratories On January 30, 2016, we entered into an Agreement and Plan of Merger, or the Merger Agreement, with Abbott Laboratories, or Abbott. The Merger Agreement provides for the merger of a newly formed, wholly owned subsidiary of Abbott with and into Alere, or the merger, with Alere surviving the merger as a wholly owned subsidiary of Abbott, or the surviving corporation. Under the terms of the Merger Agreement, holders of shares of our common stock will receive $56.00 in cash, without interest, in exchange for each share of common stock. Each share of our Series B Convertible Perpetual Preferred Stock, par value $0.001 per share, or Series B Preferred Stock, issued and outstanding immediately prior to the effective time of the merger will remain issued and outstanding immediately following the consummation of the merger as one share of Series B Convertible Preferred Stock, par value $0.001 per share, of the surviving corporation. The Merger Agreement was approved by our board of directors, and, on October 21, 2016, the holders of a majority of the outstanding shares of our common stock approved the adoption of the Merger Agreement. Completion of the merger is subject to remaining customary closing conditions, including (1) there being no judgment or law enjoining or otherwise prohibiting the consummation of the merger and (2) the expiration of the waiting period applicable to the merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or the HSR Act, and receipt of other required antitrust approvals. Under the terms of the Merger Agreement, Abbott has agreed to make certain divestitures if necessary to obtain the consent of the antitrust authorities to the transaction contemplated by the Merger Agreement, subject to certain exceptions set forth in the Merger Agreement. The obligation of each of the parties to consummate the merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Merger Agreement. The Merger Agreement contains certain termination rights and provides that, upon termination of the Merger Agreement under certain circumstances, Alere would be required to pay Abbott a termination fee equal to $177.0 million. On May 2, 2016, Abbott and Alere received a request for additional information, or a “second request,” from the United States Federal Trade Commission, or the FTC, relating to Abbott’s potential acquisition of Alere. The second request was issued under the HSR Act. In addition, Abbott has agreed voluntarily to provide the FTC at least 60 days advance notice before certifying substantial compliance with the second request and to extend the waiting period imposed by the HSR Act to not less than 60 days after Abbott and Alere have certified substantial compliance with the second request, unless the period is further extended voluntarily by the parties or terminated sooner by the FTC. Between April and October 2016, Abbott received six separate requests for additional information from the European Commission. The parties are working to provide the European Commission with information in response to these requests and continue to work cooperatively with the European Commission in connection with this review. Once the completed notification has been formally submitted to the European Commission, the European Commission has 25 business days from the day following the date of such notification, which period may be extended to 35 business days after the date of notification under certain circumstances, in which to consider whether the merger raises serious doubts as to its compatibility with the common market (as prescribed by European Union regulations). By the end of that period, the European Commission must issue a decision either clearing the merger, which may be conditional upon satisfaction of commitments, or open an in-depth “Phase II” investigation. A Phase II investigation may last a maximum of an additional 125 business days. On June 23, 2016, Abbott and Alere received a request for additional information, or a “supplemental information request,” from the Canadian Competition Bureau, or the Bureau, relating to Abbott’s potential acquisition of Alere. The supplemental information request was issued under the Competition Act of Canada, or the Competition Act. The effect of the supplemental information request is to extend the waiting period imposed by the Competition Act until 30 days after Abbott and Alere have each complied with the supplemental information request, unless the period is extended voluntarily by the parties or terminated sooner by the Bureau. On October 20, 2016, the Ministry of Commerce of the People’s Republic of China determined that it will not prohibit the acquisition of Alere by Abbott. On August 25, 2016, we filed a complaint against Abbott in Delaware Chancery Court, which seeks to compel Abbott to fulfill its obligations under the terms of the Merger Agreement to take all actions necessary to promptly obtain all required antitrust approvals for the merger. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement. On August 30, 2016, Abbott filed its response in opposition to the motion to expedite the proceedings in this matter. On September 2, 2016, the Delaware Chancery Court granted our motion to expedite the proceedings. On September 29, 2016, the Delaware Chancery Court entered an order that, among other things, adopted a detailed schedule setting forth actions required to be taken by specified dates in order to obtain all antitrust clearances required by the Merger Agreement. By order of the court, the schedule is confidential. The court order also (i) requires Abbott to provide us with advance notice of, and the right to participate (in a manner not inconsistent with the terms of the Merger Agreement) in, all future discussions with antitrust regulators worldwide; (ii) appoints a Special Master to confidentially mediate any disputes regarding compliance with the order or the parties’ obligations under the Merger Agreement; (iii) lifts the stay of the case and permits discovery to commence immediately, including with respect to potential breaches of the Merger Agreement by Abbott; and (iv) sets a preliminary injunction hearing date on our claims for January 27, 2017, if necessary. On November 3, 2016, Abbott filed a complaint against Alere in the Delaware Chancery Court. Abbott asserts a single claim against Alere for breach of contract stemming from Alere’s refusal to provide Abbott with certain categories of documents under the Merger Agreement. The complaint makes no claim for damages and seeks to compel Alere to produce certain categories of documents and information which Abbott contends Alere is obligated to produce under the terms of the Merger Agreement. Alere believes it has fulfilled its contractual obligations under the merger agreement.

Discontinued Operations, Impair

Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	9 Months Ended
	Sep. 30, 2016
Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	(20) Impairment and (Gain) Loss on Dispositions, Net In January 2016, we completed the sale of our Alere E-Santé business, which was a component of our professional diagnostics reporting unit and business segment. We received cash consideration of approximately $8.1 million, net of a final working capital adjustment totaling approximately $0.2 million, and we are eligible to receive up to $1.5 million of contingent cash consideration. As a result of this transaction, we recorded a $3.8 million gain in the three months ended March 31, 2016 on the disposition of the Alere E-Santé business. In July 2015, we sold certain assets of our Inverness Medical Innovations Australia Pty Ltd business, which was part of our professional diagnostics reporting unit and business segment, for AUD 0.2 million (approximately $0.1 million as of the date of disposition) in cash proceeds and, as a result of this transaction, we recorded a loss of $1.2 million during the three and nine months ended September 30, 2015. We recorded additional charges of approximately $0.9 million in connection with certain other business closures or divestitures during the three and nine months ended September 30, 2015. In May 2015, we sold our Alere Analytics business, which was part of our professional diagnostics reporting unit and business segment. Under the terms of the sale we received nominal consideration and agreed to contribute working capital of $2.7 million to Alere Analytics, of which $2.4 million was contributed in cash immediately prior to the closing of the sale and the remaining $0.3 million of which was deposited in escrow pending the performance by the buyers under certain contracts. As a result of this transaction we recorded a loss of $4.7 million during the second quarter of 2015. During the three months ended March 31, 2015, before identifying a buyer for Alere Analytics, our management decided to close the business, and in connection with this decision we recorded an impairment charge of $26.7 million during the period, including the write-off of $26.2 million of acquisition-related intangible assets and $0.5 million of fixed assets. In March 2015, we sold certain assets of our AdnaGen GmbH business, which was part of our professional diagnostics reporting unit and business segment, for approximately $4.6 million in cash proceeds and, as a result of this transaction, we recorded a loss of $0.3 million during the three months ended March 31, 2015. In March 2015, we sold our Gesellschaft fur Patientenhilfe DGP GmbH subsidiary, which was part of our professional diagnostics reporting unit and business segment, for €7.6 million (approximately $8.2 million at March 31, 2015) and, as a result of this transaction, we recorded a loss on disposition of $7.5 million during the three months ended March 31, 2015. In December 2014, our management decided to close our Alere Connect, LLC subsidiary, which is part of our professional diagnostics reporting unit and business segment. During the nine months ended September 30, 2015, in connection with this decision, we recorded impairment charges of $1.1 million, consisting primarily of severance costs, inventory write-offs and other closure-related expenses. The financial results for the above businesses are immaterial to our consolidated financial results.
Health Management Business [Member]
Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net	(4) Discontinued Operations On January 9, 2015, we completed the sale of our health management business to OptumHealth Care Solutions for a purchase price of $599.9 million. We used the net cash proceeds of the sale to repay $575.0 million in aggregate principal amount of outstanding indebtedness under our prior credit facility. The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statements of operations for the nine months ended September 30, 2015. The results are as follows (in thousands): Nine Months Ended Net revenue $ 7,373 Cost of net revenue (4,413 ) Sales and marketing (996 ) General and administrative (5,001 ) Interest expense (9 ) Other income (expense), net 160 Gain on disposal 366,191 Income from discontinued operations before provision for income taxes 363,305 Provision for income taxes 146,528 Income from discontinued operations, net of tax $ 216,777

Cash and Cash Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2016
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	(5) Cash and Cash Equivalents We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At September 30, 2016, our cash equivalents consisted of money market funds.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	(6) Inventories Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): September 30, 2016 December 31, 2015 Raw materials $ 123,558 $ 130,171 Work-in-process 72,562 69,178 Finished goods 152,725 147,652 $ 348,845 $ 347,001

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	(7) Stock-based Compensation We recorded stock-based compensation expense in our consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Cost of net revenue $ 456 $ 326 $ 1,536 $ 866 Research and development 494 287 1,374 893 Sales and marketing 2,475 1,260 7,035 3,605 General and administrative 7,084 5,444 21,170 14,232 $ 10,509 $ 7,317 $ 31,115 $ 19,596

Net Income (Loss) per Common Sh

Net Income (Loss) per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Net Income (Loss) per Common Share	(8) Net Income (Loss) per Common Share The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Basic and diluted net income (loss) per common share: Numerator: Income (loss) from continuing operations $ 22,027 $ (2,381 ) $ (22,841 ) $ 6,040 Preferred stock dividends (5,366 ) (5,369 ) (15,983 ) (15,927 ) Income (loss) from continuing operations attributable to common shares 16,661 (7,750 ) (38,824 ) (9,887 ) Less: Net income (loss) attributable to non-controlling interest 207 (61 ) 453 386 Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries 16,454 (7,689 ) (39,277 ) (10,273 ) Income from discontinued operations — — — 216,777 Net income (loss) available to common stockholders $ 16,454 $ (7,689 ) $ (39,277 ) $ 206,504 Denominator: Weighted-average common shares outstanding — basic 86,753 85,895 86,708 85,141 Weighted-average common shares outstanding — diluted 87,885 85,895 86,708 85,141 Basic net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ 0.19 $ (0.10 ) $ (0.45 ) $ (0.13 ) Income from discontinued operations — — — 2.56 Basic net income (loss) per common share $ 0.19 $ (0.10 ) $ (0.45 ) $ 2.43 Diluted net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ 0.19 $ (0.10 ) $ (0.45 ) $ (0.13 ) Income from discontinuing operations — — — 2.56 Diluted net income (loss) per common share $ 0.19 $ (0.10 ) $ (0.45 ) $ 2.43 The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share for our continuing operations because the inclusion thereof would be antidilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Denominator: Options to purchase shares of common stock and RSUs 5,884 7,062 7,016 7,062 Warrants — — — 4 Conversion shares related to 3% convertible senior subordinated notes — 3,411 1,693 3,411 Conversion shares related to subordinated convertible promissory notes — 27 — 27 Conversion shares related to Series B convertible preferred stock 10,239 10,239 10,239 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 16,123 20,739 18,948 20,743

Stockholders' Equity and Non-co

Stockholders' Equity and Non-controlling Interests	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Stockholders' Equity and Non-controlling Interests	(9) Stockholders’ Equity and Non-controlling Interests (a) Preferred Stock For each of the three and nine months ended September 30, 2016 and 2015, Series B preferred stock dividends amounted to $5.3 million and $15.9 million, respectively, which reduced earnings available to common stockholders for purposes of calculating net income (loss) per common share for each of the respective periods. As of September 30, 2016, $5.3 million of Series B preferred stock dividends was accrued. As of October 15, 2016, payments have been made covering all dividend periods through September 30, 2016. The Series B preferred stock dividends for the three and nine months ended September 30, 2016 and 2015 were paid in cash in the subsequent quarters. (b) Changes in Stockholders’ Equity and Non-controlling Interests A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the nine months ended September 30, 2016 is provided below (in thousands): Nine Months Ended September 30, 2016 Total Non- Total Equity Equity, beginning of period $ 2,054,165 $ 4,264 $ 2,058,429 Issuance of common stock under employee compensation plans 14,110 — 14,110 Surrender of common stock to settle taxes on restricted stock units (2,137 ) — (2,137 ) Preferred stock dividends (15,969 ) — (15,969 ) Stock-based compensation expense 31,115 — 31,115 Other adjustments — (30 ) (30 ) Net income (23,294 ) 453 (22,841 ) Total other comprehensive loss (12,308 ) — (12,308 ) Equity, end of period $ 2,045,682 $ 4,687 $ 2,050,369

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Business Combinations	(10) Business Combinations Our business acquisitions have historically been made at prices above the fair value of the assets acquired and liabilities assumed, resulting in goodwill, based on our expectations of synergies and other benefits of combining the businesses. These synergies and benefits include elimination of redundant facilities, functions and staffing; use of our existing commercial infrastructure to expand sales of the products of the acquired businesses; and use of the commercial infrastructure of the acquired businesses to expand product sales in a cost-efficient manner. Net assets acquired are recorded at their estimated fair value and are subject to adjustment upon finalization of the fair value analysis. The estimated useful lives of the individual categories of intangible assets were based on the nature of the applicable intangible asset and the expected future cash flows to be derived from the intangible asset. Amortization of intangible assets with finite lives is recognized over the shorter of the respective lives of the agreement or the period of time the intangible assets are expected to contribute to future cash flows. We amortize our finite-lived intangible assets based on patterns on which the respective economic benefits are expected to be realized. (a) Acquisition in 2016 EDTS On February 11, 2016, we acquired all of the outstanding shares of European Drug Testing Services EDTS AB, or EDTS, located in Lidingo, Sweden, a provider of services related to on-site drug testing. The aggregate purchase price was approximately $6.5 million and was paid in cash. The operating results of EDTS are included in our professional diagnostics reporting unit and business segment. Our consolidated statements of operations for the three and nine months ended September 30, 2016 included revenue totaling approximately $1.2 million and $3.8 million, respectively, related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $2.1 million, which is deductible for tax purposes. A summary of the fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,060 Intangible assets 4,220 Total assets acquired $ 7,766 Current liabilities $ 368 Non-current liabilities 928 Total liabilities assumed $ 1,296 Net assets acquired $ 6,470 Cash paid $ 6,470 The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete agreements 570 3.0 years Total intangible assets $ 4,220 (b) Acquisitions in 2015 US Diagnostics On July 10, 2015, we acquired substantially all of the assets of US Diagnostics, Inc., or USD, located in Huntsville, Alabama, a provider of instant on-site drug testing products designed for quick and accurate drug test results. The aggregate purchase price was approximately $60.1 million and was paid in cash. The operating results of USD are included in our professional diagnostics reporting unit and business segment. Our consolidated statements of operations for each of the three and nine months ended September 30, 2016 included revenue totaling approximately $5.7 million and $16.8 million, respectively, related to this business. Our consolidated statements of operations for each of the three and nine months ended September 30, 2015 included revenue totaling approximately $5.0 million related to this business. Goodwill has been recognized in the acquisition and amounted to approximately $29.4 million, which is deductible for tax purposes. A summary of the fair values of the net assets acquired from USD is as follows (in thousands): Total Current assets $ 4,652 Property, plant and equipment 182 Goodwill 29,422 Intangible assets 27,200 Total assets acquired $ 61,456 Current liabilities $ 1,321 Total liabilities assumed $ 1,321 Net assets acquired $ 60,135 Cash paid $ 60,135 The following are the intangible assets acquired in connection with the USD acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Total Weighted- Trademarks $ 1,600 3.0 - 13.0 years Customer relationships 24,900 13.0 years Non-compete agreements 700 2.0 years Total intangible assets $ 27,200

Restructuring Plans

Restructuring Plans	9 Months Ended
	Sep. 30, 2016
Restructuring and Related Activities [Abstract]
Restructuring Plans	(11) Restructuring Plans The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Statement of Operations Caption 2016 2015 2016 2015 Cost of net revenue $ 1,531 $ 522 $ 3,901 $ 2,921 Research and development 587 18 3,541 667 Sales and marketing 511 619 1,420 2,572 General and administrative 8,661 1,105 18,876 5,227 Total operating expenses 11,290 2,264 27,738 11,387 Interest expense, including amortization of original issue discounts and deferred financing costs 2 6 9 19 Total restructuring charges $ 11,292 $ 2,270 $ 27,747 $ 11,406 (a) Restructuring Plans During 2016, management developed world-wide cost reduction plans to reduce costs and improve operational efficiencies within our professional diagnostics and corporate and other business segments, primarily impacting our manufacturing and supply chain, and research and development groups, as well as closing certain business locations in Europe and the United States. The following table summarizes the restructuring activities related to the 2016 restructuring plans, in addition to our earlier restructuring plans as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three and nine months ended September 30, 2016 and 2015 and since inception of these restructuring plans (in thousands): Three Months Ended Nine Months Ended Since 2016 2015 2016 2015 Professional Diagnostics Severance-related costs $ 1,765 $ 1,322 $ 8,039 $ 5,385 $ 46,026 Facility and transition costs 426 132 1,620 4,139 13,288 Other exit costs 2 6 9 19 831 Cash charges 2,193 1,460 9,668 9,543 60,145 Fixed asset and inventory impairments 545 124 964 579 16,917 Other non-cash charges (2 ) — 208 — 2,190 Total professional diagnostics charges $ 2,736 $ 1,584 $ 10,840 $ 10,122 $ 79,252 Corporate and Other Severance-related costs $ 69 $ 686 $ 65 $ 1,297 $ 4,342 Facility and transition costs 8,487 — 16,842 (13 ) 28,164 Total corporate and other charges $ 8,556 $ 686 $ 16,907 $ 1,284 $ 32,506 Total restructuring charges $ 11,292 $ 2,270 $ 27,747 $ 11,406 $ 111,758 We anticipate incurring approximately $2.7 million and $6.0 million in additional costs under our 2016 restructuring plans related to our professional diagnostics and corporate and other business segments, respectively, primarily related to integration and operational initiatives and site closures. We may develop additional restructuring plans over the remainder of 2016. In addition, we anticipate incurring approximately $3.1 million in additional costs, related to our professional diagnostics business segment, under earlier restructuring plans as in effect at September 30, 2016, primarily related to the closure of our manufacturing facility in Israel. (b) Restructuring Reserves The following table summarizes our restructuring reserves related to the plans described above, of which $9.9 million is included in accrued expenses and other current liabilities and $0.6 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 8,104 18,462 9 26,575 Payments (5,821 ) (14,018 ) (111 ) (19,950 ) Currency adjustments 10 42 — 52 Balance, September 30, 2016 $ 3,926 $ 6,452 $ 78 $ 10,456

Long-term Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Long-term Debt	(12) Long-term Debt We had the following long-term debt balances outstanding (in thousands): September 30, 2016 December 31, 2015 A term loans (1)(2) $ 551,266 $ 575,746 B term loans (1)(2) 954,608 965,740 Revolving loans (1) 125,000 — 7.25% Senior notes (2) 441,498 446,320 6.5% Senior subordinated notes (2) 414,391 419,209 6.375% Senior subordinated notes (2) 412,363 418,133 3% Convertible senior subordinated notes (3) — 149,839 Other lines of credit — 136 Other 47,365 56,035 2,946,491 3,031,158 Less: Short-term debt and current portion of long-term debt (3) (41,424 ) (199,992 ) Long-term debt $ 2,905,067 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 to, among other things, extend the deadline date for such filing. In addition, because we had not filed our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 at or prior to the time set forth in the indentures governing our outstanding notes, we were also in default thereunder. However, with the filing of such Quarterly Report on Form 10-Q on September 6, 2016 cured this default prior to the expiration of the applicable cure periods under the indentures governing our notes. As of September 30, 2016, we were in compliance with all of our obligations and covenants under the Credit Agreement and the indentures governing our outstanding notes. (3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016. In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Secured credit facility (1) $ 19,072 $ 18,161 $ 53,949 $ 20,763 Prior credit facility (2) (3) — — — 49,437 7.25% Senior notes 9,372 8,524 26,800 25,573 6.5% Senior subordinated notes 7,618 7,274 22,254 21,741 6.375% Senior subordinated notes (4) 7,242 7,002 21,357 7,544 8.625% Senior subordinated notes (4) — 9,273 — 27,820 3% Convertible senior subordinated convertible notes — 1,246 1,847 3,738 Other 826 853 2,358 1,642 $ 44,130 $ 52,333 $ 128,565 $ 158,258 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. (3) Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility. (4) For the three and nine months ended September 30, 2015, the amounts include $0.4 million and $1.1 million, respectively, related to the amortization of fees paid for certain debt modifications. April and August 2016 Amendments to Secured Credit Facility On April 22, 2016, we and the requisite lenders under the Credit Agreement entered into an amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, (x) our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) the financial statements and certain related deliverables for the year ended December 31, 2015 by the applicable deadline under the Credit Agreement, (y) any restatement of certain financial statements as a result of our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, or (z) any breach of any representation or affirmative covenant as a result of certain deliverables being incorrect when delivered, which breach is discovered as part of the audit of our financial statements for the year ended December 31, 2015, to the extent that such breach is due to our incorrect application of revenue recognition principles for the years ended December 31, 2013, 2014 and 2015, and (ii) extend the deadlines for delivery of the financial statements for the year ended December 31, 2015, the financial statements for the quarter ended March 31, 2016 and certain related deliverables. Under the terms of this amendment, we were required to deliver our unaudited financial statements for the three months ended March 31, 2016 and certain related deliverables on or before August 18, 2016. We made the required deliveries before that date. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.250% of the sum of (i) the aggregate principal amount of such lender’s Term Loans (as defined in the Credit Agreement) outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment (as defined in the Credit Agreement) outstanding on the effective date of the amendment, or approximately $4.5 million in the aggregate for all consenting lenders. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. The amendment also increased the applicable interest rate margins for all loans outstanding under our secured credit facility by 0.25% per annum for the period from July 1, 2016 to the date of delivery of such financial reports and related deliverables under our secured credit facility. On August 18, 2016, we and the requisite lenders under the Credit Agreement entered into a further amendment to the Credit Agreement pursuant to which the requisite lenders agreed to (i) waive certain Defaults and Events of Defaults (each as defined in the Credit Agreement) that may have occurred, are occurring or will occur, resulting from, among other things, our failure to deliver to the Administrative Agents (as defined in the Credit Agreement) (x) the financial statements and certain related deliverables for the three months ended March 31, 2016, which we refer to as the Q1 Financial Reports, by the applicable deadline under the Credit Agreement or (y) the financial statements and certain related deliverables for the three months ended June 30, 2016, which we refer to as the Q2 Financial Reports, by the applicable deadline under the Credit Agreement, and (ii) extend the deadline for delivery of the Q1 Financial Reports to August 25, 2016 and the deadline for the delivery of the Q2 Financial Reports to September 13, 2016. In connection with this amendment, we paid, among other fees and expenses, to each consenting lender aggregate consent fees of 0.125% of the sum of (i) the aggregate principal amount of such lender’s Term Loans outstanding on the effective date of the amendment and (ii) such lender’s Revolving Credit Commitment outstanding on the effective date of the amendment, or approximately $2.2 million in the aggregate for all consenting lenders. The amendment was deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. May 2016 Waivers with respect to Senior Notes and Senior Subordinated Notes On April 29, 2016, we commenced consent solicitations relating to our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 7.25% senior notes, which we refer to collectively as the Notes. The consent solicitations were made to holders of record of the Notes as of April 28, 2016, and such solicitations were completed on May 9, 2016. Pursuant to the consent solicitations, the requisite holders of each series of Notes agreed to extend the deadline for delivery of certain financial information and to waive, through and until 5:00 p.m., New York City time, on August 31, 2016, any default or event of default that occurred, is continuing or may occur under the indentures under which the Notes were issued (and its consequences) in connection with any failure to timely file with the SEC or to timely furnish to the relevant trustees pursuant to the indentures, our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and our subsequent Quarterly Reports on Form 10-Q, or the Failures to File. In connection with the Failures to File, we paid, in May and July 2016, to each holder of Notes who validly delivered a consent aggregate cash payments equal to $15.00 for each $1,000 aggregate principal amount of such holder’s Notes, or an aggregate of $19.2 million. The waivers were deemed to be a debt modification, and therefore the payments were capitalized and will be amortized to interest expense over the remaining term of the debt. Maturity of our 3.0% convertible senior subordinated notes Our 3% convertible senior subordinated notes matured and were repaid in full on May 15, 2016. Based on the price of our common stock on the date of maturity, we paid all outstanding principal and accrued interest owing under such notes in cash. The aggregate amount paid to the noteholders at maturity was approximately $152.0 million, consisting of $125.0 million in cash drawn under our revolving credit facility plus $27.0 million of cash available on such date.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	(13) Fair Value Measurements We apply fair value measurement accounting to value our financial assets and liabilities. Fair value measurement accounting provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures regarding fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. Described below are the three levels of inputs that may be used to measure fair value: Level 1— Level 2— Level 3— The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description September 30, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 75 $ 75 $ — $ — Total assets $ 75 $ 75 $ — $ — Liabilities: Contingent consideration obligations (1) $ 40,500 $ — $ — $ 40,500 Total liabilities $ 40,500 $ — $ — $ 40,500 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) for additional information on the valuation of our contingent consideration obligations. Changes in the fair value of our Level 3 contingent consideration obligations during the nine months ended September 30, 2016 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (955 ) Fair value adjustments (16,290 ) Foreign currency adjustments 1 Fair value of contingent consideration obligations, September 30, 2016 $ 40,500 At September 30, 2016 and December 31, 2015, the carrying amounts of cash and cash equivalents, restricted cash, receivables, accounts payable and other current liabilities approximated their estimated fair values. The carrying amount and estimated fair value of our long-term debt (including the current portion) were both $2.9 billion at September 30, 2016. The carrying amount and estimated fair value of our long-term debt (including the current portion) were $3.1 billion and $3.0 billion, respectively, at December 31, 2015. The estimated fair value of our long-term debt was determined using market sources that were derived from available market information (Level 2 in the fair value hierarchy) and may not be representative of actual values that could have been or will be realized in the future.

Financial Information by Segmen

Financial Information by Segment	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Financial Information by Segment	(14) Financial Information by Segment Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of the chief executive officer and certain members of senior management. We currently have three reportable operating segments: (i) professional diagnostics, (ii) consumer diagnostics and (iii) corporate and other. Our operating results include license and royalty revenue which are allocated to professional diagnostics and consumer diagnostics on the basis of the original license or royalty agreement. We evaluate performance of our operating segments based on revenue and operating income (loss). Segment information for the three and nine months ended September 30, 2016 and 2015 is as follows (in thousands): Professional Consumer Corporate Other Total Three Months Ended September 30, 2016: Net revenue $ 563,007 $ 19,347 $ — $ 582,354 Operating income (loss) $ 84,341 $ 718 $ (81,627 ) $ 3,432 Depreciation and amortization $ 68,263 $ 1,263 $ 2,256 $ 71,782 Restructuring charge $ 2,733 $ — $ 8,557 $ 11,290 Stock-based compensation $ — $ — $ 10,509 $ 10,509 Three Months Ended September 30, 2015: Net revenue $ 585,021 $ 18,747 $ — $ 603,768 Operating income (loss) $ 56,520 $ 1,038 $ (26,476 ) $ 31,082 Impairment and loss on dispositions, net $ 1,923 $ — $ 151 $ 2,074 Depreciation and amortization $ 83,865 $ 717 $ 1,966 $ 86,548 Restructuring charge $ 1,578 $ — $ 686 $ 2,264 Stock-based compensation $ — $ — $ 7,317 $ 7,317 Nine Months Ended September 30, 2016: Net revenue $ 1,715,068 $ 56,583 $ — $ 1,771,651 Operating income (loss) $ 252,557 $ 1,281 $ (199,625 ) $ 54,213 (Gain) loss on dispositions, net $ 4,967 $ (8,777 ) $ — $ (3,810 ) Depreciation and amortization $ 203,488 $ 4,138 $ 6,561 $ 214,187 Restructuring charge $ 10,830 $ — $ 16,908 $ 27,738 Stock-based compensation $ — $ — $ 31,115 $ 31,115 Nine Months Ended September 30, 2015: Net revenue $ 1,774,671 $ 65,360 $ — $ 1,840,031 Operating income (loss) $ 299,303 $ 4,321 $ (156,508 ) $ 147,116 Impairment and (gain) loss on dispositions, net $ (38,643 ) $ — $ 81,051 $ 42,408 Depreciation and amortization $ 226,523 $ 2,153 $ 4,975 $ 233,651 Restructuring charge $ 10,103 $ — $ 1,284 $ 11,387 Stock-based compensation $ — $ — $ 19,596 $ 19,596 Assets: As of September 30, 2016 $ 5,410,679 $ 192,885 $ 252,110 $ 5,855,674 As of December 31, 2015 $ 5,619,901 $ 172,551 $ 130,669 $ 5,923,121 The following tables summarize our net revenue from the professional diagnostics reporting segments by groups of similar products and services for the three and nine months ended September 30, 2016 and 2015 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Cardiometabolic $ 188,731 $ 208,979 $ 587,289 $ 621,588 Infectious disease 183,375 164,822 556,777 523,059 Toxicology 155,871 162,571 460,849 468,822 Other 32,550 45,350 102,411 147,511 Total professional diagnostics net product sales and services revenue 560,527 581,722 1,707,326 1,760,980 License and royalty revenue 2,480 3,299 7,742 13,691 Total professional diagnostics net revenue $ 563,007 $ 585,021 $ 1,715,068 $ 1,774,671

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions	15) Related Party Transactions (a) SPD Joint Venture In May 2007, we completed the formation of SPD Swiss Precision Diagnostics GmbH, or SPD, our 50/50 joint venture with Procter & Gamble, or P&G, for the development, manufacturing, marketing and sale of existing and to-be-developed consumer diagnostic products, outside the cardiometabolic, diabetes and oral care fields. Upon completion of the arrangement to form the joint venture, we ceased to consolidate the operating results of our consumer diagnostic products business related to the joint venture and instead account for our 50% interest in the results of the joint venture under the equity method of accounting. We had a net payable to SPD of $7.1 million as of September 30, 2016 and $1.2 million as of December 31, 2015. The $7.1 million net payable balance as of September 30, 2016 is net of a receivable of approximately $1.3 million for costs incurred in connection with our 2008 SPD-related restructuring plans. The $1.2 million net payable balance as of December 31, 2015 is net of a receivable of approximately $1.5 million for costs incurred in connection with our 2008 SPD-related restructuring plans. We have also recorded a long-term receivable totaling approximately $6.5 million and $8.9 million as of September 30, 2016 and December 31, 2015, respectively, related to the 2008 SPD-related restructuring plans. Additionally, customer receivables associated with revenue earned after the formation of the joint venture have been classified as other receivables within prepaid and other current assets on our consolidated balance sheets in the amounts of $9.3 million and $7.8 million as of September 30, 2016 and December 31, 2015, respectively. In connection with the joint venture arrangement, the joint venture bears the collection risk associated with these receivables. Sales to the joint venture under our manufacturing agreement totaled $21.5 million and $61.0 million during the three and nine months ended September 30, 2016, respectively, and $17.3 million and $58.5 million during the three and nine months ended September 30, 2015, respectively. Additionally, services revenue generated pursuant to the long-term services agreement with the joint venture totaled $0.3 million and $0.8 million during the three and nine months ended September 30, 2016, respectively, and $0.2 million and $0.8 million during the three and nine months ended September 30, 2015, respectively. Sales under our manufacturing agreement and long-term services agreement are included in net product sales and services revenue, respectively, in our accompanying consolidated statements of operations. Under the terms of our product supply agreement, SPD purchases products from our manufacturing facilities in China. SPD in turn sells a portion of those tests back to us for final assembly and packaging. Once packaged, a portion of the tests are sold to P&G for distribution to third-party customers in North America. We defer our profit on products sold to SPD until the products are sold through to the customer. As a result of these related transactions, we have recorded $11.8 million and $9.9 million of trade receivables which are included in accounts receivable on our consolidated balance sheets as of September 30, 2016 and December 31, 2015, respectively, and $40.2 million and $24.9 million of trade accounts payable which are included in accounts payable on our consolidated balance sheets as of September 30, 2016 and December 31, 2015, respectively. The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption September 30, 2016 December 31, 2015 Accounts receivable, net of allowances $ 11,827 $ 9,873 Prepaid expenses and other current assets $ 9,343 $ 6,602 Other non-current assets $ 6,504 $ 8,895 Accounts payable $ 40,152 $ 24,887 As previously disclosed, SPD is currently involved in civil litigation brought by a competitor in the United States with respect to the advertising of one of SPD’s products in the United States. During 2015, SPD appealed the district court’s injunction with respect to sales and advertising of such product, and the work’s determination that SPD violated certain laws with respect to the advertising of such product. On September 9, 2016, the panel of the appellate court affirmed the district court’s decision and, on September 23, 2016, SPD filed a petition for a rehearing en banc (meaning before the full appellate court). In the meantime, the injunction remains stayed. In addition, a class action lawsuit was decided involving SPD and P&G in the United States District Court for the Central District of California, alleging violations of certain laws in connection with the sales and advertising of one of SPD’s products which claims are based on similar grounds as those at issue in the litigation described above in this paragraph. On August 19, 2016, the class action lawsuit was dismissed with prejudice. The plaintiffs have appealed the district court’s decision. There may be additional lawsuits against SPD or us relating to this matter in the future. The ultimate resolution of these matters is not known at this time, nor is the potential impact they or future litigation may have on SPD or us, including whether any such resolution or any damages imposed by a court would have a material adverse impact on SPD and, ultimately, by virtue of our 50% interest in SPD, on our financial position or results of operations. (b) Entrustment Loan Arrangement with SPD Shanghai Our subsidiary Alere (Shanghai) Diagnostics Co., Ltd., or Alere Shanghai, and SPD’s subsidiary SPD Trading (Shanghai) Co., Ltd., or SPD Shanghai, entered into an entrustment loan arrangement for a maximum of CNY 23 million (approximately $3.4 million at September 30, 2016), in order to finance the latter’s short-term working capital needs, with the Royal Bank of Scotland (China) Co., Ltd. Shanghai Branch, or RBS. The agreement governs the setting up of an Entrustment Loan Account with RBS, into which Alere Shanghai deposits certain monies. This restricted cash account provides a guarantee to RBS of amounts borrowed from RBS by SPD Shanghai. The Alere Shanghai RBS account is recorded as restricted cash on our balance sheet and amounted to $3.4 million at September 30, 2016. (c) TechLab On September 16, 2016, we sold our 49% interest in TechLab Inc., a company that provides diagnostic testing products used by physicians and other health care customers to diagnose, treat, and monitor intestinal diseases and other medical conditions. Prior to this sale, we accounted for this interest in TechLab as an equity method investment. Alere served as a distributor of TechLab products prior to the September 16, 2016 sale and will remain the principal global distributor of TechLab products pursuant to the terms of a distribution agreement with TechLab. We had trade payables owed to Techlab of $1.6 million and $3.2 million as of September 30, 2016 and December 31, 2015, respectively. We made product purchases from Techlab of $4.6 million and $4.5 million during the three months ended September 30, 2016 and 2015, respectively, and $13.7 million and $13.0 million during the nine months ended September 30, 2016 and 2015. As a result of the September 16, 2016 sale of our interest in TechLab, we recorded a gain in equity earnings of unconsolidated entities, net of tax, of $18.7 million.

Other Arrangements

Other Arrangements	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Arrangements	(16) Other Arrangements In September 2014, we entered into a contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, or BARDA, to develop diagnostic countermeasures for pandemic influenza. Under the terms of the contract, BARDA has agreed to provide up to $12.9 million to us to support the development of a rapid, molecular, low-cost influenza diagnostic device with PCR-like performance at the point of care. The project is designed to help support future preparedness and medical response to an influenza pandemic. Funding from BARDA is subject to successful completion of various interim feasibility and development milestones as defined in the agreement. For the three months ended September 30, 2016 and 2015, we had incurred $1.4 million and $0.8 million, respectively, of qualified expenditures under the contract, for which we had received cash reimbursement from BARDA in the amount of $1.0 million and $0.6 million, respectively, and $0.4 million and $0.6 million were recorded as receivables as of September 30, 2016 and 2015, respectively. For the nine months ended September 30, 2016 and 2015, we had incurred $3.1 million and $2.2 million, respectively, of qualified expenditures under the contract, for which we had received cash reimbursement from BARDA in the amount of $2.7 million and $1.6 million, respectively. Reimbursements of qualified expenditures under this contract are recorded as a reduction of our related qualified research and development expenditures. In February 2013, we entered into an agreement with the Bill & Melinda Gates Foundation, or the Gates Foundation, whereby we were awarded a grant by the Gates Foundation in the amount of $21.6 million to support the development and commercialization of validated, low-cost, nucleic-acid assays and cartridges for clinical tuberculosis detection and drug-resistance testing, and adaptation of an analyzer platform capable of operation in rudimentary laboratories in low-resource settings. In connection with this agreement, we also entered into a loan agreement with the Gates Foundation, or the Gates Loan Agreement, which provided for the making of subordinated term loans by the Gates Foundation to us from time to time, subject to the achievement of certain milestones, in an aggregate principal amount of up to $20.6 million. In April 2016, we and the Gates Foundation agreed to mutually terminate this grant and loan agreement and, therefore, there will be no additional grants and no advances will be available under the loan agreement. Prior to its termination, we did not borrow any amounts under the Gates Loan Agreement. As of September 30, 2016, we had received approximately $19.7 million in grant-related funding from the Gates Foundation (all of which was received prior to the April 2016 mutual termination). Grant funds were recorded upon receipt as restricted cash and deferred grant funding, with the deferred grant funding classified within accrued expenses and other current liabilities on our accompanying consolidated balance sheet. As qualified expenditures were incurred under the terms of the grant, we used the deferred funding to recognize a reduction of our related qualified research and development expenditures. For the three months ended September 30, 2015, we incurred approximately $0.3 million of qualified expenditures, and for the nine months ended September 30, 2015 we incurred approximately $3.9 million of qualified expenditures, for which we reduced our deferred grant funding balance and recorded an offset to our research and development expenses. There were no amounts remaining as restricted cash or deferred grant funding under the February 2013 grant agreement as of September 30, 2016. In addition to the February 2013 grant discussed above, we have also been awarded several smaller grants by the Gates Foundation in the aggregate amount of approximately $2.9 million to support the elimination of malaria. We incurred qualifying expenses totaling approximately $0.7 million and $0.2 million for the three months ended September 30, 2016 and 2015, respectively. We incurred qualifying expenses totaling approximately $1.0 million and $3.9 million for the nine months ended September 30, 2016 and 2015, respectively. As of September 30, 2016, $0.8 million under these grants was recorded as restricted cash and $0.7 million as deferred grant funding on our consolidated balance sheet.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(17) Commitments and Contingencies (a) Acquisition-related Contingent Consideration Obligations We have contractual contingent purchase price consideration obligations related to certain of our acquisitions. We determine the acquisition date fair value of the contingent consideration obligations based on a probability-weighted approach derived from the overall likelihood of achieving certain performance targets, including product development milestones or financial metrics. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement, as defined in fair value measurement accounting. The resultant probability-weighted earn-out payments are discounted using a discount rate based upon the weighted-average cost of capital. At each reporting date, we revalue the contingent consideration obligations to the reporting date fair values and record increases and decreases in the fair values as income or expense in our consolidated statements of operations. Increases or decreases in the fair values of the contingent consideration obligations may result from, among other things, changes in discount periods and rates, changes in the timing and amount of earn-out criteria and changes in probability assumptions with respect to the likelihood of achieving the various earn-out criteria. From time to time, we have entered into amendments to modify the provisions governing the contingent consideration obligations, and such amendments have resulted in changes to the fair value of these obligations. We may in the future enter into additional amendments that may also result in changes to such fair values. The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 102,870 2016 – 2025 (3) $ 33,100 $ 47,800 $ 377 Epocal (2) February 1, 2013 $ 75,000 $ 42,825 2016 – 2018 2,900 4,700 — Other Various $ 30,373 $ — (4) 2016 4,500 5,244 578 $ 40,500 $ 57,744 $ 955 (1) The terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric. (b) Legal Proceedings Abbott Laboratories On August 25, 2016, Alere Inc. filed suit against Abbott Laboratories in the Delaware Chancery Court, and filed an accompanying motion to expedite the proceedings. The complaint alleges, among other things, that Abbott is purposefully failing to comply with its obligations set forth in the Merger Agreement related to obtaining antitrust approvals. Specifically, the complaint alleges that Abbott: (i) purposefully failed to supply information requested by the FTC “as promptly as reasonably practicable” after such requests were made, as expressly required by the Merger Agreement; (ii) purposefully failed to supply information requested and make antitrust filings pursuant to antitrust laws in various foreign jurisdictions “as promptly as reasonably practicable” after such requests were made; (iii) purposefully failed to promptly take any and all steps necessary to avoid or eliminate impediments to obtaining antitrust clearance in the United States and in various foreign jurisdictions; (iv) purposefully failed to keep Alere informed in all material respects and on a reasonably timely basis of material communications with respect to the merger with antitrust authorities in the United States and in various foreign jurisdictions; and (v) purposefully failed to cooperate and consult with Alere, as well as give due consideration to Alere’s views with respect to antitrust matters. We asked the Delaware Chancery Court to require Abbott to specifically perform its obligations with respect to these matters, as required by the Merger Agreement. On August 30, 2016, Abbott filed its response in opposition to the motion to expedite the proceedings in this matter. On September 2, 2016, the Delaware Chancery Court granted our motion to expedite the proceedings. On September 29, 2016, the Delaware Chancery Court entered an order that, among other things, adopted a detailed schedule setting forth actions required to be taken by specified dates in order to obtain all antitrust clearances required by the Merger Agreement. By order of the court, the schedule is confidential. The court order also (i) requires Abbott to provide us with advance notice of, and the right to participate (in a manner not inconsistent with the terms of the Merger Agreement) in, all future discussions with antitrust regulators worldwide; (ii) appoints a Special Master to confidentially mediate any disputes regarding compliance with the order or the parties’ obligations under the Merger Agreement; (iii) lifts the stay of the case and permits discovery to commence immediately, including with respect to potential breaches of the Merger Agreement by Abbott; and (iv) sets a preliminary injunction hearing date on our claims for January 27, 2017, if necessary. On November 3, 2016, Abbott filed a complaint against Alere in the Delaware Chancery Court. Abbott asserts a single claim against Alere for breach of contract stemming from Alere’s refusal to provide Abbott with certain categories of documents under the Merger Agreement. The complaint makes no claim for damages and seeks to compel Alere to produce certain categories of documents and information which Abbott contends Alere is obligated to produce under the terms of the Merger Agreement. Alere believes it has fulfilled its contractual obligations under the merger agreement. U.S. Securities and Exchange Commission Subpoenas On August 28, 2015, we received a subpoena from the SEC which indicated that it is conducting a formal investigation of Alere. The SEC’s subpoena relates to, among other things, (i) our previously filed restatement and revision to our financial statements, including the accounting for deferred taxes for discontinued operations, as well as our tax strategies and policies and (ii) our sales practices and dealings with third parties (including distributors and foreign government officials) in Africa relating to sales to government entities. On January 14, 2016, we received a second subpoena from the SEC in connection with this formal investigation seeking, among other things, additional information related to sales of products and services to end-users in Africa, as well as revenue recognition relating to sales of products and services to end-users in Africa. We have also received, from time to time, requests in connection with the investigation to voluntarily produce additional information to the SEC, including information pertaining to certain other countries in Asia and Latin America, as well as additional information on revenue recognition matters and revisions to our financial statements referenced in our Annual Report on Form 10-K for the year ended December 31, 2015. We are cooperating with the SEC and have provided documents in response to the subpoenas and voluntary requests. We are unable to predict when this matter will be resolved or what further action, if any, the SEC may take in connection with it. Department of Justice Grand Jury Subpoena On March 11, 2016, we received a grand jury subpoena from the United States Department of Justice requiring the production of documents relating to, among other things, sales, sales practices and dealings with third parties (including distributors and foreign governmental officials) in Africa, Asia and Latin America and other matters related to the U.S. Foreign Corrupt Practices Act. We are cooperating with the Department of Justice and have provided information in response to the subpoena. We are unable to predict when this matter will be resolved or what further action, if any, the Department of Justice may take in connection with it. Securities Class Actions On April 21, 2016, a class action lawsuit captioned Godinez Alere Inc. Breton Alere Inc. We are unable at this time to determine the outcome of this class action lawsuit or our potential liability, if any. Matters Relating to our San Diego Facility On October 9, 2012, we received a warning letter from the FDA referencing inspectional observations set forth in a Form FDA 483 received in June 2012. The observations were the result of an inspection of our San Diego facility conducted earlier during 2012 relating to our Alere Triage products, which resulted in two recalls of certain Alere Triage products and revised release specifications for our Alere Triage meter-based products. In September 2014, as follow up to a further inspection of our San Diego facility, the FDA notified us that this inspection was classified “voluntary action indicated,” meaning that the objectionable conditions or practices found in the inspection did not meet the threshold of significance requiring regulatory action, but that formal close-out of the October 2012 warning letter could not occur until after a future inspection. In May 2012, we also received a subpoena from the Office of Inspector General of the Department of Health and Human Services, or the OIG, seeking documents relating primarily to the quality control testing and performance characteristics of Alere Triage products. We are cooperating with the government and are responding to the investigation, which is ongoing. We have been engaged in discussions with the government about this matter, including a resolution of potential related False Claims Act and common law liability exposure for the products under review. As a result of these discussions, management has accrued $20.7 million for this matter in the nine months ended September 30, 2016. We would need to obtain certain approvals before we could agree to any proposed resolution. There can be no assurance that future discussions with the government to resolve these matters will be successful, that the approvals we need will be obtained or that any potential settlement will be agreed to or finalized. We may be required to engage in litigation of this matter, which may be time consuming and costly. Based on the ongoing uncertainties and potentially wide range of outcomes associated with any potential resolution, the ultimate amount of potential loss may materially exceed the accrual we have established. We are unable to predict when these matters will be resolved or what further action, if any, the government will take in connection with them. INRatio Class Actions On May 26, 2016, a class action complaint, captioned Dina Andren, et al. v. Alere Inc et al. J.E, J.D., and all others similarly situated v. Alere Inc., Alere San Diego, Inc. and Alere Home Monitoring, Inc., Dina Andren J.E, J.D., and all others similarly situated We are unable, at this time, to predict the outcome of these class action lawsuits. Claims in the Ordinary Course and Other Matters We are also party to certain other legal proceedings and other governmental investigations, or are requested to provide information in connection with such proceedings or investigations. For example, in December 2014, we and our subsidiary, Avee Laboratories Inc., or Avee, received subpoenas from the United States Attorney for the District of New Jersey seeking marketing materials and other documents relating primarily to billing and marketing practices related to toxicology testing. In addition, we received a U.S. Department of Justice criminal subpoena addressed to Alere Toxicology Services, Inc. on July 1, 2016 which seeks records related to Medicare, Medicaid and Tricare billings dating back to 2010 for specific patient samples tested at our Austin, Texas pain management laboratory and payments made to physicians. We are cooperating with these investigations and are providing documents in response to both subpoenas. We and our subsidiary, Arriva Medical, LLC, are also in the process of responding to Civil Investigative Demands, or CIDs, from the United States Attorney for the Middle District of Tennessee in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The most recent of the CIDs was received in July 2016. The CIDs request patient and insurance billing and medical records, records related to interactions with third parties, and correspondence related to the same, dating back to January 2010. We are cooperating with the investigation and are providing documents responsive to the CIDs. We cannot predict what effect, if any, these investigations, or any resulting claims, could have on Alere or its subsidiaries. We have received, from time to time, additional subpoenas and requests for information from the United States Department of Justice, other federal government agencies and state attorneys general, and we have, in each of these cases, cooperated with the applicable governmental entity in responding to the applicable subpoena or request for information. For example, in May 2016, we received a subpoena from the U.S. Attorney for the District of New Jersey, which seeks various documents related to the accuracy, reliability and performance of the INRatio System, including documents relating to prior interactions with the FDA and others regarding the system. Our diabetes, toxicology and patient self-testing businesses are subject to audit and claims for reimbursement brought in the ordinary course by private third-party payers, including health insurers, Zone Program Integrity Contractors, or ZPICs, and Medicare Administrative Contractors, or MACs, to monitor compliance with coverage and reimbursement rules and guidelines. These types of audits and claims can include, but are not limited to, claims relating to proper documentation and support or claims relating to the medical necessity of certain testing and can lead to assertions or determinations that certain claims should not have been, or will no longer be, paid by the private third-party payer or by Medicare or Medicaid. In such cases, the payer or program may seek to recoup or offset amounts they assert have been paid in error. Our businesses may also be subject at any time to other commercial disputes, product liability claims, personal injury claims, including claims arising from or relating to product recalls, negligence claims, third-party subpoenas or various other lawsuits arising in the ordinary course of business, including infringement, employment or investor matters, and we expect that this will continue to be the case in the future. For example, several individuals have filed suits against us alleging personal injury claims in connection with the use of our INRatio products (which are in addition to the class action suits described above). Such lawsuits or claims generally seek damages or reimbursement, sometimes in substantial amounts. There are possible unfavorable outcomes related to litigation or governmental investigations that could adversely impact our business, results of operations, financial condition, and cash flows.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	(18) Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that we adopt on or before the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position, results of operations, comprehensive income or cash flows upon adoption. Please also see Note 3, Summary of Significant Accounting Policies Recently Issued Standards In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In March 2016, the FASB issued ASU No. 2016-07, Investments - Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting, In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), We believe that there were no other accounting standards recently issued that had or are expected to have a material impact on our consolidated financial statements. Recently Adopted Standards In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs Interest —Imputation of Interest (Subtopic 835-30) — Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting), In June 2014, the FASB issued ASU No. 2014-12, Compensation — Stock Compensation (Topic 718) — Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period

Equity Investments

Equity Investments	9 Months Ended
	Sep. 30, 2016
Equity Method Investments and Joint Ventures [Abstract]
Equity Investments	(19) Equity Investments We account for the results from our equity investments under the equity method of accounting in accordance with ASC 323, Investments — Equity Method and Joint Ventures, (a) SPD We recorded earnings of $6.7 million and $12.9 million during the three and nine months ended September 30, 2016, respectively, and earnings of $5.3 million and $9.5 million during the three and nine months ended September 30, 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our 50% share of SPD’s net income for the respective periods and elimination of intercompany profit in inventory related to sales from Alere to SPD which is reflected in SPD’s net income. During the nine months ended September 30, 2015, we received $12.1 million in cash from SPD as a return of capital. (b) TechLab We recorded earnings of $19.5 million and $20.5 million during the three and nine months ended September 30, 2016, respectively, and losses of $0.3 million and earnings of $1.0 million during the three and nine months ended September 30, 2015, respectively, in equity earnings of unconsolidated entities, net of tax, in our consolidated statements of operations, which represented our minority share of TechLab’s net income for the respective periods. During the nine months ended September 30, 2015, we received $2.2 million in cash from TechLab as a return of capital. On September 16, 2016, we completed the sale of our 49% interest in the TechLab business and, in connection with such sale, we recorded a gain in equity earnings of unconsolidated entities, net of tax, of $18.7 million. Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Combined Condensed Results of Operations: 2016 2015 2016 2015 Net revenue $ 56,622 $ 56,303 $ 165,133 $ 157,319 Gross profit $ 44,979 $ 43,538 $ 117,832 $ 111,368 Net income after taxes $ 14,927 $ 15,735 $ 29,396 $ 26,831 Combined Condensed Balance Sheet: September 30, 2016 December 31, 2015 Current assets $ 109,911 $ 71,542 Non-current assets 29,674 30,802 Total assets $ 139,585 $ 102,344 Current liabilities $ 52,045 $ 37,609 Non-current liabilities 5,255 5,157 Total liabilities $ 57,300 $ 42,766

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(21) Income Taxes We determine our estimated annual effective tax rate at the end of each interim period based on forecasted full-year pre-tax income (loss) by jurisdiction and permanent items. Our effective tax rate by quarter may vary based on actual quarter to date income and the forecasted mix of jurisdictional income (loss), as well as discrete items. A reconciliation between the U.S. federal statutory rate and our effective tax rate is summarized as follows: For the Three Months For the nine Months 2016 2015 2016 2015 Statutory rate 35 % 35 % 35 % 35 % State income taxes, net of federal benefit 5 % -4 % 5 % 12 % Rate differential on foreign earnings and impact of foreign inclusion 20 % -6 % 19 % 21 % Change in estimated annual effective tax rate 46 % 33 % — — Change in valuation allowance -11 % -22 % -11 % -77 % Stock-based compensation -4 % 5 % -3 % 22 % Uncertain tax positions -9 % 14 % -8 % 9 % Sale of business — 2 % — -102 % Other 6 % 22 % 4 % 46 % Contingent consideration 5 % -21 % 5 % 69 % Effective tax rate 93 % 58 % 46 % 35 % For the three months and nine months ended September 30, 2016, compared to the same periods in 2015, our effective tax rate increase is primarily attributed to change in overall profitability, jurisdictional mix of income and losses and non-recurring discrete impacts in 2015. The change in overall profitability is primarily attributable to increased expenses related to the pending transaction with Abbott, legal and consulting fees related to certain government investigations and other charges associated with our various restructuring plans.

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Guarantor Financial Information	(22) Guarantor Financial Information Our 7.25% senior notes due 2018, our 6.5% senior subordinated notes due 2020 and our 6.375% senior subordinated notes due 2023 are guaranteed, and before their redemption on October 1, 2015, our 8.625% senior subordinated notes due 2018 were guaranteed, by certain of our consolidated 100% owned subsidiaries, or the Guarantor Subsidiaries. The guarantees are full and unconditional and joint and several. The following supplemental financial information sets forth, on a consolidating basis, balance sheets as of September 30, 2016 and December 31, 2015, the related statements of operations and statements of comprehensive income (loss) for the three and nine months ended September 30, 2016 and 2015, and statements of cash flows for the nine months ended September 30, 2016 and 2015, respectively, for Alere Inc., the Guarantor Subsidiaries and our other subsidiaries, or the Non-Guarantor Subsidiaries. The supplemental financial information reflects the investments of Alere Inc. and the Guarantor Subsidiaries in the Guarantor and Non-Guarantor Subsidiaries using the equity method of accounting. We have extensive transactions and relationships between various members of the consolidated group. These transactions and relationships include intercompany pricing agreements, intellectual property royalty agreements and general and administrative and research and development cost sharing agreements. Because of these relationships, it is possible that the terms of these transactions are not the same as those that would result from transactions among wholly unrelated parties. Effective December 31, 2015, we adopted ASU 2015-03 and ASU 2015-15, and accordingly we have reclassified $34.1 million of debt issuance costs from other non-current assets to long-term debt, net of current portion on our balance sheet as of December 31, 2015, as described in Note 18 Recent Accounting Pronouncements As discussed in Note 2 Revision to Previously Reported Financial Statements The following schedules reconcile the amounts as previously reported in our consolidating financial statements to the corresponding revised amounts: Three Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 347,014 $ 1,024 $ 348,038 Cost of net revenue $ 206,803 $ 253 $ 207,056 Income from continuing operations before benefit for income taxes $ 37,740 $ (317 ) $ 37,423 Benefit for income taxes $ 33,431 $ (4,785 ) $ 28,646 Income from continuing operations $ 71,171 $ (5,102 ) $ 66,069 Three Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 327,031 $ 700 $ 327,731 Cost of net revenue $ 188,137 $ (447 ) $ 187,690 Income from continuing operations before benefit for income taxes $ 25,489 $ 1,147 $ 26,636 Benefit for income taxes $ 63,534 $ (3,929 ) $ 59,605 Income from continuing operations $ 94,371 $ (2,782 ) $ 91,589 Nine Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 1,006,296 $ (2,157 ) $ 1,004,139 Cost of net revenue $ 594,072 $ (629 ) $ 593,443 Income from continuing operations before benefit for income taxes $ 97,789 $ (4,778 ) $ 93,011 Benefit for income taxes $ 20,334 $ (3,269 ) $ 17,065 Income from continuing operations $ 118,123 $ (8,047 ) $ 110,076 Nine Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 1,037,808 $ 2,835 $ 1,040,643 Cost of net revenue $ 586,462 $ 1,399 $ 587,861 Income from continuing operations before benefit for income taxes $ 213,783 $ 236 $ 214,019 Benefit for income taxes $ 31,051 $ (4,366 ) $ 26,685 Income from continuing operations $ 254,174 $ (4,130 ) $ 250,044 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 220,694 $ 309,896 $ (74,494 ) $ 456,096 Services revenue — 112,045 11,733 — 123,778 Net product sales and services revenue — 332,739 321,629 (74,494 ) 579,874 License and royalty revenue — 3,940 1,617 (3,077 ) 2,480 Net revenue — 336,679 323,246 (77,571 ) 582,354 Cost of net product sales 130 125,740 176,740 (63,664 ) 238,946 Cost of services revenue 723 77,875 7,325 (9,284 ) 76,639 Cost of net product sales and services revenue 853 203,615 184,065 (72,948 ) 315,585 Cost of license and royalty revenue — 5 3,711 (3,075 ) 641 Cost of net revenue 853 203,620 187,776 (76,023 ) 316,226 Gross profit (loss) (853 ) 133,059 135,470 (1,548 ) 266,128 Operating expenses: Research and development 3,228 20,338 7,864 — 31,430 Sales and marketing 1,867 52,928 47,184 — 101,979 General and administrative 75,261 18,319 36,196 (489 ) 129,287 Operating income (loss) (81,209 ) 41,474 44,226 (1,059 ) 3,432 Interest expense, including amortization of original issue discounts and deferred financing costs (43,291 ) (713 ) (2,831 ) 2,705 (44,130 ) Other income (expense), net (11,058 ) 1,574 (2,124 ) (2,704 ) (14,312 ) Income (loss) before provision (benefit) for income taxes (135,558 ) 42,335 39,271 (1,058 ) (55,010 ) Provision (benefit) for income taxes (227,263 ) 75,980 100,395 — (50,888 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax 91,705 (33,645 ) (61,124 ) (1,058 ) (4,122 ) Equity in earnings of subsidiaries, net of tax (88,559 ) — — 88,559 — Equity earnings of unconsolidated entities, net of tax 18,881 — 6,677 591 26,149 Net income (loss) 22,027 (33,645 ) (54,447 ) 88,092 22,027 Less: Net income attributable to non-controlling interests — — 207 — 207 Net income (loss) attributable to Alere Inc. and Subsidiaries 22,027 (33,645 ) (54,654 ) 88,092 21,820 Preferred stock dividends (5,366 ) — — — (5,366 ) Net income (loss) available to common stockholders $ 16,661 $ (33,645 ) $ (54,654 ) $ 88,092 $ 16,454 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 228,963 $ 310,571 $ (67,406 ) $ 472,128 Services revenue — 115,829 12,512 — 128,341 Net product sales and services revenue — 344,792 323,083 (67,406 ) 600,469 License and royalty revenue — 3,246 4,648 (4,595 ) 3,299 Net revenue — 348,038 327,731 (72,001 ) 603,768 Cost of net product sales 2,091 125,106 175,341 (56,724 ) 245,814 Cost of services revenue 74 81,549 6,999 (8,771 ) 79,851 Cost of net product sales and services revenue 2,165 206,655 182,340 (65,495 ) 325,665 Cost of license and royalty revenue (19 ) 401 5,350 (4,595 ) 1,137 Cost of net revenue 2,146 207,056 187,690 (70,090 ) 326,802 Gross profit (loss) (2,146 ) 140,982 140,041 (1,911 ) 276,966 Operating expenses: Research and development 5,670 15,015 15,326 — 36,011 Sales and marketing 1,335 53,862 51,296 — 106,493 General and administrative 22,960 34,817 43,529 — 101,306 Impairment and (gain) loss on dispositions, net 150 85 1,839 — 2,074 Operating income (loss) (32,261 ) 37,203 28,051 (1,911 ) 31,082 Interest expense, including amortization of original issue discounts and deferred financing costs (51,705 ) (2,613 ) (4,999 ) 6,984 (52,333 ) Other income (expense), net 4,225 2,833 3,584 (6,984 ) 3,658 Income (loss) from continuing operations before provision (benefit) for income taxes (79,741 ) 37,423 26,636 (1,911 ) (17,593 ) Provision (benefit) for income taxes 78,040 (28,646 ) (59,605 ) (1 ) (10,212 ) Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax (157,781 ) 66,069 86,241 (1,910 ) (7,381 ) Equity in earnings of subsidiaries, net of tax 155,764 — — (155,764 ) — Equity earnings (losses) of unconsolidated entities, net of tax (364 ) — 5,348 16 5,000 Net income (loss) (2,381 ) 66,069 91,589 (157,658 ) (2,381 ) Less: Net loss attributable to non-controlling interests — — (61 ) — (61 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (2,381 ) 66,069 91,650 (157,658 ) (2,320 ) Preferred stock dividends (5,369 ) — — — (5,369 ) Net income (loss) available to common stockholders $ (7,750 ) $ 66,069 $ 91,650 $ (157,658 ) $ (7,689 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 668,028 $ 942,273 $ (210,688 ) $ 1,399,613 Services revenue — 329,227 35,069 — 364,296 Net product sales and services revenue — 997,255 977,342 (210,688 ) 1,763,909 License and royalty revenue — 10,308 6,183 (8,749 ) 7,742 Net revenue — 1,007,563 983,525 (219,437 ) 1,771,651 Cost of net product sales 464 377,293 531,200 (182,152 ) 726,805 Cost of services revenue 827 229,573 23,125 (25,492 ) 228,033 Cost of net product sales and services revenue 1,291 606,866 554,325 (207,644 ) 954,838 Cost of license and royalty revenue — 15 11,300 (8,748 ) 2,567 Cost of net revenue 1,291 606,881 565,625 (216,392 ) 957,405 Gross profit (loss) (1,291 ) 400,682 417,900 (3,045 ) 814,246 Operating expenses: Research and development 10,359 50,991 25,588 — 86,938 Sales and marketing 4,771 160,548 138,989 — 304,308 General and administrative 177,616 81,965 113,505 (489 ) 372,597 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (194,037 ) 107,178 143,628 (2,556 ) 54,213 Interest expense, including amortization of original issue discounts and deferred financing costs (126,235 ) (5,588 ) (8,673 ) 11,931 (128,565 ) Other income (expense), net (17,214 ) 8,179 (8,807 ) (11,931 ) (29,773 ) Income (loss) before provision (benefit) for income taxes (337,486 ) 109,769 126,148 (2,556 ) (104,125 ) Provision (benefit) for income taxes (207,552 ) 69,471 90,102 — (47,979 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (129,934 ) 40,298 36,046 (2,556 ) (56,146 ) Equity in earnings of subsidiaries, net of tax 86,943 — — (86,943 ) — Equity earnings of unconsolidated entities, net of tax 20,150 — 12,815 340 33,305 Net income (loss) (22,841 ) 40,298 48,861 (89,159 ) (22,841 ) Less: Net income attributable to non-controlling interests — — 453 — 453 Net income (loss) attributable to Alere Inc. and Subsidiaries (22,841 ) 40,298 48,408 (89,159 ) (23,294 ) Preferred stock dividends (15,983 ) — — — (15,983 ) Net income (loss) available to common stockholders $ (38,824 ) $ 40,298 $ 48,408 $ (89,159 ) $ (39,277 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 655,594 $ 985,966 $ (194,045 ) $ 1,447,515 Services revenue — 338,869 39,956 — 378,825 Net product sales and services revenue — 994,463 1,025,922 (194,045 ) 1,826,340 License and royalty revenue — 9,676 14,721 (10,706 ) 13,691 Net revenue — 1,004,139 1,040,643 (204,751 ) 1,840,031 Cost of net product sales 2,924 358,354 551,340 (168,810 ) 743,808 Cost of services revenue 204 233,470 22,963 (24,360 ) 232,277 Cost of net product sales and services revenue 3,128 591,824 574,303 (193,170 ) 976,085 Cost of license and royalty revenue (40 ) 1,619 13,558 (10,706 ) 4,431 Cost of net revenue 3,088 593,443 587,861 (203,876 ) 980,516 Gross profit (loss) (3,088 ) 410,696 452,782 (875 ) 859,515 Operating expenses: Research and development 11,213 43,927 36,085 — 91,225 Sales and marketing 4,165 159,190 160,241 — 323,596 General and administrative 67,873 123,875 63,422 — 255,170 Impairment and (gain) loss on dispositions, net 81,051 (8,719 ) (29,924 ) — 42,408 Operating income (loss) (167,390 ) 92,423 222,958 (875 ) 147,116 Interest expense, including amortization of original issue discounts and deferred financing costs (156,889 ) (8,958 ) (13,744 ) 21,333 (158,258 ) Other income (expense), net 11,468 9,546 4,805 (21,333 ) 4,486 Income (loss) from continuing operations before provision (benefit) for income taxes (312,811 ) 93,011 214,019 (875 ) (6,656 ) Provision (benefit) for income taxes 41,067 (17,065 ) (26,685 ) 307 (2,376 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (353,878 ) 110,076 240,704 (1,182 ) (4,280 ) Equity in earnings of subsidiaries, net of tax 357,024 — — (357,024 ) — Equity earnings of unconsolidated entities, net of tax 982 — 9,340 (2 ) 10,320 Income from continuing operations 4,128 110,076 250,044 (358,208 ) 6,040 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income 222,817 108,164 250,044 (358,208 ) 222,817 Less: Net income attributable to non-controlling interests — — 386 — 386 Net income attributable to Alere Inc. and Subsidiaries 222,817 108,164 249,658 (358,208 ) 222,431 Preferred stock dividends (15,927 ) — — — (15,927 ) Net income available to common stockholders $ 206,890 $ 108,164 $ 249,658 $ (358,208 ) $ 206,504 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ 22,027 $ (33,645 ) $ (54,447 ) $ 88,092 $ 22,027 Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 2,433 (272 ) 6,577 (11 ) 8,727 Minimum pension liability adjustment — — 221 — 221 Other comprehensive income (loss), before tax 2,433 (272 ) 6,798 (11 ) 8,948 Other comprehensive income (loss) 2,433 (272 ) 6,798 (11 ) 8,948 Comprehensive income (loss) 24,460 (33,917 ) (47,649 ) 88,081 30,975 Less: Comprehensive income attributable to non-controlling interests — — 207 — 207 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 24,460 $ (33,917 ) $ (47,856 ) $ 88,081 $ 30,768 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (2,381 ) $ 66,069 $ 91,589 $ (157,658 ) $ (2,381 ) Other comprehensive loss, before tax: Changes in cumulative translation adjustment (748 ) (570 ) (87,314 ) (180 ) (88,812 ) Minimum pension liability adjustment — — 419 — 419 Other comprehensive loss, before tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Other comprehensive loss, net of tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Comprehensive income (loss) (3,129 ) 65,499 4,694 (157,838 ) (90,774 ) Less: Comprehensive loss attributable to non-controlling interests — — (61 ) — (61 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (3,129 ) $ 65,499 $ 4,755 $ (157,838 ) $ (90,713 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (22,841 ) $ 40,298 $ 48,861 $ (89,159 ) $ (22,841 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 2,824 (1,100 ) (14,936 ) (3 ) (13,215 ) Minimum pension liability adjustment — — 907 — 907 Other comprehensive income (loss), before tax 2,824 (1,100 ) (14,029 ) (3 ) (12,308 ) Other comprehensive income (loss) 2,824 (1,100 ) (14,029 ) (3 ) (12,308 ) Comprehensive income (loss) (20,017 ) 39,198 34,832 (89,162 ) (35,149 ) Less: Comprehensive income attributable to non-controlling interests — — 453 — 453 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (20,017 ) $ 39,198 $ 34,379 $ (89,162 ) $ (35,602 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income $ 222,817 $ 108,164 $ 250,044 $ (358,208 ) $ 222,817 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (1,208 ) (453 ) (120,587 ) (180 ) (122,428 ) Minimum pension liability adjustment — — (1,337 ) — (1,337 ) Other comprehensive loss, before tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Other comprehensive loss, net of tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Comprehensive income 221,609 107,711 128,120 (358,388 ) 99,052 Less: Comprehensive income attributable to non-controlling interests — — 386 — 386 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 221,609 $ 107,711 $ 127,734 $ (358,388 ) $ 98,666 CONSOLIDATING BALANCE SHEET September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 201,982 $ 545 $ 363,686 $ — $ 566,213 Restricted cash 757 — 4,242 — 4,999 Marketable securities — 75 — — 75 Accounts receivable, net of allowances — 190,077 237,164 — 427,241 Inventories, net — 178,382 194,560 (24,097 ) 348,845 Prepaid expenses and other current assets 10,499 35,605 111,243 6,486 163,833 Intercompany receivables 1,052,091 904,512 213,963 (2,170,566 ) — Total current assets 1,265,329 1,309,196 1,124,858 (2,188,177 ) 1,511,206 Property, plant and equipment, net 27,797 231,197 190,075 (2,756 ) 446,313 Goodwill — 1,822,771 982,911 — 2,805,682 Other intangible assets with indefinite lives — 7,511 20,539 (59 ) 27,991 Finite-lived intangible assets, net 2,618 537,041 328,326 (3,200 ) 864,785 Restricted cash — — 42,438 — 42,438 Other non-current assets 559 2,058 14,335 (733 ) 16,219 Investments in subsidiaries 3,378,517 158,194 57,650 (3,594,361 ) — Investments in unconsolidated entities 684 14,765 50,747 14,689 80,885 Deferred tax assets 212,822 — 58,758 (214,942 ) 56,638 Non-current income tax receivable 3,517 — — — 3,517 Intercompany notes receivables 1,765,528 710,007 602 (2,476,137 ) — Total assets $ 6,657,371 $ 4,792,740 $ 2,871,239 $ (8,465,676 ) $ 5,855,674 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,073 $ — $ 1,351 $ — $ 41,424 Current portion of capital lease obligations — 1,764 1,949 — 3,713 Accounts payable 41,465 77,717 92,294 — 211,476 Accrued expenses and other current liabilities 115,152 139,909 192,714 2,122 449,897 Intercompany payables 1,052,028 777,234 341,304 (2,170,566 ) — Total current liabilities 1,248,718 996,624 629,612 (2,168,444 ) 706,510 Long-term liabilities: Long-term debt, net of current portion 2,859,054 — 46,013 — 2,905,067 Capital lease obligations, net of current portion — 2,322 5,711 — 8,033 Deferred tax liabilities — 218,898 46,355 (212,740 ) 52,513 Other long-term liabilities 16,821 42,279 74,815 (733 ) 133,182 Intercompany notes payables 487,096 1,163,898 825,143 (2,476,137 ) — Total long-term liabilities 3,362,971 1,427,397 998,037 (2,689,610 ) 3,098,795 Total stockholders’ equity 2,045,682 2,368,719 1,238,903 (3,607,622 ) 2,045,682 Non-controlling interests — — 4,687 — 4,687 Total equity 2,045,682 2,368,719 1,243,590 (3,607,622 ) 2,050,369 Total liabilities and equity $ 6,657,371 $ 4,792,740 $ 2,871,239 $ (8,465,676 ) $ 5,855,674 CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 253,242 — 445,833 Inventories, net — 173,383 194,192 (20,574 ) 347,001 Prepaid expenses and other current assets 7,576 27,095 110,961 6,601 152,233 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 1,237,474 812,957 50,691 (2,101,122 ) — Total current assets 1,385,453 1,227,340 959,592 (2,115,095 ) 1,457,290 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current assets 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,294,857 158,195 57,650 (3,510,702 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets 91,220 — 51,329 (128,556 ) 13,993 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 6,729,213 $ 4,761,562 $ 2,763,898 $ (8,331,552 ) $ 5,923,121 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities 62,287 126,346 133,594 2,238 324,465 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 773,839 205,241 (2,101,122 ) — Total current liabilities 1,397,394 979,093 446,931 (2,098,884 ) 724,534 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities — 219,224 54,749 (126,355 ) 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,277,654 1,460,541 1,112,885 (2,710,922 ) 3,140,158 Total stockholders’ equity 2,054,165 2,321,928 1,199,818 (3,521,746 ) 2,054,165 Non-controlling interests — — 4,264 — 4,264 Total equity 2,054,165 2,321,928 1,204,082 (3,521,746 ) 2,058,429 Total liabilities and equity $ 6,729,213 $ 4,761,562 $ 2,763,898 $ (8,331,552 ) $ 5,923,121 CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (22,841 ) $ 40,298 $ 48,861 $ (89,159 ) $ (22,841 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Equity in earnings of subsidiaries, net of tax (86,943 ) — — 86,943 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 9,186 9 110 — 9,305 Depreciation and amortization 6,829 133,532 72,848 978 214,187 Non-cash stock-based compensation expense 16,347 7,595 7,173 — 31,115 Impairment of inventory — — 915 — 915 Impairment of long-lived assets — 548 86 — 634 Loss on sale of fixed assets 75 4,530 887 — 5,492 Equity earnings of unconsolidated entities, net of tax (20,150 ) — (12,815 ) (340 ) (33,305 ) Deferred income taxes (6,392 ) (300 ) (18,550 ) — (25,242 ) Gain on dispositions — — (3,810 ) — (3,810 ) Other non-cash items 815 (1,824 ) 8,684 (7 ) 7,668 Non-cash change in fair value of contingent purchase price consideration (1,800 ) (14,323 ) (167 ) — (16,290 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 2,502 19,549 — 22,051 Inventories, net — (34,902 ) 1,666 1,576 (31,660 ) Prepaid expenses and other current assets 547 (8,417 ) (14,876 ) 116 (22,630 ) Accounts payable 25,483 2,517 (9,507 ) — 18,493 Accrued expenses and other current liabilities 41,025 15,149 60,896 (6,387 ) 110,683 Other non-current liabilities (112,172 ) (2,170 ) (3,137 ) — (117,479 ) Cash paid for contingent consideration (321 ) — (3 ) — (324 ) Intercompany payable (receivable) 269,507 (143,767 ) (132,020 ) 6,280 — Net cash provided by operating activities 119,195 977 26,790 — 146,962 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 493 — (294 ) — 199 Purchases of property, plant and equipment (3,783 ) (20,325 ) (27,529 ) 1,642 (49,995 ) Proceeds from sale of property, plant and equipment 92 367 2,333 (1,642 ) 1,150 Cash received from (used in) dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,958 ) — (5,958 ) Cash received from sales of marketable securities. — 88 — — 88 Cash received from equity method investments 3,357 — — — 3,357 Cash paid for investments (184 ) — — — (184 ) Proceeds from sale of equity investments. 38,157 — 2,594 — 40,751 (Increase) decrease in other assets (50 ) (104 ) 614 — 460 Net cash provided by (used in) investing activities 36,745 (19,974 ) (5,433 ) — 11,338 Cash Flows from Financing Activities: Cash paid for financing costs (29,186 ) — — — (29,186 ) Cash paid for contingent purchase price consideration — — (575 ) — (575 ) Cash paid for dividends (15,969 ) — — — (15,969 ) Proceeds from issuance of common stock, net of issuance costs 13,923 — — — 13,923 Proceeds from issuance of long-term debt — — 462 — 462 Payments on long-term debt — — (1,722 ) — (1,722 ) Payments on long-term debt (186,879 ) — (938 ) — (187,817 ) Net proceeds (payments) under revolving credit facilities 125,000 — (124 ) — 124,876 Principal payments on capital lease obligations — (1,782 ) (1,321 ) — (3,103 ) Net cash used in financing activities (93,111 ) (1,782 ) (4,218 ) — (99,111 ) Foreign exchange effect on cash and cash equivalents — 174 4,650 — 4,824 Net increase (decrease) in cash and cash equivalents 62,829 (20,605 ) 21,789 — 64,013 Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 201,982 $ 545 $ 363,686 $ — $ 566,213 CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 222,817 $ 108,164 $ 250,044 $ (358,208 ) $ 222,817 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income from continuing operations 4,128 110,076 250,044 (358,208 ) 6,040 Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (357,024 ) — — 357,024 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 10,542 19 66 — 10,627 Depreciation and amortization 7,891 128,363 97,390 7 233,651 Non-cash stock-based compensation expense 10,600 4,251 4,745 — 19,596 Impairment of inventory — 133 68 — 201 Impairment of long-lived assets — 64 314 — 378 Loss on disposition of fixed assets — 2,768 505 — 3,273 Equity earnings of unconsolidated entities, net of tax (982 ) — (9,340 ) 2 (10,320 ) Deferred income taxes (8,687 ) (27,430 ) (7,794 ) 439 (43,472 ) Loss related to impairment and net (gain) loss on dispositions 81,051 (8,804 ) (29,924 ) — 42,323 Loss on extinguishment of debt 3,480 — — — 3,480 Other non-cash items (376 ) (1,054 ) (3,358 ) 3 (4,785 ) Non-cash change in fair value of contingent purchase price consideration (33,667 ) 16,616 (34,860 ) — (51,911 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (9,213 ) 6,052 — (3,161 ) Inventories, net — (31,708 ) (26,651 ) 207 (58,152 ) Prepaid expenses and other current assets 3,098 (28,016 ) 4,917 5,048 (14,953 ) Accounts payable (7,435 ) 777 (9,342 ) — (16,000 ) Accrued expenses and other current liabilities (1,455 ) 72,936 (27,203 ) (9,306 ) 34,972 Other non-current liabilities (16,114 ) 740 5,389 1,445 (8,540 ) Cash paid for contingent purchase price consideration (6,302 ) — (13 ) — (6,315 ) Intercompany payable (receivable) 447,475 (282,519 ) (167,580 ) 2,624 — Net cash provided by (used in) continuing operations 136,223 (52,001 ) 53,425 (715 ) 136,932 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities 136,223 (51,683 ) 53,425 (715 ) 137,250 Cash Flows from Investing Activities: Increase in restricted cash (421,157 ) — (17,608 ) — (438,765 ) Purchases of property, plant and equipment (7,514 ) (25,915 ) (36,093 ) 1,575 (67,947 ) Proceeds from sale of property, plant and equipment — 846 1,554 (914 ) 1,486 Cash received from (used in) disposition, net of cash divested 593,066 (8,722 ) 2,281 — 586,625 Cash paid for business acquisitions, net of cash acquired (60,135 ) — — — (60,135 ) Cash received from (paid for) sales of marketable securities — 103 (4 ) — 99 Cash received from equity method investments 2,205 — 12,092 — 14,297 (Increase) decrease in other assets 368 497 (219 ) 235 881 Net cash provided by (used in) continuing operations 106,833 (33,191 ) (37,997 ) 896 36,541 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 106,833 (33,400 ) (37,997 ) 896 36,332 Cash Flows from Financing Activities: Cash paid for financing costs (15,836 ) — (217 ) — (16,053 ) Cash paid for contingent purchase price consideration (13,640 ) — (439 ) — (14,079 ) Cash paid for dividends (15,970 ) — — — (15,970 ) Proceeds from issuance of common stock, net of issuance costs 76,457 — — — 76,457 Proceeds from issuance of long-term debt 2,119,125 — 42,897 — 2,162,022 Payments on short-term debt — — (25,584 ) — (25,584 ) Payments on long-term debt (2,128,625 ) — (540 ) — (2,129,165 ) Net proceeds (payments) under revolving credit facilities (127,000 ) — 397 — (126,603 ) Excess tax benefits on exercised stock options 3,264 2,531 307 — 6,102 Principal payments on capital lease obligations — (1,876 ) (2,463 ) — (4,339 ) Net cash provided by (used in) continuing operations (102,225 ) 655 14,358 — (87,212 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash provided by (used in) financing activities (102,225 ) 579 14,358 — (87,288 ) Foreign exchange effect on cash and cash equivalents 16 (301 ) (8,208 ) (181 ) (8,674 ) Net increase (decrease) in cash and cash equivalents 140,847 (84,805 ) 21,578 — 77,620 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents, end of period $ 142,996 $ 7,649 $ 328,736 $ — $ 479,381

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	(23) Subsequent Events Arriva LLC Billing Number On October 12, 2016, our subsidiary, Arriva Medical, LLC, or Arriva, which is our durable medical equipment, or DME, supply business that specializes in the furnishing of diabetic testing supplies via mail order, received a notice, dated October 5, 2016, that its Medicare enrollment will be revoked by CMS, based on CMS’ assertion that, over a five year period, Arriva had allegedly submitted claims for 211 deceased patients (even if the products were appropriately ordered in advance of the patient’s death). The CMS letter only identifies 47 of the 211 claims. Our initial appeal of this determination was denied by CMS on November 2, 2016 and, therefore, Arriva’s Medicare enrollment will be revoked effective November 4, 2016, pending the outcome of further appeals. We have conducted an initial investigation into the issue and do not believe that Arriva received or retained improper reimbursement for the DME items furnished. We are continuing to work through the appeals process, with the goal that Arriva’s enrollment status will be reactivated retroactively to November 4, 2016. Unless and until the enrollment status is reactivated, Arriva will be ineligible for reimbursement for any products or services furnished on or after November 4, 2016. If the enrollment is reactivated retroactive to November 4, 2016, we would be able to bill and be reimbursed for all covered products or services furnished. The Company’s results of operation for the nine months ended September 30, 2016 included approximately $88 million in revenue attributable to Arriva.

Basis of Presentation of Fina29

Basis of Presentation of Financial Information (Policies)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation of Financial Information	(1) Basis of Presentation of Financial Information The accompanying consolidated financial statements of Alere Inc. are unaudited. In the opinion of management, the unaudited consolidated financial statements contain all adjustments considered normal and recurring and necessary for their fair statement. Interim results are not necessarily indicative of results to be expected for the year. These interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these consolidated financial statements do not include all of the information and footnotes necessary for a complete presentation of financial position, results of operations, comprehensive income and cash flows. Our audited consolidated financial statements for the year ended December 31, 2015 included information and footnotes necessary for such presentation and were included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on August 8, 2016. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and notes thereto for the year ended December 31, 2015. Certain amounts presented may not recalculate directly, due to rounding.
Cash and Cash Equivalents	We consider all highly-liquid cash investments with original maturities of three months or less at the date of acquisition to be cash equivalents. At September 30, 2016, our cash equivalents consisted of money market funds.

Revision of Previously Report30

Revision of Previously Reported Consolidated Financial Statements (Tables)	9 Months Ended
	Sep. 30, 2016
Accounting Changes and Error Corrections [Abstract]
Restated and Revised Consolidated Statement of Operations	The following schedules reconcile the amounts as previously reported in the applicable financial statement to the corresponding revised amounts: Three Months Ended September 30, 2015 Revised Consolidated Statement of Operations (in thousands, As Previously Reported Adjustment As Revised Net product sales $ 470,404 $ 1,724 $ 472,128 Net product sales and services revenue $ 598,745 $ 1,724 $ 600,469 Net revenue $ 602,044 $ 1,724 $ 603,768 Cost of net product sales $ 246,055 $ (241 ) $ 245,814 Cost of service revenue $ 79,803 $ 48 $ 79,851 Cost of net product sales and services revenue $ 325,858 $ (193 ) $ 325,665 Cost of net revenue $ 326,995 $ (193 ) $ 326,802 Gross profit $ 275,049 $ 1,917 $ 276,966 Operating income $ 29,165 $ 1,917 $ 31,082 Other income (expense), net $ 4,745 $ (1,087 ) $ 3,658 Loss from continuing operations before provision for income taxes $ (18,423 ) $ 830 $ (17,593 ) Benefit for income taxes $ 18,924 $ (8,712 ) $ 10,212 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax $ 501 $ (7,882 ) $ (7,381 ) Income (loss) from continuing operations $ 5,501 $ (7,882 ) $ (2,381 ) Net income (loss) $ 5,501 $ (7,882 ) $ (2,381 ) Net income (loss) attributable to Alere Inc. and Subsidiaries $ 5,562 $ (7,882 ) $ (2,320 ) Net income (loss) available to common stockholders $ 193 $ (7,882 ) $ (7,689 ) Basic and diluted loss per common share: Income from continuing operations $ — $ (0.10 ) $ (0.10 ) Basic and diluted net loss per common share: Net loss per common share $ — $ (0.10 ) $ (0.10 ) Nine Months Ended September 30, 2015 Revised Consolidated Statement of Operations (in thousands, As Previously Reported Adjustment As Revised Net product sales $ 1,446,837 $ 678 $ 1,447,515 Net product sales and services revenue $ 1,825,662 $ 678 $ 1,826,340 Net revenue $ 1,839,353 $ 678 $ 1,840,031 Cost of net product sales $ 743,177 $ 631 $ 743,808 Cost of service revenue $ 232,137 $ 140 $ 232,277 Cost of net product sales and services revenue $ 975,314 $ 771 $ 976,085 Cost of net revenue $ 979,745 $ 771 $ 980,516 Gross profit $ 859,608 $ (93 ) $ 859,515 Sales and marketing $ 322,756 $ 840 $ 323,596 General and administrative $ 254,810 $ 360 $ 255,170 Operating income $ 148,409 $ (1,293 ) $ 147,116 Other income (expense), net $ 7,735 $ (3,249 ) $ 4,486 Loss from continuing operations before benefit for income $ (2,114 ) $ (4,542 ) $ (6,656 ) Benefit for income taxes $ 10,009 $ (7,633 ) $ 2,376 Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax $ 7,895 $ (12,175 ) $ (4,280 ) Income from continuing operations $ 18,215 $ (12,175 ) $ 6,040 Net income $ 234,992 $ (12,175 ) $ 222,817 Net income attributable to Alere Inc. and Subsidiaries $ 234,606 $ (12,175 ) $ 222,431 Net income available to common stockholders $ 218,679 $ (12,175 ) $ 206,504 Basic and diluted income per common share: Income from continuing operations $ 2.57 $ (0.14 ) $ 2.43 Basic and diluted net income per common share: Net income per common share $ 2.57 $ (0.14 ) $ 2.43
Restated and Revised Consolidated Statement of Comprehensive Income (Loss)	Three Months Ended September 30, 2015 Revised Consolidated Statement of Comprehensive Loss (in thousands) As Previously Reported Adjustment As Revised Net income (loss) $ 5,501 $ (7,882 ) $ (2,381 ) Comprehensive loss $ (82,892 ) $ (7,882 ) $ (90,774 ) Comprehensive loss attributable to Alere Inc. and Subsidiaries $ (82,831 ) $ (7,882 ) $ (90,713 ) Nine Months Ended September 30, 2015 Revised Consolidated Statement of Comprehensive Income (in thousands) As Previously Reported Adjustment As Revised Net income $ 234,992 $ (12,175 ) $ 222,817 Comprehensive income $ 111,227 $ (12,175 ) $ 99,052 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 110,841 $ (12,175 ) $ 98,666
Restated and Revised Consolidated Statement of Cash Flows	Nine Months Ended September 30, 2015 Revised Consolidated Statement of Cash Flows (in thousands) As Previously Reported Adjustment As Revised Net income $ 234,992 $ (12,175 ) $ 222,817 Income from continuing operations $ 18,215 $ (12,175 ) $ 6,040 Depreciation and amortization $ 233,511 $ 140 $ 233,651 Deferred income taxes $ (46,740 ) $ 3,268 $ (43,472 ) Accounts receivable, net $ (11,269 ) $ 8,108 $ (3,161 ) Inventories, net $ (58,781 ) $ 629 $ (58,152 ) Accrued expenses and other current liabilities $ 35,192 $ (220 ) $ 34,972 Other non-current liabilities $ (8,790 ) $ 250 $ (8,540 )

Discontinued Operations, Impa31

Discontinued Operations, Impairment and (Gain) Loss on Dispositions, Net (Tables)	9 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Summarized Financial Information Related to Health Management Business	The following summarized financial information related to the health management business has been segregated from continuing operations and reported as discontinued operations in our consolidated statements of operations for the nine months ended September 30, 2015. The results are as follows (in thousands): Nine Months Ended Net revenue $ 7,373 Cost of net revenue (4,413 ) Sales and marketing (996 ) General and administrative (5,001 ) Interest expense (9 ) Other income (expense), net 160 Gain on disposal 366,191 Income from discontinued operations before provision for income taxes 363,305 Provision for income taxes 146,528 Income from discontinued operations, net of tax $ 216,777

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories are Stated at Lower of Cost (First In, First Out) or Market	Inventories are stated at the lower of cost (first in, first out) or market and are comprised of the following (in thousands): September 30, 2016 December 31, 2015 Raw materials $ 123,558 $ 130,171 Work-in-process 72,562 69,178 Finished goods 152,725 147,652 $ 348,845 $ 347,001

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation Expense	We recorded stock-based compensation expense in our consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015, as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Cost of net revenue $ 456 $ 326 $ 1,536 $ 866 Research and development 494 287 1,374 893 Sales and marketing 2,475 1,260 7,035 3,605 General and administrative 7,084 5,444 21,170 14,232 $ 10,509 $ 7,317 $ 31,115 $ 19,596

Net Income (Loss) per Common 34

Net Income (Loss) per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income (Loss) Per Common Share	The following table sets forth the computation of basic and diluted net income (loss) per common share for the periods presented (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Basic and diluted net income (loss) per common share: Numerator: Income (loss) from continuing operations $ 22,027 $ (2,381 ) $ (22,841 ) $ 6,040 Preferred stock dividends (5,366 ) (5,369 ) (15,983 ) (15,927 ) Income (loss) from continuing operations attributable to common shares 16,661 (7,750 ) (38,824 ) (9,887 ) Less: Net income (loss) attributable to non-controlling interest 207 (61 ) 453 386 Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries 16,454 (7,689 ) (39,277 ) (10,273 ) Income from discontinued operations — — — 216,777 Net income (loss) available to common stockholders $ 16,454 $ (7,689 ) $ (39,277 ) $ 206,504 Denominator: Weighted-average common shares outstanding — basic 86,753 85,895 86,708 85,141 Weighted-average common shares outstanding — diluted 87,885 85,895 86,708 85,141 Basic net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ 0.19 $ (0.10 ) $ (0.45 ) $ (0.13 ) Income from discontinued operations — — — 2.56 Basic net income (loss) per common share $ 0.19 $ (0.10 ) $ (0.45 ) $ 2.43 Diluted net income (loss) per common share: Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries $ 0.19 $ (0.10 ) $ (0.45 ) $ (0.13 ) Income from discontinuing operations — — — 2.56 Diluted net income (loss) per common share $ 0.19 $ (0.10 ) $ (0.45 ) $ 2.43
Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share	The following potential dilutive securities were not included in the calculation of diluted net income (loss) per common share for our continuing operations because the inclusion thereof would be antidilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Denominator: Options to purchase shares of common stock and RSUs 5,884 7,062 7,016 7,062 Warrants — — — 4 Conversion shares related to 3% convertible senior subordinated notes — 3,411 1,693 3,411 Conversion shares related to subordinated convertible promissory notes — 27 — 27 Conversion shares related to Series B convertible preferred stock 10,239 10,239 10,239 10,239 Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding 16,123 20,739 18,948 20,743

Stockholders' Equity and Non-35

Stockholders' Equity and Non-controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2016
Equity [Abstract]
Summary of Changes in Stockholders' Equity and Non-Controlling Interests Comprising Total Equity	A summary of the changes in stockholders’ equity and non-controlling interests comprising total equity for the nine months ended September 30, 2016 is provided below (in thousands): Nine Months Ended September 30, 2016 Total Non- Total Equity Equity, beginning of period $ 2,054,165 $ 4,264 $ 2,058,429 Issuance of common stock under employee compensation plans 14,110 — 14,110 Surrender of common stock to settle taxes on restricted stock units (2,137 ) — (2,137 ) Preferred stock dividends (15,969 ) — (15,969 ) Stock-based compensation expense 31,115 — 31,115 Other adjustments — (30 ) (30 ) Net income (23,294 ) 453 (22,841 ) Total other comprehensive loss (12,308 ) — (12,308 ) Equity, end of period $ 2,045,682 $ 4,687 $ 2,050,369

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Summary of Aggregate Purchase Price Allocation	A summary of the fair values of the net assets acquired from EDTS is as follows (in thousands): Fair Value Current assets $ 1,371 Property, plant and equipment 115 Goodwill 2,060 Intangible assets 4,220 Total assets acquired $ 7,766 Current liabilities $ 368 Non-current liabilities 928 Total liabilities assumed $ 1,296 Net assets acquired $ 6,470 Cash paid $ 6,470 A summary of the fair values of the net assets acquired from USD is as follows (in thousands): Total Current assets $ 4,652 Property, plant and equipment 182 Goodwill 29,422 Intangible assets 27,200 Total assets acquired $ 61,456 Current liabilities $ 1,321 Total liabilities assumed $ 1,321 Net assets acquired $ 60,135 Cash paid $ 60,135
Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives	The following table provides information regarding the intangible assets acquired in connection with the EDTS acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Fair Value Weighted- Core technology and patents $ 540 10.0 years Trademarks and trade names 310 20.0 years Customer relationships 2,800 14.0 years Non-compete agreements 570 3.0 years Total intangible assets $ 4,220 The following are the intangible assets acquired in connection with the USD acquisition and their respective fair values and weighted-average useful lives (dollars in thousands): Total Weighted- Trademarks $ 1,600 3.0 - 13.0 years Customer relationships 24,900 13.0 years Non-compete agreements 700 2.0 years Total intangible assets $ 27,200

Restructuring Plans (Tables)

Restructuring Plans (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring and Related Activities [Abstract]
Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income	The following table sets forth aggregate restructuring charges recorded in our consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Statement of Operations Caption 2016 2015 2016 2015 Cost of net revenue $ 1,531 $ 522 $ 3,901 $ 2,921 Research and development 587 18 3,541 667 Sales and marketing 511 619 1,420 2,572 General and administrative 8,661 1,105 18,876 5,227 Total operating expenses 11,290 2,264 27,738 11,387 Interest expense, including amortization of original issue discounts and deferred financing costs 2 6 9 19 Total restructuring charges $ 11,292 $ 2,270 $ 27,747 $ 11,406
Restructuring Activities Related to Restructuring Plans	The following table summarizes the restructuring activities related to the 2016 restructuring plans, in addition to our earlier restructuring plans as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, for the three and nine months ended September 30, 2016 and 2015 and since inception of these restructuring plans (in thousands): Three Months Ended Nine Months Ended Since 2016 2015 2016 2015 Professional Diagnostics Severance-related costs $ 1,765 $ 1,322 $ 8,039 $ 5,385 $ 46,026 Facility and transition costs 426 132 1,620 4,139 13,288 Other exit costs 2 6 9 19 831 Cash charges 2,193 1,460 9,668 9,543 60,145 Fixed asset and inventory impairments 545 124 964 579 16,917 Other non-cash charges (2 ) — 208 — 2,190 Total professional diagnostics charges $ 2,736 $ 1,584 $ 10,840 $ 10,122 $ 79,252 Corporate and Other Severance-related costs $ 69 $ 686 $ 65 $ 1,297 $ 4,342 Facility and transition costs 8,487 — 16,842 (13 ) 28,164 Total corporate and other charges $ 8,556 $ 686 $ 16,907 $ 1,284 $ 32,506 Total restructuring charges $ 11,292 $ 2,270 $ 27,747 $ 11,406 $ 111,758
Cash Activity for Restructuring Reserves	The following table summarizes our restructuring reserves related to the plans described above, of which $9.9 million is included in accrued expenses and other current liabilities and $0.6 million is included in other long-term liabilities on our accompanying consolidated balance sheets (in thousands): Severance- Facility and Other Exit Total Balance, December 31, 2015 $ 1,633 $ 1,966 $ 180 $ 3,779 Cash charges 8,104 18,462 9 26,575 Payments (5,821 ) (14,018 ) (111 ) (19,950 ) Currency adjustments 10 42 — 52 Balance, September 30, 2016 $ 3,926 $ 6,452 $ 78 $ 10,456

Long-term Debt (Tables)

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Long-Term Debt Balances Outstanding	We had the following long-term debt balances outstanding (in thousands): September 30, 2016 December 31, 2015 A term loans (1)(2) $ 551,266 $ 575,746 B term loans (1)(2) 954,608 965,740 Revolving loans (1) 125,000 — 7.25% Senior notes (2) 441,498 446,320 6.5% Senior subordinated notes (2) 414,391 419,209 6.375% Senior subordinated notes (2) 412,363 418,133 3% Convertible senior subordinated notes (3) — 149,839 Other lines of credit — 136 Other 47,365 56,035 2,946,491 3,031,158 Less: Short-term debt and current portion of long-term debt (3) (41,424 ) (199,992 ) Long-term debt $ 2,905,067 $ 2,831,166 (1) Incurred under our secured credit facility entered into on June 18, 2015. (2) As discussed more fully below in this Note 12, (i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 to, among other things, extend the deadline date for such filing. In addition, because we had not filed our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 at or prior to the time set forth in the indentures governing our outstanding notes, we were also in default thereunder. However, with the filing of such Quarterly Report on Form 10-Q on September 6, 2016 cured this default prior to the expiration of the applicable cure periods under the indentures governing our notes. As of September 30, 2016, we were in compliance with all of our obligations and covenants under the Credit Agreement and the indentures governing our outstanding notes. (3) The principal amount of the 3% convertible senior subordinated notes is included in the short-term debt and current portion of long-term debt on our consolidated balance sheets as of December 31, 2015, as these notes matured (and were fully paid and discharged) in May 2016.
Long-Term Debt Interest Expense	In connection with our significant long-term debt issuances, we recorded interest expense, including amortization and write-offs of deferred financing costs and original issue discounts, in our accompanying consolidated statements of operations for the three and nine months ended September 30, 2016 and 2015 as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Secured credit facility (1) $ 19,072 $ 18,161 $ 53,949 $ 20,763 Prior credit facility (2) (3) — — — 49,437 7.25% Senior notes 9,372 8,524 26,800 25,573 6.5% Senior subordinated notes 7,618 7,274 22,254 21,741 6.375% Senior subordinated notes (4) 7,242 7,002 21,357 7,544 8.625% Senior subordinated notes (4) — 9,273 — 27,820 3% Convertible senior subordinated convertible notes — 1,246 1,847 3,738 Other 826 853 2,358 1,642 $ 44,130 $ 52,333 $ 128,565 $ 158,258 (1) Includes “A” term loans, “B” term loans, and revolving line of credit loans. (2) Includes the following loans under our prior credit facility: “A” term loans, including the “Delayed-Draw” term loans; “B” term loans, including the term loans previously referred to as “Incremental B-1” term loans and “Incremental B-2” term loans and later converted into and consolidated into the “B” term loans; and revolving line of credit loans. (3) Includes a $3.5 million loss on extinguishment of debt associated with our prior credit facility. (4) For the three and nine months ended September 30, 2015, the amounts include $0.4 million and $1.1 million, respectively, related to the amortization of fees paid for certain debt modifications.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques	The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015, and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value (in thousands): Description September 30, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 75 $ 75 $ — $ — Total assets $ 75 $ 75 $ — $ — Liabilities: Contingent consideration obligations (1) $ 40,500 $ — $ — $ 40,500 Total liabilities $ 40,500 $ — $ — $ 40,500 Description December 31, Quoted Prices in Significant Other Unobservable Inputs Assets: Marketable securities $ 164 $ 164 $ — $ — Total assets $ 164 $ 164 $ — $ — Liabilities: Contingent consideration obligations (1) $ 57,744 $ — $ — $ 57,744 Total liabilities $ 57,744 $ — $ — $ 57,744 (1) We determine the fair value of the contingent consideration obligations based on a probability-weighted approach derived from earn-out criteria estimates and a probability assessment with respect to the likelihood of achieving the various earn-out criteria. The measurement is based upon significant inputs not observable in the market. Significant increases or decreases in any of these inputs could result in a significantly higher or lower fair value measurement. Changes in the fair value of these contingent consideration obligations are recorded as income or expense within operating income in our consolidated statements of operations. See Note 17(a) for additional information on the valuation of our contingent consideration obligations.
Changes in Fair Value of Contingent Consideration Obligations	Changes in the fair value of our Level 3 contingent consideration obligations during the nine months ended September 30, 2016 were as follows (in thousands): Fair value of contingent consideration obligations, December 31, 2015 $ 57,744 Payments (955 ) Fair value adjustments (16,290 ) Foreign currency adjustments 1 Fair value of contingent consideration obligations, September 30, 2016 $ 40,500

Financial Information by Segm40

Financial Information by Segment (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Performance of Our Operating Segments Based on Revenue and Operating Income (Loss)	Segment information for the three and nine months ended September 30, 2016 and 2015 is as follows (in thousands): Professional Consumer Corporate Other Total Three Months Ended September 30, 2016: Net revenue $ 563,007 $ 19,347 $ — $ 582,354 Operating income (loss) $ 84,341 $ 718 $ (81,627 ) $ 3,432 Depreciation and amortization $ 68,263 $ 1,263 $ 2,256 $ 71,782 Restructuring charge $ 2,733 $ — $ 8,557 $ 11,290 Stock-based compensation $ — $ — $ 10,509 $ 10,509 Three Months Ended September 30, 2015: Net revenue $ 585,021 $ 18,747 $ — $ 603,768 Operating income (loss) $ 56,520 $ 1,038 $ (26,476 ) $ 31,082 Impairment and loss on dispositions, net $ 1,923 $ — $ 151 $ 2,074 Depreciation and amortization $ 83,865 $ 717 $ 1,966 $ 86,548 Restructuring charge $ 1,578 $ — $ 686 $ 2,264 Stock-based compensation $ — $ — $ 7,317 $ 7,317 Nine Months Ended September 30, 2016: Net revenue $ 1,715,068 $ 56,583 $ — $ 1,771,651 Operating income (loss) $ 252,557 $ 1,281 $ (199,625 ) $ 54,213 (Gain) loss on dispositions, net $ 4,967 $ (8,777 ) $ — $ (3,810 ) Depreciation and amortization $ 203,488 $ 4,138 $ 6,561 $ 214,187 Restructuring charge $ 10,830 $ — $ 16,908 $ 27,738 Stock-based compensation $ — $ — $ 31,115 $ 31,115 Nine Months Ended September 30, 2015: Net revenue $ 1,774,671 $ 65,360 $ — $ 1,840,031 Operating income (loss) $ 299,303 $ 4,321 $ (156,508 ) $ 147,116 Impairment and (gain) loss on dispositions, net $ (38,643 ) $ — $ 81,051 $ 42,408 Depreciation and amortization $ 226,523 $ 2,153 $ 4,975 $ 233,651 Restructuring charge $ 10,103 $ — $ 1,284 $ 11,387 Stock-based compensation $ — $ — $ 19,596 $ 19,596 Assets: As of September 30, 2016 $ 5,410,679 $ 192,885 $ 252,110 $ 5,855,674 As of December 31, 2015 $ 5,619,901 $ 172,551 $ 130,669 $ 5,923,121
Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services	The following tables summarize our net revenue from the professional diagnostics reporting segments by groups of similar products and services for the three and nine months ended September 30, 2016 and 2015 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2016 2015 2016 2015 Cardiometabolic $ 188,731 $ 208,979 $ 587,289 $ 621,588 Infectious disease 183,375 164,822 556,777 523,059 Toxicology 155,871 162,571 460,849 468,822 Other 32,550 45,350 102,411 147,511 Total professional diagnostics net product sales and services revenue 560,527 581,722 1,707,326 1,760,980 License and royalty revenue 2,480 3,299 7,742 13,691 Total professional diagnostics net revenue $ 563,007 $ 585,021 $ 1,715,068 $ 1,774,671

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Balances with SPD within Consolidated Balance Sheets	The following table summarizes our related party balances with SPD within our consolidated balance sheets (in thousands): Balance Sheet Caption September 30, 2016 December 31, 2015 Accounts receivable, net of allowances $ 11,827 $ 9,873 Prepaid expenses and other current assets $ 9,343 $ 6,602 Other non-current assets $ 6,504 $ 8,895 Accounts payable $ 40,152 $ 24,887

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions	The following table summarizes our contractual contingent purchase price consideration obligations related to certain of our acquisitions (in thousands): Acquisition Acquisition Date Acquisition Maximum Remaining Estimated Estimated Payments TwistDx, Inc. (1) March 11, 2010 $ 35,600 $ 102,870 2016 – 2025 (3) $ 33,100 $ 47,800 $ 377 Epocal (2) February 1, 2013 $ 75,000 $ 42,825 2016 – 2018 2,900 4,700 — Other Various $ 30,373 $ — (4) 2016 4,500 5,244 578 $ 40,500 $ 57,744 $ 955 (1) The terms of the acquisition agreement require us to pay earn-outs upon successfully meeting certain revenue and product development targets through 2025. (2) The terms of the acquisition agreement require us to pay earn-outs and management incentive payments upon successfully meeting certain product development and United States Food and Drug Administration regulatory approval milestones from the date of acquisition through December 31, 2018. (3) The maximum earn-out period ends on the fifteenth anniversary of the acquisition date. (4) The maximum remaining earn-out potential for the other acquisitions is not determinable due to the nature of one of the earn-outs, which is tied to an unlimited revenue metric.

Equity Investments (Tables)

Equity Investments (Tables)	9 Months Ended
	Sep. 30, 2016
Financial Information Combined Condensed Results of Operations	CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 220,694 $ 309,896 $ (74,494 ) $ 456,096 Services revenue — 112,045 11,733 — 123,778 Net product sales and services revenue — 332,739 321,629 (74,494 ) 579,874 License and royalty revenue — 3,940 1,617 (3,077 ) 2,480 Net revenue — 336,679 323,246 (77,571 ) 582,354 Cost of net product sales 130 125,740 176,740 (63,664 ) 238,946 Cost of services revenue 723 77,875 7,325 (9,284 ) 76,639 Cost of net product sales and services revenue 853 203,615 184,065 (72,948 ) 315,585 Cost of license and royalty revenue — 5 3,711 (3,075 ) 641 Cost of net revenue 853 203,620 187,776 (76,023 ) 316,226 Gross profit (loss) (853 ) 133,059 135,470 (1,548 ) 266,128 Operating expenses: Research and development 3,228 20,338 7,864 — 31,430 Sales and marketing 1,867 52,928 47,184 — 101,979 General and administrative 75,261 18,319 36,196 (489 ) 129,287 Operating income (loss) (81,209 ) 41,474 44,226 (1,059 ) 3,432 Interest expense, including amortization of original issue discounts and deferred financing costs (43,291 ) (713 ) (2,831 ) 2,705 (44,130 ) Other income (expense), net (11,058 ) 1,574 (2,124 ) (2,704 ) (14,312 ) Income (loss) before provision (benefit) for income taxes (135,558 ) 42,335 39,271 (1,058 ) (55,010 ) Provision (benefit) for income taxes (227,263 ) 75,980 100,395 — (50,888 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax 91,705 (33,645 ) (61,124 ) (1,058 ) (4,122 ) Equity in earnings of subsidiaries, net of tax (88,559 ) — — 88,559 — Equity earnings of unconsolidated entities, net of tax 18,881 — 6,677 591 26,149 Net income (loss) 22,027 (33,645 ) (54,447 ) 88,092 22,027 Less: Net income attributable to non-controlling interests — — 207 — 207 Net income (loss) attributable to Alere Inc. and Subsidiaries 22,027 (33,645 ) (54,654 ) 88,092 21,820 Preferred stock dividends (5,366 ) — — — (5,366 ) Net income (loss) available to common stockholders $ 16,661 $ (33,645 ) $ (54,654 ) $ 88,092 $ 16,454 CONSOLIDATING STATEMENT OF OPERATIONS For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 228,963 $ 310,571 $ (67,406 ) $ 472,128 Services revenue — 115,829 12,512 — 128,341 Net product sales and services revenue — 344,792 323,083 (67,406 ) 600,469 License and royalty revenue — 3,246 4,648 (4,595 ) 3,299 Net revenue — 348,038 327,731 (72,001 ) 603,768 Cost of net product sales 2,091 125,106 175,341 (56,724 ) 245,814 Cost of services revenue 74 81,549 6,999 (8,771 ) 79,851 Cost of net product sales and services revenue 2,165 206,655 182,340 (65,495 ) 325,665 Cost of license and royalty revenue (19 ) 401 5,350 (4,595 ) 1,137 Cost of net revenue 2,146 207,056 187,690 (70,090 ) 326,802 Gross profit (loss) (2,146 ) 140,982 140,041 (1,911 ) 276,966 Operating expenses: Research and development 5,670 15,015 15,326 — 36,011 Sales and marketing 1,335 53,862 51,296 — 106,493 General and administrative 22,960 34,817 43,529 — 101,306 Impairment and (gain) loss on dispositions, net 150 85 1,839 — 2,074 Operating income (loss) (32,261 ) 37,203 28,051 (1,911 ) 31,082 Interest expense, including amortization of original issue discounts and deferred financing costs (51,705 ) (2,613 ) (4,999 ) 6,984 (52,333 ) Other income (expense), net 4,225 2,833 3,584 (6,984 ) 3,658 Income (loss) from continuing operations before provision (benefit) for income taxes (79,741 ) 37,423 26,636 (1,911 ) (17,593 ) Provision (benefit) for income taxes 78,040 (28,646 ) (59,605 ) (1 ) (10,212 ) Income (loss) from continuing operations before equity in earnings (losses) of subsidiaries and unconsolidated entities, net of tax (157,781 ) 66,069 86,241 (1,910 ) (7,381 ) Equity in earnings of subsidiaries, net of tax 155,764 — — (155,764 ) — Equity earnings (losses) of unconsolidated entities, net of tax (364 ) — 5,348 16 5,000 Net income (loss) (2,381 ) 66,069 91,589 (157,658 ) (2,381 ) Less: Net loss attributable to non-controlling interests — — (61 ) — (61 ) Net income (loss) attributable to Alere Inc. and Subsidiaries (2,381 ) 66,069 91,650 (157,658 ) (2,320 ) Preferred stock dividends (5,369 ) — — — (5,369 ) Net income (loss) available to common stockholders $ (7,750 ) $ 66,069 $ 91,650 $ (157,658 ) $ (7,689 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 668,028 $ 942,273 $ (210,688 ) $ 1,399,613 Services revenue — 329,227 35,069 — 364,296 Net product sales and services revenue — 997,255 977,342 (210,688 ) 1,763,909 License and royalty revenue — 10,308 6,183 (8,749 ) 7,742 Net revenue — 1,007,563 983,525 (219,437 ) 1,771,651 Cost of net product sales 464 377,293 531,200 (182,152 ) 726,805 Cost of services revenue 827 229,573 23,125 (25,492 ) 228,033 Cost of net product sales and services revenue 1,291 606,866 554,325 (207,644 ) 954,838 Cost of license and royalty revenue — 15 11,300 (8,748 ) 2,567 Cost of net revenue 1,291 606,881 565,625 (216,392 ) 957,405 Gross profit (loss) (1,291 ) 400,682 417,900 (3,045 ) 814,246 Operating expenses: Research and development 10,359 50,991 25,588 — 86,938 Sales and marketing 4,771 160,548 138,989 — 304,308 General and administrative 177,616 81,965 113,505 (489 ) 372,597 Impairment and (gain) loss on dispositions, net — — (3,810 ) — (3,810 ) Operating income (loss) (194,037 ) 107,178 143,628 (2,556 ) 54,213 Interest expense, including amortization of original issue discounts and deferred financing costs (126,235 ) (5,588 ) (8,673 ) 11,931 (128,565 ) Other income (expense), net (17,214 ) 8,179 (8,807 ) (11,931 ) (29,773 ) Income (loss) before provision (benefit) for income taxes (337,486 ) 109,769 126,148 (2,556 ) (104,125 ) Provision (benefit) for income taxes (207,552 ) 69,471 90,102 — (47,979 ) Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax (129,934 ) 40,298 36,046 (2,556 ) (56,146 ) Equity in earnings of subsidiaries, net of tax 86,943 — — (86,943 ) — Equity earnings of unconsolidated entities, net of tax 20,150 — 12,815 340 33,305 Net income (loss) (22,841 ) 40,298 48,861 (89,159 ) (22,841 ) Less: Net income attributable to non-controlling interests — — 453 — 453 Net income (loss) attributable to Alere Inc. and Subsidiaries (22,841 ) 40,298 48,408 (89,159 ) (23,294 ) Preferred stock dividends (15,983 ) — — — (15,983 ) Net income (loss) available to common stockholders $ (38,824 ) $ 40,298 $ 48,408 $ (89,159 ) $ (39,277 ) CONSOLIDATING STATEMENT OF OPERATIONS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Net product sales $ — $ 655,594 $ 985,966 $ (194,045 ) $ 1,447,515 Services revenue — 338,869 39,956 — 378,825 Net product sales and services revenue — 994,463 1,025,922 (194,045 ) 1,826,340 License and royalty revenue — 9,676 14,721 (10,706 ) 13,691 Net revenue — 1,004,139 1,040,643 (204,751 ) 1,840,031 Cost of net product sales 2,924 358,354 551,340 (168,810 ) 743,808 Cost of services revenue 204 233,470 22,963 (24,360 ) 232,277 Cost of net product sales and services revenue 3,128 591,824 574,303 (193,170 ) 976,085 Cost of license and royalty revenue (40 ) 1,619 13,558 (10,706 ) 4,431 Cost of net revenue 3,088 593,443 587,861 (203,876 ) 980,516 Gross profit (loss) (3,088 ) 410,696 452,782 (875 ) 859,515 Operating expenses: Research and development 11,213 43,927 36,085 — 91,225 Sales and marketing 4,165 159,190 160,241 — 323,596 General and administrative 67,873 123,875 63,422 — 255,170 Impairment and (gain) loss on dispositions, net 81,051 (8,719 ) (29,924 ) — 42,408 Operating income (loss) (167,390 ) 92,423 222,958 (875 ) 147,116 Interest expense, including amortization of original issue discounts and deferred financing costs (156,889 ) (8,958 ) (13,744 ) 21,333 (158,258 ) Other income (expense), net 11,468 9,546 4,805 (21,333 ) 4,486 Income (loss) from continuing operations before provision (benefit) for income taxes (312,811 ) 93,011 214,019 (875 ) (6,656 ) Provision (benefit) for income taxes 41,067 (17,065 ) (26,685 ) 307 (2,376 ) Income (loss) from continuing operations before equity in earnings of subsidiaries and unconsolidated entities, net of tax (353,878 ) 110,076 240,704 (1,182 ) (4,280 ) Equity in earnings of subsidiaries, net of tax 357,024 — — (357,024 ) — Equity earnings of unconsolidated entities, net of tax 982 — 9,340 (2 ) 10,320 Income from continuing operations 4,128 110,076 250,044 (358,208 ) 6,040 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Net income 222,817 108,164 250,044 (358,208 ) 222,817 Less: Net income attributable to non-controlling interests — — 386 — 386 Net income attributable to Alere Inc. and Subsidiaries 222,817 108,164 249,658 (358,208 ) 222,431 Preferred stock dividends (15,927 ) — — — (15,927 ) Net income available to common stockholders $ 206,890 $ 108,164 $ 249,658 $ (358,208 ) $ 206,504
Financial Information Combined Condensed Balance Sheet	CONSOLIDATING BALANCE SHEET September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 201,982 $ 545 $ 363,686 $ — $ 566,213 Restricted cash 757 — 4,242 — 4,999 Marketable securities — 75 — — 75 Accounts receivable, net of allowances — 190,077 237,164 — 427,241 Inventories, net — 178,382 194,560 (24,097 ) 348,845 Prepaid expenses and other current assets 10,499 35,605 111,243 6,486 163,833 Intercompany receivables 1,052,091 904,512 213,963 (2,170,566 ) — Total current assets 1,265,329 1,309,196 1,124,858 (2,188,177 ) 1,511,206 Property, plant and equipment, net 27,797 231,197 190,075 (2,756 ) 446,313 Goodwill — 1,822,771 982,911 — 2,805,682 Other intangible assets with indefinite lives — 7,511 20,539 (59 ) 27,991 Finite-lived intangible assets, net 2,618 537,041 328,326 (3,200 ) 864,785 Restricted cash — — 42,438 — 42,438 Other non-current assets 559 2,058 14,335 (733 ) 16,219 Investments in subsidiaries 3,378,517 158,194 57,650 (3,594,361 ) — Investments in unconsolidated entities 684 14,765 50,747 14,689 80,885 Deferred tax assets 212,822 — 58,758 (214,942 ) 56,638 Non-current income tax receivable 3,517 — — — 3,517 Intercompany notes receivables 1,765,528 710,007 602 (2,476,137 ) — Total assets $ 6,657,371 $ 4,792,740 $ 2,871,239 $ (8,465,676 ) $ 5,855,674 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 40,073 $ — $ 1,351 $ — $ 41,424 Current portion of capital lease obligations — 1,764 1,949 — 3,713 Accounts payable 41,465 77,717 92,294 — 211,476 Accrued expenses and other current liabilities 115,152 139,909 192,714 2,122 449,897 Intercompany payables 1,052,028 777,234 341,304 (2,170,566 ) — Total current liabilities 1,248,718 996,624 629,612 (2,168,444 ) 706,510 Long-term liabilities: Long-term debt, net of current portion 2,859,054 — 46,013 — 2,905,067 Capital lease obligations, net of current portion — 2,322 5,711 — 8,033 Deferred tax liabilities — 218,898 46,355 (212,740 ) 52,513 Other long-term liabilities 16,821 42,279 74,815 (733 ) 133,182 Intercompany notes payables 487,096 1,163,898 825,143 (2,476,137 ) — Total long-term liabilities 3,362,971 1,427,397 998,037 (2,689,610 ) 3,098,795 Total stockholders’ equity 2,045,682 2,368,719 1,238,903 (3,607,622 ) 2,045,682 Non-controlling interests — — 4,687 — 4,687 Total equity 2,045,682 2,368,719 1,243,590 (3,607,622 ) 2,050,369 Total liabilities and equity $ 6,657,371 $ 4,792,740 $ 2,871,239 $ (8,465,676 ) $ 5,855,674 CONSOLIDATING BALANCE SHEET December 31, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 139,153 $ 21,150 $ 341,897 $ — $ 502,200 Restricted cash 1,250 — 4,444 — 5,694 Marketable securities — 164 — — 164 Accounts receivable, net of allowances — 192,591 253,242 — 445,833 Inventories, net — 173,383 194,192 (20,574 ) 347,001 Prepaid expenses and other current assets 7,576 27,095 110,961 6,601 152,233 Assets held for sale — current — — 4,165 — 4,165 Intercompany receivables 1,237,474 812,957 50,691 (2,101,122 ) — Total current assets 1,385,453 1,227,340 959,592 (2,115,095 ) 1,457,290 Property, plant and equipment, net 31,384 228,065 188,084 (1,494 ) 446,039 Goodwill — 1,823,919 1,012,996 — 2,836,915 Other intangible assets with indefinite lives — 7,638 20,531 (59 ) 28,110 Finite-lived intangible assets, net 2,951 627,269 370,261 (3,200 ) 997,281 Restricted cash — — 43,228 — 43,228 Other non-current assets 804 2,340 15,380 (446 ) 18,078 Investments in subsidiaries 3,294,857 158,195 57,650 (3,510,702 ) — Investments in unconsolidated entities 502 14,764 37,947 12,120 65,333 Deferred tax assets 91,220 — 51,329 (128,556 ) 13,993 Non-current income tax receivable 3,517 — — — 3,517 Assets held for sale — non-current 13,337 — — — 13,337 Intercompany notes receivables 1,905,188 672,032 6,900 (2,584,120 ) — Total assets $ 6,729,213 $ 4,761,562 $ 2,763,898 $ (8,331,552 ) $ 5,923,121 LIABILITIES AND EQUITY Current liabilities: Short-term debt and current portion of long-term debt $ 197,084 $ — $ 2,908 $ — $ 199,992 Current portion of capital lease obligations — 2,018 1,944 — 3,962 Accounts payable 15,981 76,890 102,881 — 195,752 Accrued expenses and other current liabilities 62,287 126,346 133,594 2,238 324,465 Liabilities related to assets held for sale — current — — 363 — 363 Intercompany payables 1,122,042 773,839 205,241 (2,101,122 ) — Total current liabilities 1,397,394 979,093 446,931 (2,098,884 ) 724,534 Long-term liabilities: Long-term debt, net of current portion 2,784,913 — 46,253 — 2,831,166 Capital lease obligations, net of current portion — 840 6,341 — 7,181 Deferred tax liabilities — 219,224 54,749 (126,355 ) 147,618 Other long-term liabilities 14,962 59,309 80,369 (447 ) 154,193 Intercompany notes payables 477,779 1,181,168 925,173 (2,584,120 ) — Total long-term liabilities 3,277,654 1,460,541 1,112,885 (2,710,922 ) 3,140,158 Total stockholders’ equity 2,054,165 2,321,928 1,199,818 (3,521,746 ) 2,054,165 Non-controlling interests — — 4,264 — 4,264 Total equity 2,054,165 2,321,928 1,204,082 (3,521,746 ) 2,058,429 Total liabilities and equity $ 6,729,213 $ 4,761,562 $ 2,763,898 $ (8,331,552 ) $ 5,923,121
Swiss Precision Diagnostics And TechLab [Member]
Financial Information Combined Condensed Results of Operations	Summarized financial information for SPD and TechLab on a combined basis is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Combined Condensed Results of Operations: 2016 2015 2016 2015 Net revenue $ 56,622 $ 56,303 $ 165,133 $ 157,319 Gross profit $ 44,979 $ 43,538 $ 117,832 $ 111,368 Net income after taxes $ 14,927 $ 15,735 $ 29,396 $ 26,831
Financial Information Combined Condensed Balance Sheet	Combined Condensed Balance Sheet: September 30, 2016 December 31, 2015 Current assets $ 109,911 $ 71,542 Non-current assets 29,674 30,802 Total assets $ 139,585 $ 102,344 Current liabilities $ 52,045 $ 37,609 Non-current liabilities 5,255 5,157 Total liabilities $ 57,300 $ 42,766

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Reconciliation between U.S. Federal Statutory Rate and Effective Tax Rate	A reconciliation between the U.S. federal statutory rate and our effective tax rate is summarized as follows: For the Three Months For the nine Months 2016 2015 2016 2015 Statutory rate 35 % 35 % 35 % 35 % State income taxes, net of federal benefit 5 % -4 % 5 % 12 % Rate differential on foreign earnings and impact of foreign inclusion 20 % -6 % 19 % 21 % Change in estimated annual effective tax rate 46 % 33 % — — Change in valuation allowance -11 % -22 % -11 % -77 % Stock-based compensation -4 % 5 % -3 % 22 % Uncertain tax positions -9 % 14 % -8 % 9 % Sale of business — 2 % — -102 % Other 6 % 22 % 4 % 46 % Contingent consideration 5 % -21 % 5 % 69 % Effective tax rate 93 % 58 % 46 % 35 %

Guarantor Financial Informati45

Guarantor Financial Information (Tables)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Reconciliation of Previously Reported and Revised Consolidating Financial Statements	Three Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 347,014 $ 1,024 $ 348,038 Cost of net revenue $ 206,803 $ 253 $ 207,056 Income from continuing operations before benefit for income taxes $ 37,740 $ (317 ) $ 37,423 Benefit for income taxes $ 33,431 $ (4,785 ) $ 28,646 Income from continuing operations $ 71,171 $ (5,102 ) $ 66,069 Three Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 327,031 $ 700 $ 327,731 Cost of net revenue $ 188,137 $ (447 ) $ 187,690 Income from continuing operations before benefit for income taxes $ 25,489 $ 1,147 $ 26,636 Benefit for income taxes $ 63,534 $ (3,929 ) $ 59,605 Income from continuing operations $ 94,371 $ (2,782 ) $ 91,589 Nine Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 1,006,296 $ (2,157 ) $ 1,004,139 Cost of net revenue $ 594,072 $ (629 ) $ 593,443 Income from continuing operations before benefit for income taxes $ 97,789 $ (4,778 ) $ 93,011 Benefit for income taxes $ 20,334 $ (3,269 ) $ 17,065 Income from continuing operations $ 118,123 $ (8,047 ) $ 110,076 Nine Months Ended September 30, 2015 Revised Consolidating Statement of Operations- Non-Guarantor Subsidiaries (in thousands) As Previously Revision As Net revenue $ 1,037,808 $ 2,835 $ 1,040,643 Cost of net revenue $ 586,462 $ 1,399 $ 587,861 Income from continuing operations before benefit for income taxes $ 213,783 $ 236 $ 214,019 Benefit for income taxes $ 31,051 $ (4,366 ) $ 26,685 Income from continuing operations $ 254,174 $ (4,130 ) $ 250,044
Guarantor Financial Information Consolidating Statement of Comprehensive Income (Loss)	CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ 22,027 $ (33,645 ) $ (54,447 ) $ 88,092 $ 22,027 Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 2,433 (272 ) 6,577 (11 ) 8,727 Minimum pension liability adjustment — — 221 — 221 Other comprehensive income (loss), before tax 2,433 (272 ) 6,798 (11 ) 8,948 Other comprehensive income (loss) 2,433 (272 ) 6,798 (11 ) 8,948 Comprehensive income (loss) 24,460 (33,917 ) (47,649 ) 88,081 30,975 Less: Comprehensive income attributable to non-controlling interests — — 207 — 207 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ 24,460 $ (33,917 ) $ (47,856 ) $ 88,081 $ 30,768 CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Three Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (2,381 ) $ 66,069 $ 91,589 $ (157,658 ) $ (2,381 ) Other comprehensive loss, before tax: Changes in cumulative translation adjustment (748 ) (570 ) (87,314 ) (180 ) (88,812 ) Minimum pension liability adjustment — — 419 — 419 Other comprehensive loss, before tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Other comprehensive loss, net of tax (748 ) (570 ) (86,895 ) (180 ) (88,393 ) Comprehensive income (loss) (3,129 ) 65,499 4,694 (157,838 ) (90,774 ) Less: Comprehensive loss attributable to non-controlling interests — — (61 ) — (61 ) Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (3,129 ) $ 65,499 $ 4,755 $ (157,838 ) $ (90,713 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income (loss) $ (22,841 ) $ 40,298 $ 48,861 $ (89,159 ) $ (22,841 ) Other comprehensive income (loss), before tax: Changes in cumulative translation adjustment 2,824 (1,100 ) (14,936 ) (3 ) (13,215 ) Minimum pension liability adjustment — — 907 — 907 Other comprehensive income (loss), before tax 2,824 (1,100 ) (14,029 ) (3 ) (12,308 ) Other comprehensive income (loss) 2,824 (1,100 ) (14,029 ) (3 ) (12,308 ) Comprehensive income (loss) (20,017 ) 39,198 34,832 (89,162 ) (35,149 ) Less: Comprehensive income attributable to non-controlling interests — — 453 — 453 Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries $ (20,017 ) $ 39,198 $ 34,379 $ (89,162 ) $ (35,602 ) CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non- Eliminations Consolidated Net income $ 222,817 $ 108,164 $ 250,044 $ (358,208 ) $ 222,817 Other comprehensive loss, before tax: Changes in cumulative translation adjustment (1,208 ) (453 ) (120,587 ) (180 ) (122,428 ) Minimum pension liability adjustment — — (1,337 ) — (1,337 ) Other comprehensive loss, before tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Other comprehensive loss, net of tax (1,208 ) (453 ) (121,924 ) (180 ) (123,765 ) Comprehensive income 221,609 107,711 128,120 (358,388 ) 99,052 Less: Comprehensive income attributable to non-controlling interests — — 386 — 386 Comprehensive income attributable to Alere Inc. and Subsidiaries $ 221,609 $ 107,711 $ 127,734 $ (358,388 ) $ 98,666
Guarantor Financial Information Consolidating Statement of Cash Flows	CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2016 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income (loss) $ (22,841 ) $ 40,298 $ 48,861 $ (89,159 ) $ (22,841 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Equity in earnings of subsidiaries, net of tax (86,943 ) — — 86,943 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 9,186 9 110 — 9,305 Depreciation and amortization 6,829 133,532 72,848 978 214,187 Non-cash stock-based compensation expense 16,347 7,595 7,173 — 31,115 Impairment of inventory — — 915 — 915 Impairment of long-lived assets — 548 86 — 634 Loss on sale of fixed assets 75 4,530 887 — 5,492 Equity earnings of unconsolidated entities, net of tax (20,150 ) — (12,815 ) (340 ) (33,305 ) Deferred income taxes (6,392 ) (300 ) (18,550 ) — (25,242 ) Gain on dispositions — — (3,810 ) — (3,810 ) Other non-cash items 815 (1,824 ) 8,684 (7 ) 7,668 Non-cash change in fair value of contingent purchase price consideration (1,800 ) (14,323 ) (167 ) — (16,290 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — 2,502 19,549 — 22,051 Inventories, net — (34,902 ) 1,666 1,576 (31,660 ) Prepaid expenses and other current assets 547 (8,417 ) (14,876 ) 116 (22,630 ) Accounts payable 25,483 2,517 (9,507 ) — 18,493 Accrued expenses and other current liabilities 41,025 15,149 60,896 (6,387 ) 110,683 Other non-current liabilities (112,172 ) (2,170 ) (3,137 ) — (117,479 ) Cash paid for contingent consideration (321 ) — (3 ) — (324 ) Intercompany payable (receivable) 269,507 (143,767 ) (132,020 ) 6,280 — Net cash provided by operating activities 119,195 977 26,790 — 146,962 Cash Flows from Investing Activities: (Increase) decrease in restricted cash 493 — (294 ) — 199 Purchases of property, plant and equipment (3,783 ) (20,325 ) (27,529 ) 1,642 (49,995 ) Proceeds from sale of property, plant and equipment 92 367 2,333 (1,642 ) 1,150 Cash received from (used in) dispositions, net of cash divested (1,337 ) — 22,807 — 21,470 Cash paid for business acquisitions, net of cash acquired — — (5,958 ) — (5,958 ) Cash received from sales of marketable securities. — 88 — — 88 Cash received from equity method investments 3,357 — — — 3,357 Cash paid for investments (184 ) — — — (184 ) Proceeds from sale of equity investments. 38,157 — 2,594 — 40,751 (Increase) decrease in other assets (50 ) (104 ) 614 — 460 Net cash provided by (used in) investing activities 36,745 (19,974 ) (5,433 ) — 11,338 Cash Flows from Financing Activities: Cash paid for financing costs (29,186 ) — — — (29,186 ) Cash paid for contingent purchase price consideration — — (575 ) — (575 ) Cash paid for dividends (15,969 ) — — — (15,969 ) Proceeds from issuance of common stock, net of issuance costs 13,923 — — — 13,923 Proceeds from issuance of long-term debt — — 462 — 462 Payments on long-term debt — — (1,722 ) — (1,722 ) Payments on long-term debt (186,879 ) — (938 ) — (187,817 ) Net proceeds (payments) under revolving credit facilities 125,000 — (124 ) — 124,876 Principal payments on capital lease obligations — (1,782 ) (1,321 ) — (3,103 ) Net cash used in financing activities (93,111 ) (1,782 ) (4,218 ) — (99,111 ) Foreign exchange effect on cash and cash equivalents — 174 4,650 — 4,824 Net increase (decrease) in cash and cash equivalents 62,829 (20,605 ) 21,789 — 64,013 Cash and cash equivalents, beginning of period 139,153 21,150 341,897 — 502,200 Cash and cash equivalents, end of period $ 201,982 $ 545 $ 363,686 $ — $ 566,213 CONSOLIDATING STATEMENT OF CASH FLOWS For the Nine Months Ended September 30, 2015 (in thousands) Issuer Guarantor Non-Guarantor Eliminations Consolidated Cash Flows from Operating Activities: Net income $ 222,817 $ 108,164 $ 250,044 $ (358,208 ) $ 222,817 Income (loss) from discontinued operations, net of tax 218,689 (1,912 ) — — 216,777 Income from continuing operations 4,128 110,076 250,044 (358,208 ) 6,040 Adjustments to reconcile net income from continuing operations to net cash provided by (used in) operating activities: Equity in earnings of subsidiaries, net of tax (357,024 ) — — 357,024 — Non-cash interest expense, including amortization of original issue discounts and deferred financing costs 10,542 19 66 — 10,627 Depreciation and amortization 7,891 128,363 97,390 7 233,651 Non-cash stock-based compensation expense 10,600 4,251 4,745 — 19,596 Impairment of inventory — 133 68 — 201 Impairment of long-lived assets — 64 314 — 378 Loss on disposition of fixed assets — 2,768 505 — 3,273 Equity earnings of unconsolidated entities, net of tax (982 ) — (9,340 ) 2 (10,320 ) Deferred income taxes (8,687 ) (27,430 ) (7,794 ) 439 (43,472 ) Loss related to impairment and net (gain) loss on dispositions 81,051 (8,804 ) (29,924 ) — 42,323 Loss on extinguishment of debt 3,480 — — — 3,480 Other non-cash items (376 ) (1,054 ) (3,358 ) 3 (4,785 ) Non-cash change in fair value of contingent purchase price consideration (33,667 ) 16,616 (34,860 ) — (51,911 ) Changes in assets and liabilities, net of acquisitions: Accounts receivable, net — (9,213 ) 6,052 — (3,161 ) Inventories, net — (31,708 ) (26,651 ) 207 (58,152 ) Prepaid expenses and other current assets 3,098 (28,016 ) 4,917 5,048 (14,953 ) Accounts payable (7,435 ) 777 (9,342 ) — (16,000 ) Accrued expenses and other current liabilities (1,455 ) 72,936 (27,203 ) (9,306 ) 34,972 Other non-current liabilities (16,114 ) 740 5,389 1,445 (8,540 ) Cash paid for contingent purchase price consideration (6,302 ) — (13 ) — (6,315 ) Intercompany payable (receivable) 447,475 (282,519 ) (167,580 ) 2,624 — Net cash provided by (used in) continuing operations 136,223 (52,001 ) 53,425 (715 ) 136,932 Net cash provided by discontinued operations — 318 — — 318 Net cash provided by (used in) operating activities 136,223 (51,683 ) 53,425 (715 ) 137,250 Cash Flows from Investing Activities: Increase in restricted cash (421,157 ) — (17,608 ) — (438,765 ) Purchases of property, plant and equipment (7,514 ) (25,915 ) (36,093 ) 1,575 (67,947 ) Proceeds from sale of property, plant and equipment — 846 1,554 (914 ) 1,486 Cash received from (used in) disposition, net of cash divested 593,066 (8,722 ) 2,281 — 586,625 Cash paid for business acquisitions, net of cash acquired (60,135 ) — — — (60,135 ) Cash received from (paid for) sales of marketable securities — 103 (4 ) — 99 Cash received from equity method investments 2,205 — 12,092 — 14,297 (Increase) decrease in other assets 368 497 (219 ) 235 881 Net cash provided by (used in) continuing operations 106,833 (33,191 ) (37,997 ) 896 36,541 Net cash used in discontinued operations — (209 ) — — (209 ) Net cash provided by (used in) investing activities 106,833 (33,400 ) (37,997 ) 896 36,332 Cash Flows from Financing Activities: Cash paid for financing costs (15,836 ) — (217 ) — (16,053 ) Cash paid for contingent purchase price consideration (13,640 ) — (439 ) — (14,079 ) Cash paid for dividends (15,970 ) — — — (15,970 ) Proceeds from issuance of common stock, net of issuance costs 76,457 — — — 76,457 Proceeds from issuance of long-term debt 2,119,125 — 42,897 — 2,162,022 Payments on short-term debt — — (25,584 ) — (25,584 ) Payments on long-term debt (2,128,625 ) — (540 ) — (2,129,165 ) Net proceeds (payments) under revolving credit facilities (127,000 ) — 397 — (126,603 ) Excess tax benefits on exercised stock options 3,264 2,531 307 — 6,102 Principal payments on capital lease obligations — (1,876 ) (2,463 ) — (4,339 ) Net cash provided by (used in) continuing operations (102,225 ) 655 14,358 — (87,212 ) Net cash used in discontinued operations — (76 ) — — (76 ) Net cash provided by (used in) financing activities (102,225 ) 579 14,358 — (87,288 ) Foreign exchange effect on cash and cash equivalents 16 (301 ) (8,208 ) (181 ) (8,674 ) Net increase (decrease) in cash and cash equivalents 140,847 (84,805 ) 21,578 — 77,620 Cash and cash equivalents, beginning of period — continuing operations 2,149 69,154 307,158 — 378,461 Cash and cash equivalents, beginning of period — discontinued operations — 23,300 — — 23,300 Cash and cash equivalents, end of period $ 142,996 $ 7,649 $ 328,736 $ — $ 479,381

Revision of Previously Report46

Revision of Previously Reported Consolidated Financial Statements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 582,354	$ 603,768	$ 1,771,651	$ 1,840,031
Other income (expense), net	$ (14,312)	3,658	$ (29,773)	4,486
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		1,724		678
Other income (expense), net		$ (1,087)		(3,249)
Operating expenses				1,200
Benefit for income taxes				$ (8,600)

Revision of Previously Report47

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales	$ 456,096	$ 472,128	$ 1,399,613	$ 1,447,515
Net product sales and services revenue	579,874	600,469	1,763,909	1,826,340
Net revenue	582,354	603,768	1,771,651	1,840,031
Cost of net product sales	238,946	245,814	726,805	743,808
Cost of service revenue	76,639	79,851	228,033	232,277
Cost of net product sales and services revenue	315,585	325,665	954,838	976,085
Cost of net revenue	316,226	326,802	957,405	980,516
Gross profit	266,128	276,966	814,246	859,515
Sales and marketing	101,979	106,493	304,308	323,596
General and administrative	129,287	101,306	372,597	255,170
Operating income	3,432	31,082	54,213	147,116
Other income (expense), net	(14,312)	3,658	(29,773)	4,486
Income (loss) from continuing operations before provision (benefit) for income taxes	(55,010)	(17,593)	(104,125)	(6,656)
Benefit for income taxes	(50,888)	(10,212)	(47,979)	(2,376)
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax	(4,122)	(7,381)	(56,146)	(4,280)
Income (loss) from continuing operations	22,027	(2,381)	(22,841)	6,040
Net income (loss)	22,027	(2,381)	(22,841)	222,817
Net income (loss) attributable to Alere Inc. and Subsidiaries	21,820	(2,320)	(23,294)	222,431
Net income (loss) available to common stockholders	$ 16,454	$ (7,689)	$ (39,277)	$ 206,504
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted income (loss) per common share: Income (loss) from continuing operations		$ (0.10)		$ 2.43
Basic and diluted net income (loss) per common share: Net income (loss) per common share		$ (0.10)		$ 2.43
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 470,404		$ 1,446,837
Net product sales and services revenue		598,745		1,825,662
Net revenue		602,044		1,839,353
Cost of net product sales		246,055		743,177
Cost of service revenue		79,803		232,137
Cost of net product sales and services revenue		325,858		975,314
Cost of net revenue		326,995		979,745
Gross profit		275,049		859,608
Sales and marketing				322,756
General and administrative				254,810
Operating income		29,165		148,409
Other income (expense), net		4,745		7,735
Income (loss) from continuing operations before provision (benefit) for income taxes		(18,423)		(2,114)
Benefit for income taxes		18,924		10,009
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax		501		7,895
Income (loss) from continuing operations		5,501		18,215
Net income (loss)		5,501		234,992
Net income (loss) attributable to Alere Inc. and Subsidiaries		5,562		234,606
Net income (loss) available to common stockholders		$ 193		$ 218,679
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted income (loss) per common share: Income (loss) from continuing operations		$ 0		$ 2.57
Basic and diluted net income (loss) per common share: Net income (loss) per common share		$ 0		$ 2.57
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net product sales		$ 1,724		$ 678
Net product sales and services revenue		1,724		678
Net revenue		1,724		678
Cost of net product sales		(241)		631
Cost of service revenue		48		140
Cost of net product sales and services revenue		(193)		771
Cost of net revenue		(193)		771
Gross profit		1,917		(93)
Sales and marketing				840
General and administrative				360
Operating income		1,917		(1,293)
Other income (expense), net		(1,087)		(3,249)
Income (loss) from continuing operations before provision (benefit) for income taxes		830		(4,542)
Benefit for income taxes		(8,712)		(7,633)
Income (loss) from continuing operations before equity earnings of unconsolidated entities, net of tax		(7,882)		(12,175)
Income (loss) from continuing operations		(7,882)		(12,175)
Net income (loss)		(7,882)		(12,175)
Net income (loss) attributable to Alere Inc. and Subsidiaries		(7,882)		(12,175)
Net income (loss) available to common stockholders		$ (7,882)		$ (12,175)
Basic and diluted net loss per common share attributable to Alere Inc. and Subsidiaries:
Basic and diluted income (loss) per common share: Income (loss) from continuing operations		$ (0.10)		$ (0.14)
Basic and diluted net income (loss) per common share: Net income (loss) per common share		$ (0.10)		$ (0.14)

Revision of Previously Report48

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)	$ 22,027	$ (2,381)	$ (22,841)	$ 222,817
Comprehensive income (loss)	30,975	(90,774)	(35,149)	99,052
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ 30,768	(90,713)	$ (35,602)	98,666
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		5,501		234,992
Comprehensive income (loss)		(82,892)		111,227
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries		(82,831)		110,841
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income (loss)		(7,882)		(12,175)
Comprehensive income (loss)		(7,882)		(12,175)
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries		$ (7,882)		$ (12,175)

Revision of Previously Report49

Revision of Previously Reported Consolidated Financial Statements - Restated and Revised Consolidated Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income	$ 22,027	$ (2,381)	$ (22,841)	$ 222,817
Income from continuing operations	22,027	(2,381)	(22,841)	6,040
Depreciation and amortization	$ 71,782	86,548	214,187	233,651
Deferred income taxes			(25,242)	(43,472)
Accounts receivable, net			22,051	(3,161)
Inventories, net			(31,660)	(58,152)
Accrued expenses and other current liabilities			110,683	34,972
Other non-current liabilities			$ (117,479)	(8,540)
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		5,501		234,992
Income from continuing operations		5,501		18,215
Depreciation and amortization				233,511
Deferred income taxes				(46,740)
Accounts receivable, net				(11,269)
Inventories, net				(58,781)
Accrued expenses and other current liabilities				35,192
Other non-current liabilities				(8,790)
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net income		(7,882)		(12,175)
Income from continuing operations		$ (7,882)		(12,175)
Depreciation and amortization				140
Deferred income taxes				3,268
Accounts receivable, net				8,108
Inventories, net				629
Accrued expenses and other current liabilities				(220)
Other non-current liabilities				$ 250

Merger Agreement - Additional I

Merger Agreement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jan. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Preferred Stock, par value		$ 0.001	$ 0.001
Merger Agreement [Member]
Business Acquisition [Line Items]
Right to receive cash by each common stockholder	$ 56
Termination fee of agreement	$ 177
Merger Agreement [Member] | Series B Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001
Merger Agreement [Member] | Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred Stock, par value	$ 0.001

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Detail) - Health Management Business [Member] $ in Millions	Jan. 09, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary	$ 599.9
Prior Credit Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of senior secured credit facility	$ 575

Discontinued Operations - Summa

Discontinued Operations - Summarized Financial Information Related to Health Management Business (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income from discontinued operations, net of tax	$ 0	$ 0	$ 0	$ 216,777
Health Management Business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue				7,373
Cost of net revenue				(4,413)
Sales and marketing				(996)
General and administrative				(5,001)
Interest expense				(9)
Other income (expense), net				160
Gain on disposal				366,191
Income from discontinued operations before provision for income taxes				363,305
Provision for income taxes				146,528
Income from discontinued operations, net of tax				$ 216,777

Cash and Cash Equivalents - Add

Cash and Cash Equivalents - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016
Cash and Cash Equivalents [Abstract]
Cash investments maturity period	Three months or less

Inventories - Inventories are S

Inventories - Inventories are Stated at Lower of Cost (First In, First Out) or Market (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 123,558	$ 130,171
Work-in-process	72,562	69,178
Finished goods	152,725	147,652
Inventories, net	$ 348,845	$ 347,001

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 10,509	$ 7,317	$ 31,115	$ 19,596
Cost of Net Revenue [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	456	326	1,536	866
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	494	287	1,374	893
Sales and Marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	2,475	1,260	7,035	3,605
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation	$ 7,084	$ 5,444	$ 21,170	$ 14,232

Net Income (Loss) Per Common 56

Net Income (Loss) Per Common Share - Computation of Basic and Diluted Net Income (Loss) Per Common Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator:
Income (loss) from continuing operations	$ 22,027	$ (2,381)	$ (22,841)	$ 6,040
Preferred stock dividends	(5,366)	(5,369)	(15,983)	(15,927)
Income (loss) from continuing operations attributable to common shares	16,661	(7,750)	(38,824)	(9,887)
Less: Net income (loss) attributable to non-controlling interest	207	(61)	453	386
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	16,454	(7,689)	(39,277)	(10,273)
Income from discontinued operations	0	0	0	216,777
Net income (loss) available to common stockholders	$ 16,454	$ (7,689)	$ (39,277)	$ 206,504
Denominator:
Weighted-average common shares outstanding - basic	86,753	85,895	86,708	85,141
Weighted-average common shares outstanding - diluted	87,885	85,895	86,708	85,141
Basic net income (loss) per common share:
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	$ 0.19	$ (0.10)	$ (0.45)	$ (0.13)
Income from discontinued operations	0	0	0	2.56
Basic net income (loss) per common share	0.19	(0.10)	(0.45)	2.43
Diluted net income (loss) per common share:
Income (loss) from continuing operations attributable to Alere Inc. and Subsidiaries	0.19	(0.10)	(0.45)	(0.13)
Income from discontinuing operations	0	0	0	2.56
Diluted net income (loss) per common share	$ 0.19	$ (0.10)	$ (0.45)	$ 2.43

Net Income (Loss) Per Common 57

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	16,123	20,739	18,948	20,743
Options to Purchase Shares of Common Stock and RSUs [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	5,884	7,062	7,016	7,062
Warrants [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	0	0	4
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	3,411	1,693	3,411
Conversion Shares Related to Subordinated Convertible Promissory Notes [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	0	27	0	27
Conversion Shares Related to Series B Convertible Preferred Stock [Member]
Denominator:
Total number of antidilutive potentially issuable shares of common stock excluded from diluted common shares outstanding	10,239	10,239	10,239	10,239

Net Income (Loss) Per Common 58

Net Income (Loss) Per Common Share - Potential Dilutive Securities Not Included in Calculation of Diluted Net Income (Loss) Per Common Share (Parenthetical) (Detail)	Sep. 30, 2016	Sep. 30, 2015
Conversion Shares Related to 3% Convertible Senior Subordinated Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Interest rate of debt instrument	3.00%	3.00%

Stockholders' Equity and Non-59

Stockholders' Equity and Non-controlling Interests - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Class of Stock [Line Items]
Preferred stock dividends	$ 5,366	$ 5,369	$ 15,983	$ 15,927
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock dividends	5,300	5,300	15,900	15,900
Preferred stock dividends accrued	5,300		5,300
Preferred stock dividends cash paid	$ 5,300	$ 5,300	$ 15,900	$ 15,900

Stockholders' Equity and Non-60

Stockholders' Equity and Non-controlling Interests - Summary of Changes in Stockholders' Equity and Non-controlling Interests Comprising Total Equity (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			$ 2,058,429
Issuance of common stock under employee compensation plans			14,110
Surrender of common stock to settle taxes on restricted stock units			(2,137)
Preferred stock dividends			(15,969)
Stock-based compensation expense			31,115
Other adjustments			(30)
Net income	$ 22,027	$ (2,381)	(22,841)	$ 222,817
Total other comprehensive loss	8,948	$ (88,393)	(12,308)	$ (123,765)
Equity, end of period	2,050,369		2,050,369
Total Stockholders' Equity [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			2,054,165
Issuance of common stock under employee compensation plans			14,110
Surrender of common stock to settle taxes on restricted stock units			(2,137)
Preferred stock dividends			(15,969)
Stock-based compensation expense			31,115
Other adjustments			0
Net income			(23,294)
Total other comprehensive loss			(12,308)
Equity, end of period	2,045,682		2,045,682
Non-controlling Interests [Member]
Equity And Noncontrolling Interests [Line Items]
Equity, beginning of period			4,264
Issuance of common stock under employee compensation plans			0
Surrender of common stock to settle taxes on restricted stock units			0
Preferred stock dividends			0
Stock-based compensation expense			0
Other adjustments			(30)
Net income			453
Total other comprehensive loss			0
Equity, end of period	$ 4,687		$ 4,687

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Feb. 11, 2016	Dec. 31, 2015	Jul. 10, 2015
Business Acquisition [Line Items]
Goodwill	$ 2,805,682		$ 2,805,682			$ 2,836,915
EDTS [Member]
Business Acquisition [Line Items]
Preliminary aggregate purchase price					$ 6,500
Total revenue related to acquisition	1,200		3,800
Goodwill	2,100		2,100
US Diagnostics [Member]
Business Acquisition [Line Items]
Preliminary aggregate purchase price							$ 60,100
Total revenue related to acquisition	$ 5,700	$ 5,000	$ 16,800	$ 5,000
Goodwill		$ 29,400		$ 29,400

Business Combinations - Summary

Business Combinations - Summary of Aggregate Purchase Price Allocation (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Current assets	$ 1,371	$ 4,652
Property, plant and equipment	115	182
Goodwill	2,060	29,422
Intangible assets	4,220	27,200
Total assets acquired	7,766	61,456
Current liabilities	368	1,321
Non-current liabilities	928
Total liabilities assumed	1,296	1,321
Net assets acquired	6,470	60,135
Cash paid	$ 6,470	$ 60,135

Business Combinations - Intangi

Business Combinations - Intangible Assets Acquired and their Respective Fair Values and Weighted-Average Useful Lives (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Finite And Infinite Lived Intangible Assets [Line Items]
Total intangible assets	$ 4,220	$ 27,200
Core Technology and Patents [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 540
Weighted-average Useful Life	10 years
Trademarks and Trade Names [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 310
Weighted-average Useful Life	20 years
Customer Relationships [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 2,800	$ 24,900
Weighted-average Useful Life	14 years	13 years
Non-Competition Agreements [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount	$ 570	$ 700
Weighted-average Useful Life	3 years	2 years
Trademarks [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible asset, amount		$ 1,600
Trademarks [Member] | Minimum [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Weighted-average Useful Life		3 years
Trademarks [Member] | Maximum [Member]
Finite And Infinite Lived Intangible Assets [Line Items]
Weighted-average Useful Life		13 years

Restructuring Plans - Aggregate

Restructuring Plans - Aggregate Charges Associated with Restructuring Plans Recorded in Operating Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 11,290	$ 2,264	$ 27,738	$ 11,387
Restructuring charges	11,292	2,270	27,747	11,406
Interest Expense, Including Amortization of Original Issue Discounts and Deferred Financing Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	6	9	19
Cost of Net Revenue [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,531	522	3,901	2,921
Research and Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	587	18	3,541	667
Sales and Marketing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	511	619	1,420	2,572
General and Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8,661	1,105	18,876	5,227
Total Operating Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 11,290	$ 2,264	$ 27,738	$ 11,387

Restructuring Plans - Restructu

Restructuring Plans - Restructuring Activities Related to Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		105 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 11,290	$ 2,264	$ 27,738	$ 11,387
Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,733	1,578	10,830	10,103
Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8,557	686	16,908	1,284
2016 Restructuring Plans [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	11,292	2,270	27,747	11,406	$ 111,758
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,736	1,584	10,840	10,122	79,252
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,765	1,322	8,039	5,385	46,026
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	426	132	1,620	4,139	13,288
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Cash Charges [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,193	1,460	9,668	9,543	60,145
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Fixed Asset and Inventory Impairments [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	545	124	964	579	16,917
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	6	9	19	831
2016 Restructuring Plans [Member] | Professional Diagnostics [Member] | Other Non-Cash Recoveries [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	0	(208)	0	(2,190)
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	8,556	686	16,907	1,284	32,506
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Severance-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	69	686	65	1,297	4,342
2016 Restructuring Plans [Member] | Corporate and Other [Member] | Facility and Transition Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 8,487	$ 0	$ 16,842	$ (13)	$ 28,164

Restructuring Plans - Additiona

Restructuring Plans - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves included in accrued expenses and other current liabilities	$ 9.9
Restructuring reserves included in other long-term liabilities	0.6
2016 Restructuring Plans [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	2.7
2016 Restructuring Plans [Member] | Corporate and Other [Member]
Restructuring Cost and Reserve [Line Items]
Additional costs	6
Restructuring Plans Prior to 2016 [Member] | Professional Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Cash charges remain unpaid	$ 3.1

Restructuring Plans - Cash Acti

Restructuring Plans - Cash Activity for Restructuring Reserves (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Cash charges	$ 11,290	$ 2,264	$ 27,738	$ 11,387
Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			3,779
Cash charges			26,575
Payments			(19,950)
Currency adjustments			52
Restructuring Reserve, Ending Balance	10,456		10,456
Severance-Related Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			1,633
Cash charges			8,104
Payments			(5,821)
Currency adjustments			10
Restructuring Reserve, Ending Balance	3,926		3,926
Facility and Transition Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			1,966
Cash charges			18,462
Payments			(14,018)
Currency adjustments			42
Restructuring Reserve, Ending Balance	6,452		6,452
Other Exit Costs [Member] | Restructuring Reserve [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Beginning Balance			180
Cash charges			9
Payments			(111)
Currency adjustments			0
Restructuring Reserve, Ending Balance	$ 78		$ 78

Long-Term Debt - Long-Term Debt

Long-Term Debt - Long-Term Debt Balances Outstanding (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, Total	$ 2,946,491	$ 3,031,158
Less: Short-term debt and current portion of long-term debt	(41,424)	(199,992)
Long-term debt	2,905,067	2,831,166
Revolver Facility [Member]
Debt Instrument [Line Items]
Long-term debt, Total	125,000	0
A Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	551,266	575,746
B Term Loans [Member]
Debt Instrument [Line Items]
Long-term debt, Total	954,608	965,740
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	441,498	446,320
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	414,391	419,209
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	412,363	418,133
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0	149,839
Other Lines of Credit [Member]
Debt Instrument [Line Items]
Long-term debt, Total	0	136
Other [Member]
Debt Instrument [Line Items]
Long-term debt, Total	$ 47,365	$ 56,035

Long-Term Debt - Long-Term De69

Long-Term Debt - Long-Term Debt Balances Outstanding (Parenthetical) (Detail)	Dec. 31, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt Instrument [Line Items]
Description of default under credit agreement		(i) on March 31, 2016 we were in default under the credit agreement governing our secured credit facility, or the Credit Agreement, and the respective indentures governing our 7.25% senior notes, our 6.5% senior subordinated notes, our 6.375% senior subordinated notes and our 3% convertible senior subordinated notes as a result of our failure to timely furnish to the holders of such debt our annual financial statements for the year ended December 31, 2015 and (ii) we subsequently entered into an amendment to the Credit Agreement and solicited consents from the requisite holders of our senior notes and senior subordinated notes (other than holders of our 3% convertible senior subordinated notes) to waive certain defaults and extend the deadline dates for the filing and delivery, as applicable, of our Annual Report on Form 10-K for the year ended December 31, 2015, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and certain related deliverables in order to avoid events of default under the Credit Agreement and the indentures governing our notes. As discussed more fully below in this Note 12, in August 2016 we entered into a further amendment to the Credit Agreement with respect to our failure to timely file our Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 to extend the deadline date for such filing.
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%
Maturity date	May 31, 2016

Long-Term Debt - Long-Term De70

Long-Term Debt - Long-Term Debt Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 44,130	$ 52,333	$ 128,565	$ 158,258
Secured Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	19,072	18,161	53,949	20,763
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	0	0	49,437
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	9,372	8,524	26,800	25,573
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,618	7,274	22,254	21,741
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	7,242	7,002	21,357	7,544
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	9,273	0	27,820
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	0	1,246	1,847	3,738
Other [Member]
Debt Instrument [Line Items]
Long-term debt issuance cost	$ 826	$ 853	$ 2,358	$ 1,642

Long-Term Debt - Long-Term De71

Long-Term Debt - Long-Term Debt Interest Expense (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 0	$ 3,480
Amortization fee	$ 400		$ 1,100
Prior Credit Facility [Member]
Debt Instrument [Line Items]
Loss on extinguishment of debt		$ 3,500
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	7.25%	7.25%	7.25%	7.25%
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.50%	6.50%	6.50%	6.50%
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	6.375%	6.375%	6.375%	6.375%
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	8.625%	8.625%	8.625%
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Long-term debt, Interest rate	3.00%	3.00%	3.00%	3.00%

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Aug. 18, 2016	Jul. 01, 2016	May 15, 2016	Apr. 22, 2016	Jul. 31, 2016	May 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Debt Instrument [Line Items]
Rate of aggregate consent fee	0.125%			0.25%
Amount of aggregate consent fee	$ 2,200,000			$ 4,500,000
Increase in applicable interest rate margin for all loans outstanding		0.25%
Consent aggregate payments per 1,000 aggregate principal amount					$ 15	$ 15
Aggregate payments to note holders					$ 19,200,000	$ 19,200,000
Repayment of long term debt							$ 187,817,000	$ 2,129,165,000
3% Convertible Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Repayment of long term debt			$ 152,000,000
3% Convertible Senior Subordinated Notes [Member] | Cash [Member]
Debt Instrument [Line Items]
Repayment of long term debt			27,000,000
3% Convertible Senior Subordinated Notes [Member] | Revolver Facility [Member]
Debt Instrument [Line Items]
Repayment of long term debt			$ 125,000,000

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis, Valuation Techniques (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	$ 75	$ 164
Total assets	75	164
Liabilities:
Contingent consideration obligations	40,500	57,744
Total liabilities	40,500	57,744
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	75	164
Total assets	75	164
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	0	0
Total liabilities	0	0
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent consideration obligations	40,500	57,744
Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]
Assets:
Marketable securities	0	0
Total assets	0	0
Liabilities:
Contingent consideration obligations	40,500	57,744
Total liabilities	$ 40,500	$ 57,744

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Contingent Consideration Obligations (Detail) - Unobservable Inputs (Level 3) [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value of contingent consideration obligations, Beginning balance	$ 57,744
Payments	(955)
Fair value adjustments	(16,290)
Foreign currency adjustments	1
Fair value of contingent consideration obligations, Ending balance	$ 40,500

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Billions	Sep. 30, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Estimated fair value of long-term debt	$ 2.9	$ 3
Long-term debt, Total	$ 2.9	$ 3.1

Financial Information by Segm76

Financial Information by Segment - Performance of Our Operating Segments Based on Revenue and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Segment Reporting Information [Line Items]
Net revenue	$ 582,354	$ 603,768	$ 1,771,651	$ 1,840,031
Operating income (loss)	3,432	31,082	54,213	147,116
(Gain) loss on dispositions, net			(3,810)
Impairment and (gain) loss on dispositions, net	0	2,074	(3,810)	42,408
Depreciation and amortization	71,782	86,548	214,187	233,651
Restructuring charge	11,290	2,264	27,738	11,387
Stock-based compensation	10,509	7,317	31,115	19,596
Assets	5,855,674		5,855,674		$ 5,923,121
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	563,007	585,021	1,715,068	1,774,671
Operating income (loss)	84,341	56,520	252,557	299,303
(Gain) loss on dispositions, net			4,967
Impairment and (gain) loss on dispositions, net		1,923		(38,643)
Depreciation and amortization	68,263	83,865	203,488	226,523
Restructuring charge	2,733	1,578	10,830	10,103
Stock-based compensation	0	0	0	0
Assets	5,410,679		5,410,679		5,619,901
Consumer Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	19,347	18,747	56,583	65,360
Operating income (loss)	718	1,038	1,281	4,321
(Gain) loss on dispositions, net			(8,777)
Impairment and (gain) loss on dispositions, net		0		0
Depreciation and amortization	1,263	717	4,138	2,153
Restructuring charge	0	0	0	0
Stock-based compensation	0	0	0	0
Assets	192,885		192,885		172,551
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Operating income (loss)	(81,627)	(26,476)	(199,625)	(156,508)
(Gain) loss on dispositions, net			0
Impairment and (gain) loss on dispositions, net		151		81,051
Depreciation and amortization	2,256	1,966	6,561	4,975
Restructuring charge	8,557	686	16,908	1,284
Stock-based compensation	10,509	$ 7,317	31,115	$ 19,596
Assets	$ 252,110		$ 252,110		$ 130,669

Financial Information by Segm77

Financial Information by Segment - Summary of Company's Net Revenue from Professional Diagnostics Reporting Segments by Groups of Similar Products and Services (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Sales revenue net	$ 579,874	$ 600,469	$ 1,763,909	$ 1,826,340
Total professional diagnostics net product sales and services revenue	123,778	128,341	364,296	378,825
License and royalty revenue	2,480	3,299	7,742	13,691
Net revenue	582,354	603,768	1,771,651	1,840,031
Professional Diagnostics [Member]
Segment Reporting Information [Line Items]
Net revenue	563,007	585,021	1,715,068	1,774,671
Reportable Subsegments [Member]
Segment Reporting Information [Line Items]
Total professional diagnostics net product sales and services revenue	560,527	581,722	1,707,326	1,760,980
License and royalty revenue	2,480	3,299	7,742	13,691
Net revenue	563,007	585,021	1,715,068	1,774,671
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Cardiometabolic [Member]
Segment Reporting Information [Line Items]
Sales revenue net	188,731	208,979	587,289	621,588
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Infectious Disease [Member]
Segment Reporting Information [Line Items]
Sales revenue net	183,375	164,822	556,777	523,059
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Toxicology [Member]
Segment Reporting Information [Line Items]
Sales revenue net	155,871	162,571	460,849	468,822
Reportable Subsegments [Member] | Professional Diagnostics [Member] | Other [Member]
Segment Reporting Information [Line Items]
Sales revenue net	$ 32,550	$ 45,350	$ 102,411	$ 147,511

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ in Thousands	Sep. 16, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2016CNY (¥)	May 31, 2007
Related Party Transaction [Line Items]
Restructuring charges			$ 11,290	$ 2,264	$ 27,738	$ 11,387
SPD [Member]
Related Party Transaction [Line Items]
Equity method investment ownership percentage		50.00%	50.00%		50.00%			50.00%	50.00%
SPD Shanghai [Member]
Related Party Transaction [Line Items]
Restricted cash		$ 3,400	$ 3,400		$ 3,400
SPD Shanghai [Member] | Maximum [Member] | Alere Shanghai [Member]
Related Party Transaction [Line Items]
Loan arrangement from related party		3,400	3,400		3,400			¥ 23,000,000
TechLab [Member]
Related Party Transaction [Line Items]
Net payable to SPD		1,600	1,600		1,600		$ 3,200
Purchases from related party			4,600	4,500	13,700	13,000
Percentage of equity method investments sold	49.00%
Gain (Loss) recorded in equity earnings of unconsolidated entities	$ 18,700	18,700
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Net payable to SPD		7,100	7,100		7,100		1,200
Restructuring charges					1,300		1,500
Long-term receivable cost related to restructuring plan		6,500	6,500		6,500		8,900
Customer receivables associated with revenue earned after SPD was completed have been classified as other receivables		9,300	9,300		9,300		7,800
Trade receivables from SPD		11,800	11,800		11,800		9,900
Trade payable to SPD		$ 40,200	40,200		40,200		$ 24,900
SPD Joint Venture [Member] | Sales Revenue Goods [Member]
Related Party Transaction [Line Items]
Revenue from joint venture			21,500	17,300	61,000	58,500
SPD Joint Venture [Member] | Sales Revenue Services [Member]
Related Party Transaction [Line Items]
Revenue from joint venture			$ 300	$ 200	$ 800	$ 800

Related Party Transactions - Re

Related Party Transactions - Related Party Balances with SPD within Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	$ 427,241	$ 445,833
Prepaid expenses and other current assets	163,833	152,233
Other non-current assets	16,219	18,078
Accounts payable	211,476	195,752
SPD Joint Venture [Member]
Related Party Transaction [Line Items]
Accounts receivable, net of allowances	11,827	9,873
Prepaid expenses and other current assets	9,343	6,602
Other non-current assets	6,504	8,895
Accounts payable	$ 40,152	$ 24,887

Other Arrangements - Additional

Other Arrangements - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2014	Feb. 28, 2013	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
The amount provided for development of diagnostic device by BARDA as defined in the agreement	$ 12,900,000
Net expenditure incurred under the contract			$ 1,400,000	$ 800,000	$ 3,100,000	$ 2,200,000
The amount of cash reimbursement received from BARDA			1,000,000	600,000	2,700,000	1,600,000
Amount of accounts receivables			400,000	600,000	400,000	600,000
Restricted cash			4,999,000		4,999,000		$ 5,694,000
Gates Foundation [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded		$ 21,600,000
Cash received from grant-related funding					19,700,000
Qualified expenditures				300,000		3,900,000
Deferred grant funding			0		0
Restricted cash			0		0
Gates Foundation [Member] | Malaria Program [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue from grant awarded					2,900,000
Qualified expenditures			700,000	$ 200,000	1,000,000	$ 3,900,000
Deferred grant funding			700,000		700,000
Restricted cash			$ 800,000		$ 800,000
Gates Loan Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Aggregate principal amount of subordinated term loan		$ 20,600,000

Commitments and Contingencies -

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]
Estimated Fair Value	$ 40,500,000	$ 57,744,000
Payments Made During 2016	955,000
Loss Contingency Accrual	$ 20,700,000
TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Mar. 11, 2010
Acquisition Date Fair Value	$ 35,600,000
Maximum Remaining Earn-out Potential	102,870,000
Estimated Fair Value	33,100,000	47,800,000
Payments Made During 2016	$ 377,000
Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Feb. 1, 2013
Acquisition Date Fair Value	$ 75,000,000
Maximum Remaining Earn-out Potential	42,825,000
Estimated Fair Value	2,900,000	4,700,000
Payments Made During 2016	$ 0
Other [Member]
Business Acquisition, Contingent Consideration [Line Items]
Acquisition Date	Various
Acquisition Date Fair Value	$ 30,373,000
Maximum Remaining Earn-out Potential	$ 0
Remaining Earn-out Period	2,016
Estimated Fair Value	$ 4,500,000	$ 5,244,000
Payments Made During 2016	$ 578,000
Minimum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016
Minimum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,016
Maximum [Member] | TwistDx, Inc. [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,025
Maximum [Member] | Epocal [Member]
Business Acquisition, Contingent Consideration [Line Items]
Remaining Earn-out Period	2,018

Commitments and Contingencies82

Commitments and Contingencies - Contractual Contingent Purchase Price Consideration Obligations Related to Certain Acquisitions (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Earn-out period	15 years

Commitments and Contingencies83

Commitments and Contingencies - Additional Information (Detail) - Plaintiff	93 Months Ended	102 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Dina Andren [Member]
Loss Contingencies [Line Items]
Number of plaintiffs	7
J.E, J.D., and All Others Similarly Situated [Member]
Loss Contingencies [Line Items]
Number of plaintiffs		2

Recent Accounting Pronounceme84

Recent Accounting Pronouncements - Additional Information (Detail) $ in Millions	Dec. 31, 2015USD ($)
Accounting Standards Update 2015-03 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Debt issuance costs	$ 34.1

Equity Investments - Additional

Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 16, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	May 31, 2007
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax			$ 26,149	$ 5,000	$ 33,305	$ 10,320
Return of capital					3,357	14,297
SPD [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax			$ 6,700	5,300	$ 12,900	9,500
Equity method investment ownership percentage		50.00%	50.00%		50.00%		50.00%
Return of capital						12,100
TechLab [Member]
Schedule of Equity Method Investments [Line Items]
Equity earnings of unconsolidated entities, net of tax			$ 19,500	$ 300	$ 20,500	1,000
Return of capital						$ 2,200
Percentage of equity method investments sold	49.00%
Gain (Loss) on sale of equity method investment	$ 18,700	$ 18,700

Equity Investments - Financial

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Results of Operations (Detail) - TechLab [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Schedule of Equity Method Investments [Line Items]
Net revenue	$ 56,622	$ 56,303	$ 165,133	$ 157,319
Gross profit	44,979	43,538	117,832	111,368
Net income after taxes	$ 14,927	$ 15,735	$ 29,396	$ 26,831

Equity Investments - Financia87

Equity Investments - Financial Information for SPD and TechLab on Combined Condensed Balance Sheet (Detail) - Equity Method Investee [Member] - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Current assets	$ 109,911	$ 71,542
Non-current assets	29,674	30,802
Total assets	139,585	102,344
Current liabilities	52,045	37,609
Non-current liabilities	5,255	5,157
Total liabilities	$ 57,300	$ 42,766

Impairment and (Gain) Loss on D

Impairment and (Gain) Loss on Dispositions, Net - Additional Information (Detail) $ in Thousands, € in Millions, AUD in Millions

1 Months Ended

3 Months Ended

9 Months Ended

Jan. 31, 2016USD ($)

Mar. 31, 2015USD ($)

Mar. 31, 2015EUR (€)

Mar. 31, 2016USD ($)

Sep. 30, 2015USD ($)

Jun. 30, 2015USD ($)

Mar. 31, 2015USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2015USD ($)

Jul. 31, 2015USD ($)

Jul. 31, 2015AUD

May 31, 2015USD ($)

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (loss) from sale of assets

$ 3,810

Alere E-Sante [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Sale of business, cash received

$ 8,100

Sale of business, working capital adjustment

200

Sale of business, contingent consideration

$ 1,500

Gain (Loss) on sale of disposal group

$ 3,800

AdnaGen GmbH [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (loss) from sale of assets

$ (300)

Proceeds from sale of assets

$ 4,600

Gesellschaft Fur Patientenhilfe DGP GmbH [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (Loss) on sale of disposal group

(7,500)

Cash proceeds from sale of business

$ 8,200

€ 7.6

Alere Analytics [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Impairment charges

26,700

Write-off of intangible assets

26,200

Write-off of fixed assets

$ 500

Contribution to working capital

$ 2,700

Gain (loss) from sale of assets

$ 4,700

Alere Analytics [Member] | Cash [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Contribution to working capital

2,400

Alere Analytics [Member] | Escrow [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Contribution to working capital

$ 300

Alere Connect LLC [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Impairment charges

$ 1,100

Inverness Medical Innovations Australia Pty Ltd business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Gain (Loss) on sale of disposal group

$ (1,200)

(1,200)

Cash consideration received at date of disposition

$ 100

AUD 0.2

Additional charges recorded in connection with certain other business closures or divestitures

$ 900

$ 900

Income Taxes - Reconciliation b

Income Taxes - Reconciliation between U.S. Federal Statutory Rate and Effective Tax Rate (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Statutory rate	35.00%	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	5.00%	(4.00%)	5.00%	12.00%
Rate differential on foreign earnings and impact of foreign inclusion	20.00%	(6.00%)	19.00%	21.00%
Change in estimated annual effective tax rate	46.00%	33.00%
Change in valuation allowance	(11.00%)	(22.00%)	(11.00%)	(77.00%)
Stock-based compensation	(4.00%)	5.00%	(3.00%)	22.00%
Uncertain tax positions	(9.00%)	14.00%	(8.00%)	9.00%
Sale of business		2.00%		(102.00%)
Other	6.00%	22.00%	4.00%	46.00%
Contingent consideration	5.00%	(21.00%)	5.00%	69.00%
Effective tax rate	93.00%	58.00%	46.00%	35.00%

Guarantor Financial Informati90

Guarantor Financial Information - Additional Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015
Accounting Standards Update 2015-03 [Member]
Debt Instrument [Line Items]
Debt issuance cost		$ 34.1
7.25% Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	7.25%	7.25%	7.25%
Maturity year of debt instrument	2,018
6.5% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.50%	6.50%	6.50%
Maturity year of debt instrument	2,020
6.375% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	6.375%	6.375%	6.375%
Maturity year of debt instrument	2,023
8.625% Senior Subordinated Notes [Member]
Debt Instrument [Line Items]
Interest rate of debt instrument	8.625%		8.625%
Maturity year of debt instrument	2,018
Maturity date	Oct. 1, 2015

Guarantor Financial Informati91

Guarantor Financial Information - Revised Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 582,354	$ 603,768	$ 1,771,651	$ 1,840,031
Cost of net revenue	316,226	326,802	957,405	980,516
Income (loss) from continuing operations before provision (benefit) for income taxes	(55,010)	(17,593)	(104,125)	(6,656)
Benefit for income taxes	(50,888)	(10,212)	(47,979)	(2,376)
Income (loss) from continuing operations	22,027	(2,381)	(22,841)	6,040
Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	336,679	348,038	1,007,563	1,004,139
Cost of net revenue	203,620	207,056	606,881	593,443
Income (loss) from continuing operations before provision (benefit) for income taxes	42,335	37,423	109,769	93,011
Benefit for income taxes	75,980	(28,646)	69,471	17,065
Income (loss) from continuing operations		66,069		110,076
Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	323,246	327,731	983,525	1,040,643
Cost of net revenue	187,776	187,690	565,625	587,861
Income (loss) from continuing operations before provision (benefit) for income taxes	39,271	26,636	126,148	214,019
Benefit for income taxes	$ 100,395	(59,605)	$ 90,102	26,685
Income (loss) from continuing operations		91,589		250,044
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		602,044		1,839,353
Cost of net revenue		326,995		979,745
Income (loss) from continuing operations before provision (benefit) for income taxes		(18,423)		(2,114)
Benefit for income taxes		18,924		10,009
Income (loss) from continuing operations		5,501		18,215
As Previously Reported [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		347,014		1,006,296
Cost of net revenue		206,803		594,072
Income (loss) from continuing operations before provision (benefit) for income taxes		37,740		97,789
Benefit for income taxes		(33,431)		20,334
Income (loss) from continuing operations		71,171		118,123
As Previously Reported [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		327,031		1,037,808
Cost of net revenue		188,137		586,462
Income (loss) from continuing operations before provision (benefit) for income taxes		25,489		213,783
Benefit for income taxes		(63,534)		31,051
Income (loss) from continuing operations		94,371		254,174
Revision Adjustment [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		1,724		678
Cost of net revenue		(193)		771
Income (loss) from continuing operations before provision (benefit) for income taxes		830		(4,542)
Benefit for income taxes		(8,712)		(7,633)
Income (loss) from continuing operations		(7,882)		(12,175)
Revision Adjustment [Member] | Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		1,024		(2,157)
Cost of net revenue		253		(629)
Income (loss) from continuing operations before provision (benefit) for income taxes		(317)		(4,778)
Benefit for income taxes		4,785		(3,269)
Income (loss) from continuing operations		(5,102)		(8,047)
Revision Adjustment [Member] | Non-Guarantor Subsidiaries [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue		700		2,835
Cost of net revenue		(447)		1,399
Income (loss) from continuing operations before provision (benefit) for income taxes		1,147		236
Benefit for income taxes		3,929		(4,366)
Income (loss) from continuing operations		$ (2,782)		$ (4,130)

Guarantor Financial Informati92

Guarantor Financial Information - Consolidating Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Financial Statements, Captions [Line Items]
Net product sales	$ 456,096	$ 472,128	$ 1,399,613	$ 1,447,515
Services revenue	123,778	128,341	364,296	378,825
Net product sales and services revenue	579,874	600,469	1,763,909	1,826,340
License and royalty revenue	2,480	3,299	7,742	13,691
Net revenue	582,354	603,768	1,771,651	1,840,031
Cost of net product sales	238,946	245,814	726,805	743,808
Cost of services revenue	76,639	79,851	228,033	232,277
Cost of net product sales and services revenue	315,585	325,665	954,838	976,085
Cost of license and royalty revenue	641	1,137	2,567	4,431
Cost of net revenue	316,226	326,802	957,405	980,516
Gross profit (loss)	266,128	276,966	814,246	859,515
Operating expenses:
Research and development	31,430	36,011	86,938	91,225
Sales and marketing	101,979	106,493	304,308	323,596
General and administrative	129,287	101,306	372,597	255,170
Impairment and (gain) loss on dispositions, net	0	2,074	(3,810)	42,408
Operating income (loss)	3,432	31,082	54,213	147,116
Interest expense, including amortization of original issue discounts and deferred financing costs	(44,130)	(52,333)	(128,565)	(158,258)
Other income (expense), net	(14,312)	3,658	(29,773)	4,486
Income (loss) from continuing operations before provision (benefit) for income taxes	(55,010)	(17,593)	(104,125)	(6,656)
Provision (benefit) for income taxes	(50,888)	(10,212)	(47,979)	(2,376)
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(4,122)	(7,381)	(56,146)	(4,280)
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings (losses) of unconsolidated entities, net of tax	26,149	5,000	33,305	10,320
Income (loss) from continuing operations	22,027	(2,381)	(22,841)	6,040
Income (loss) from discontinued operations, net of tax	0	0	0	216,777
Net income (loss)	22,027	(2,381)	(22,841)	222,817
Less: Net income (loss) attributable to non-controlling interests	207	(61)	453	386
Net income (loss) attributable to Alere Inc. and Subsidiaries	21,820	(2,320)	(23,294)	222,431
Preferred stock dividends	(5,366)	(5,369)	(15,983)	(15,927)
Net income (loss) available to common stockholders	16,454	(7,689)	(39,277)	206,504
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	0	0	0	0
Services revenue	0	0	0	0
Net product sales and services revenue	0	0	0	0
License and royalty revenue	0	0	0	0
Net revenue	0	0	0	0
Cost of net product sales	130	2,091	464	2,924
Cost of services revenue	723	74	827	204
Cost of net product sales and services revenue	853	2,165	1,291	3,128
Cost of license and royalty revenue	0	(19)	0	(40)
Cost of net revenue	853	2,146	1,291	3,088
Gross profit (loss)	(853)	(2,146)	(1,291)	(3,088)
Operating expenses:
Research and development	3,228	5,670	10,359	11,213
Sales and marketing	1,867	1,335	4,771	4,165
General and administrative	75,261	22,960	177,616	67,873
Impairment and (gain) loss on dispositions, net		150	0	81,051
Operating income (loss)	(81,209)	(32,261)	(194,037)	(167,390)
Interest expense, including amortization of original issue discounts and deferred financing costs	(43,291)	(51,705)	(126,235)	(156,889)
Other income (expense), net	(11,058)	4,225	(17,214)	11,468
Income (loss) from continuing operations before provision (benefit) for income taxes	(135,558)	(79,741)	(337,486)	(312,811)
Provision (benefit) for income taxes	(227,263)	78,040	(207,552)	41,067
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	91,705	(157,781)	(129,934)	(353,878)
Equity in earnings of subsidiaries, net of tax	(88,559)	155,764	86,943	357,024
Equity earnings (losses) of unconsolidated entities, net of tax	18,881	(364)	20,150	982
Income (loss) from continuing operations				4,128
Income (loss) from discontinued operations, net of tax				218,689
Net income (loss)	22,027	(2,381)	(22,841)	222,817
Less: Net income (loss) attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	22,027	(2,381)	(22,841)	222,817
Preferred stock dividends	(5,366)	(5,369)	(15,983)	(15,927)
Net income (loss) available to common stockholders	16,661	(7,750)	(38,824)	206,890
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	220,694	228,963	668,028	655,594
Services revenue	112,045	115,829	329,227	338,869
Net product sales and services revenue	332,739	344,792	997,255	994,463
License and royalty revenue	3,940	3,246	10,308	9,676
Net revenue	336,679	348,038	1,007,563	1,004,139
Cost of net product sales	125,740	125,106	377,293	358,354
Cost of services revenue	77,875	81,549	229,573	233,470
Cost of net product sales and services revenue	203,615	206,655	606,866	591,824
Cost of license and royalty revenue	5	401	15	1,619
Cost of net revenue	203,620	207,056	606,881	593,443
Gross profit (loss)	133,059	140,982	400,682	410,696
Operating expenses:
Research and development	20,338	15,015	50,991	43,927
Sales and marketing	52,928	53,862	160,548	159,190
General and administrative	18,319	34,817	81,965	123,875
Impairment and (gain) loss on dispositions, net		85	0	(8,719)
Operating income (loss)	41,474	37,203	107,178	92,423
Interest expense, including amortization of original issue discounts and deferred financing costs	(713)	(2,613)	(5,588)	(8,958)
Other income (expense), net	1,574	2,833	8,179	9,546
Income (loss) from continuing operations before provision (benefit) for income taxes	42,335	37,423	109,769	93,011
Provision (benefit) for income taxes	75,980	(28,646)	69,471	17,065
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(33,645)	66,069	40,298	110,076
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings (losses) of unconsolidated entities, net of tax	0	0	0	0
Income (loss) from continuing operations		66,069		110,076
Income (loss) from discontinued operations, net of tax				(1,912)
Net income (loss)	(33,645)	66,069	40,298	108,164
Less: Net income (loss) attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	(33,645)	66,069	40,298	108,164
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	(33,645)	66,069	40,298	108,164
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	309,896	310,571	942,273	985,966
Services revenue	11,733	12,512	35,069	39,956
Net product sales and services revenue	321,629	323,083	977,342	1,025,922
License and royalty revenue	1,617	4,648	6,183	14,721
Net revenue	323,246	327,731	983,525	1,040,643
Cost of net product sales	176,740	175,341	531,200	551,340
Cost of services revenue	7,325	6,999	23,125	22,963
Cost of net product sales and services revenue	184,065	182,340	554,325	574,303
Cost of license and royalty revenue	3,711	5,350	11,300	13,558
Cost of net revenue	187,776	187,690	565,625	587,861
Gross profit (loss)	135,470	140,041	417,900	452,782
Operating expenses:
Research and development	7,864	15,326	25,588	36,085
Sales and marketing	47,184	51,296	138,989	160,241
General and administrative	36,196	43,529	113,505	63,422
Impairment and (gain) loss on dispositions, net		1,839	(3,810)	(29,924)
Operating income (loss)	44,226	28,051	143,628	222,958
Interest expense, including amortization of original issue discounts and deferred financing costs	(2,831)	(4,999)	(8,673)	(13,744)
Other income (expense), net	(2,124)	3,584	(8,807)	4,805
Income (loss) from continuing operations before provision (benefit) for income taxes	39,271	26,636	126,148	214,019
Provision (benefit) for income taxes	100,395	(59,605)	90,102	26,685
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(61,124)	86,241	36,046	240,704
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Equity earnings (losses) of unconsolidated entities, net of tax	6,677	5,348	12,815	9,340
Income (loss) from continuing operations		91,589		250,044
Income (loss) from discontinued operations, net of tax				0
Net income (loss)	(54,447)	91,589	48,861	250,044
Less: Net income (loss) attributable to non-controlling interests	207	(61)	453	386
Net income (loss) attributable to Alere Inc. and Subsidiaries	(54,654)	91,650	48,408	249,658
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	(54,654)	91,650	48,408	249,658
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net product sales	(74,494)	(67,406)	(210,688)	(194,045)
Services revenue	0	0	0	0
Net product sales and services revenue	(74,494)	(67,406)	(210,688)	(194,045)
License and royalty revenue	(3,077)	(4,595)	(8,749)	(10,706)
Net revenue	(77,571)	(72,001)	(219,437)	(204,751)
Cost of net product sales	(63,664)	(56,724)	(182,152)	(168,810)
Cost of services revenue	(9,284)	(8,771)	(25,492)	(24,360)
Cost of net product sales and services revenue	(72,948)	(65,495)	(207,644)	(193,170)
Cost of license and royalty revenue	(3,075)	(4,595)	(8,748)	(10,706)
Cost of net revenue	(76,023)	(70,090)	(216,392)	(203,876)
Gross profit (loss)	(1,548)	(1,911)	(3,045)	(875)
Operating expenses:
Research and development	0	0	0	0
Sales and marketing	0	0	0	0
General and administrative	(489)	0	(489)	0
Impairment and (gain) loss on dispositions, net		0	0	0
Operating income (loss)	(1,059)	(1,911)	(2,556)	(875)
Interest expense, including amortization of original issue discounts and deferred financing costs	2,705	6,984	11,931	21,333
Other income (expense), net	(2,704)	(6,984)	(11,931)	(21,333)
Income (loss) from continuing operations before provision (benefit) for income taxes	(1,058)	(1,911)	(2,556)	(875)
Provision (benefit) for income taxes	0	(1)	0	307
Income (loss) before equity in earnings of subsidiaries and unconsolidated entities, net of tax	(1,058)	(1,910)	(2,556)	(1,182)
Equity in earnings of subsidiaries, net of tax	88,559	(155,764)	(86,943)	(357,024)
Equity earnings (losses) of unconsolidated entities, net of tax	591	16	340	(2)
Income (loss) from continuing operations				(358,208)
Income (loss) from discontinued operations, net of tax				0
Net income (loss)	88,092	(157,658)	(89,159)	(358,208)
Less: Net income (loss) attributable to non-controlling interests	0	0	0	0
Net income (loss) attributable to Alere Inc. and Subsidiaries	88,092	(157,658)	(89,159)	(358,208)
Preferred stock dividends	0	0	0	0
Net income (loss) available to common stockholders	$ 88,092	$ (157,658)	$ (89,159)	$ (358,208)

Guarantor Financial Informati93

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	$ 22,027	$ (2,381)	$ (22,841)	$ 222,817
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	8,727	(88,812)	(13,215)	(122,428)
Minimum pension liability adjustment	221	419	907	(1,337)
Other comprehensive income (loss), before tax	8,948	(88,393)	(12,308)	(123,765)
Other comprehensive income (loss)	8,948	(88,393)	(12,308)	(123,765)
Comprehensive income (loss)	30,975	(90,774)	(35,149)	99,052
Less: Comprehensive income (loss) attributable to non-controlling interests	207	(61)	453	386
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	30,768	(90,713)	(35,602)	98,666
Issuer [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	22,027	(2,381)	(22,841)	222,817
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	2,433	(748)	2,824	(1,208)
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	2,433	(748)	2,824	(1,208)
Other comprehensive income (loss)	2,433	(748)	2,824	(1,208)
Comprehensive income (loss)	24,460	(3,129)	(20,017)	221,609
Less: Comprehensive income (loss) attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	24,460	(3,129)	(20,017)	221,609
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(33,645)	66,069	40,298	108,164
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(272)	(570)	(1,100)	(453)
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	(272)	(570)	(1,100)	(453)
Other comprehensive income (loss)	(272)	(570)	(1,100)	(453)
Comprehensive income (loss)	(33,917)	65,499	39,198	107,711
Less: Comprehensive income (loss) attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(33,917)	65,499	39,198	107,711
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	(54,447)	91,589	48,861	250,044
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	6,577	(87,314)	(14,936)	(120,587)
Minimum pension liability adjustment	221	419	907	(1,337)
Other comprehensive income (loss), before tax	6,798	(86,895)	(14,029)	(121,924)
Other comprehensive income (loss)	6,798	(86,895)	(14,029)	(121,924)
Comprehensive income (loss)	(47,649)	4,694	34,832	128,120
Less: Comprehensive income (loss) attributable to non-controlling interests	207	(61)	453	386
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	(47,856)	4,755	34,379	127,734
Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Net income (loss)	88,092	(157,658)	(89,159)	(358,208)
Other comprehensive income (loss), before tax:
Changes in cumulative translation adjustment	(11)	(180)	(3)	(180)
Minimum pension liability adjustment	0	0	0	0
Other comprehensive income (loss), before tax	(11)	(180)	(3)	(180)
Other comprehensive income (loss)	(11)	(180)	(3)	(180)
Comprehensive income (loss)	88,081	(157,838)	(89,162)	(358,388)
Less: Comprehensive income (loss) attributable to non-controlling interests	0	0	0	0
Comprehensive income (loss) attributable to Alere Inc. and Subsidiaries	$ 88,081	$ (157,838)	$ (89,162)	$ (358,388)

Guarantor Financial Informati94

Guarantor Financial Information - Consolidating Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Jan. 09, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 566,213	$ 502,200	$ 479,381	$ 378,461
Restricted cash	4,999	5,694
Marketable securities	75	164
Accounts receivable, net of allowances	427,241	445,833
Inventories, net	348,845	347,001
Prepaid expenses and other current assets	163,833	152,233
Assets held for sale - current	0	4,165
Intercompany receivables	0	0
Total current assets	1,511,206	1,457,290
Property, plant and equipment, net	446,313	446,039
Goodwill	2,805,682	2,836,915
Other intangible assets with indefinite lives	27,991	28,110
Finite-lived intangible assets, net	864,785	997,281
Restricted cash	42,438	43,228
Other non-current assets	16,219	18,078
Investments in subsidiaries	0	0
Investments in unconsolidated entities	80,885	65,333
Deferred tax assets	56,638	13,993
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current	0	13,337
Intercompany notes receivables	0	0
Total assets	5,855,674	5,923,121
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	41,424	199,992
Current portion of capital lease obligations	3,713	3,962
Accounts payable	211,476	195,752
Accrued expenses and other current liabilities	449,897	324,465
Liabilities related to assets held for sale - current	0	363
Intercompany payables	0	0
Total current liabilities	706,510	724,534
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	2,905,067	2,831,166
Capital lease obligations, net of current portion	8,033	7,181
Deferred tax liabilities	52,513	147,618
Other long-term liabilities	133,182	154,193
Intercompany notes payables	0	0
Total long-term liabilities	3,098,795	3,140,158
Total stockholders' equity	2,045,682	2,054,165
Non-controlling interests	4,687	4,264
Total equity	2,050,369	2,058,429
Total liabilities and equity	5,855,674	5,923,121
Issuer [Member]
CURRENT ASSETS:
Cash and cash equivalents	201,982	139,153	142,996	2,149
Restricted cash	757	1,250
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	0	0
Prepaid expenses and other current assets	10,499	7,576
Assets held for sale - current		0
Intercompany receivables	1,052,091	1,237,474
Total current assets	1,265,329	1,385,453
Property, plant and equipment, net	27,797	31,384
Goodwill	0	0
Other intangible assets with indefinite lives	0	0
Finite-lived intangible assets, net	2,618	2,951
Restricted cash	0	0
Other non-current assets	559	804
Investments in subsidiaries	3,378,517	3,294,857
Investments in unconsolidated entities	684	502
Deferred tax assets	212,822	91,220
Non-current income tax receivable	3,517	3,517
Assets held for sale - non-current		13,337
Intercompany notes receivables	1,765,528	1,905,188
Total assets	6,657,371	6,729,213
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	40,073	197,084
Current portion of capital lease obligations	0	0
Accounts payable	41,465	15,981
Accrued expenses and other current liabilities	115,152	62,287
Liabilities related to assets held for sale - current		0
Intercompany payables	1,052,028	1,122,042
Total current liabilities	1,248,718	1,397,394
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	2,859,054	2,784,913
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	0	0
Other long-term liabilities	16,821	14,962
Intercompany notes payables	487,096	477,779
Total long-term liabilities	3,362,971	3,277,654
Total stockholders' equity	2,045,682	2,054,165
Non-controlling interests	0	0
Total equity	2,045,682	2,054,165
Total liabilities and equity	6,657,371	6,729,213
Guarantor Subsidiaries [Member]
CURRENT ASSETS:
Cash and cash equivalents	545	21,150	7,649	69,154
Restricted cash	0	0
Marketable securities	75	164
Accounts receivable, net of allowances	190,077	192,591
Inventories, net	178,382	173,383
Prepaid expenses and other current assets	35,605	27,095
Assets held for sale - current		0
Intercompany receivables	904,512	812,957
Total current assets	1,309,196	1,227,340
Property, plant and equipment, net	231,197	228,065
Goodwill	1,822,771	1,823,919
Other intangible assets with indefinite lives	7,511	7,638
Finite-lived intangible assets, net	537,041	627,269
Restricted cash	0	0
Other non-current assets	2,058	2,340
Investments in subsidiaries	158,194	158,195
Investments in unconsolidated entities	14,765	14,764
Deferred tax assets	0	0
Non-current income tax receivable	0	0
Assets held for sale - non-current		0
Intercompany notes receivables	710,007	672,032
Total assets	4,792,740	4,761,562
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	1,764	2,018
Accounts payable	77,717	76,890
Accrued expenses and other current liabilities	139,909	126,346
Liabilities related to assets held for sale - current		0
Intercompany payables	777,234	773,839
Total current liabilities	996,624	979,093
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	2,322	840
Deferred tax liabilities	218,898	219,224
Other long-term liabilities	42,279	59,309
Intercompany notes payables	1,163,898	1,181,168
Total long-term liabilities	1,427,397	1,460,541
Total stockholders' equity	2,368,719	2,321,928
Non-controlling interests	0	0
Total equity	2,368,719	2,321,928
Total liabilities and equity	4,792,740	4,761,562
Non-Guarantor Subsidiaries [Member]
CURRENT ASSETS:
Cash and cash equivalents	363,686	341,897	328,736	307,158
Restricted cash	4,242	4,444
Marketable securities	0	0
Accounts receivable, net of allowances	237,164	253,242
Inventories, net	194,560	194,192
Prepaid expenses and other current assets	111,243	110,961
Assets held for sale - current		4,165
Intercompany receivables	213,963	50,691
Total current assets	1,124,858	959,592
Property, plant and equipment, net	190,075	188,084
Goodwill	982,911	1,012,996
Other intangible assets with indefinite lives	20,539	20,531
Finite-lived intangible assets, net	328,326	370,261
Restricted cash	42,438	43,228
Other non-current assets	14,335	15,380
Investments in subsidiaries	57,650	57,650
Investments in unconsolidated entities	50,747	37,947
Deferred tax assets	58,758	51,329
Non-current income tax receivable	0	0
Assets held for sale - non-current		0
Intercompany notes receivables	602	6,900
Total assets	2,871,239	2,763,898
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	1,351	2,908
Current portion of capital lease obligations	1,949	1,944
Accounts payable	92,294	102,881
Accrued expenses and other current liabilities	192,714	133,594
Liabilities related to assets held for sale - current		363
Intercompany payables	341,304	205,241
Total current liabilities	629,612	446,931
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	46,013	46,253
Capital lease obligations, net of current portion	5,711	6,341
Deferred tax liabilities	46,355	54,749
Other long-term liabilities	74,815	80,369
Intercompany notes payables	825,143	925,173
Total long-term liabilities	998,037	1,112,885
Total stockholders' equity	1,238,903	1,199,818
Non-controlling interests	4,687	4,264
Total equity	1,243,590	1,204,082
Total liabilities and equity	2,871,239	2,763,898
Eliminations [Member]
CURRENT ASSETS:
Cash and cash equivalents	0	0	$ 0	$ 0
Restricted cash	0	0
Marketable securities	0	0
Accounts receivable, net of allowances	0	0
Inventories, net	(24,097)	(20,574)
Prepaid expenses and other current assets	6,486	6,601
Assets held for sale - current		0
Intercompany receivables	(2,170,566)	(2,101,122)
Total current assets	(2,188,177)	(2,115,095)
Property, plant and equipment, net	(2,756)	(1,494)
Goodwill	0	0
Other intangible assets with indefinite lives	(59)	(59)
Finite-lived intangible assets, net	(3,200)	(3,200)
Restricted cash	0	0
Other non-current assets	(733)	(446)
Investments in subsidiaries	(3,594,361)	(3,510,702)
Investments in unconsolidated entities	14,689	12,120
Deferred tax assets	(214,942)	(128,556)
Non-current income tax receivable	0	0
Assets held for sale - non-current		0
Intercompany notes receivables	(2,476,137)	(2,584,120)
Total assets	(8,465,676)	(8,331,552)
CURRENT LIABILITIES:
Short-term debt and current portion of long-term debt	0	0
Current portion of capital lease obligations	0	0
Accounts payable	0	0
Accrued expenses and other current liabilities	(2,122)	(2,238)
Liabilities related to assets held for sale - current		0
Intercompany payables	(2,170,566)	(2,101,122)
Total current liabilities	(2,168,444)	(2,098,884)
LONG-TERM LIABILITIES:
Long-term debt, net of current portion	0	0
Capital lease obligations, net of current portion	0	0
Deferred tax liabilities	(212,740)	(126,355)
Other long-term liabilities	(733)	(447)
Intercompany notes payables	(2,476,137)	(2,584,120)
Total long-term liabilities	(2,689,610)	(2,710,922)
Total stockholders' equity	(3,607,622)	(3,521,746)
Non-controlling interests	0	0
Total equity	(3,607,622)	(3,521,746)
Total liabilities and equity	$ (8,465,676)	$ (8,331,552)

Guarantor Financial Informati95

Guarantor Financial Information - Consolidating Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Cash Flows from Operating Activities:
Net income	$ 22,027	$ (2,381)	$ (22,841)	$ 222,817
Income (loss) from discontinued operations, net of tax	0	0	0	216,777
Income (loss) from continuing operations	22,027	(2,381)	(22,841)	6,040
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			9,305	10,627
Depreciation and amortization	71,782	86,548	214,187	233,651
Non-cash stock-based compensation expense	10,509	7,317	31,115	19,596
Impairment of inventory			915	201
Impairment of long-lived assets			634	378
Loss on disposition of fixed assets			5,492	3,273
Equity earnings of unconsolidated entities, net of tax	(26,149)	(5,000)	(33,305)	(10,320)
Deferred income taxes			(25,242)	(43,472)
(Gain) loss related to impairment and net loss on dispositions			(3,810)	42,323
Loss on extinguishment of debt			0	3,480
Other non-cash items			7,668	(4,785)
Non-cash change in fair value of contingent purchase price consideration			(16,290)	(51,911)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			22,051	(3,161)
Inventories, net			(31,660)	(58,152)
Prepaid expenses and other current assets			(22,630)	(14,953)
Accounts payable			18,493	(16,000)
Accrued expenses and other current liabilities			110,683	34,972
Other non-current liabilities			(117,479)	(8,540)
Cash paid for contingent consideration			(324)	(6,315)
Intercompany payable (receivable)			0	0
Net cash provided by (used in) continuing operations			146,962	136,932
Net cash provided by discontinued operations			0	318
Net cash provided by operating activities			146,962	137,250
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			199	(438,765)
Purchases of property, plant and equipment			(49,995)	(67,947)
Proceeds from sale of property, plant and equipment			1,150	1,486
Cash received from (used in) disposition, net of cash divested			21,470	586,625
Cash paid for business acquisitions, net of cash acquired			(5,958)	(60,135)
Cash received from (paid for) sales of marketable securities			88	99
Cash received from equity method investments			3,357	14,297
Cash paid for investments			(184)	0
Proceeds from sale of equity investments			40,751	0
(Increase) decrease in other assets			460	881
Net cash provided by continuing operations			11,338	36,541
Net cash used in discontinued operations			0	(209)
Net cash provided by investing activities			11,338	36,332
Cash Flows from Financing Activities:
Cash paid for financing costs			(29,186)	(16,053)
Cash paid for contingent purchase price consideration			(575)	(14,079)
Cash paid for dividends			(15,969)	(15,970)
Proceeds from issuance of common stock, net of issuance costs			13,923	76,457
Proceeds from issuance of long-term debt			462	2,162,022
Payments on short-term debt			(1,722)	(25,584)
Payments on long-term debt			(187,817)	(2,129,165)
Net proceeds (payments) under revolving credit facilities			124,876	(126,603)
Excess tax benefits on exercised stock options			0	6,102
Principal payments on capital lease obligations			(3,103)	(4,339)
Net cash used in continuing operations			(99,111)	(87,212)
Net cash used in discontinued operations			0	(76)
Net cash used in financing activities			(99,111)	(87,288)
Foreign exchange effect on cash and cash equivalents			4,824	(8,674)
Net increase (decrease) in cash and cash equivalents			64,013	77,620
Cash and cash equivalents, beginning of period - continuing operations			502,200	378,461
Cash and cash equivalents, beginning of period - discontinued operations			0	23,300
Cash and cash equivalents of continuing operations, end of period	566,213	479,381	566,213	479,381
Issuer [Member]
Cash Flows from Operating Activities:
Net income	22,027	(2,381)	(22,841)	222,817
Income (loss) from discontinued operations, net of tax				218,689
Income (loss) from continuing operations				4,128
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	88,559	(155,764)	(86,943)	(357,024)
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			9,186	10,542
Depreciation and amortization			6,829	7,891
Non-cash stock-based compensation expense			16,347	10,600
Impairment of inventory			0	0
Impairment of long-lived assets			0	0
Loss on disposition of fixed assets			75	0
Equity earnings of unconsolidated entities, net of tax	(18,881)	364	(20,150)	(982)
Deferred income taxes			(6,392)	(8,687)
(Gain) loss related to impairment and net loss on dispositions			0	81,051
Loss on extinguishment of debt				3,480
Other non-cash items			815	(376)
Non-cash change in fair value of contingent purchase price consideration			(1,800)	(33,667)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			0	0
Inventories, net			0	0
Prepaid expenses and other current assets			547	3,098
Accounts payable			25,483	(7,435)
Accrued expenses and other current liabilities			41,025	(1,455)
Other non-current liabilities			(112,172)	(16,114)
Cash paid for contingent consideration			(321)	(6,302)
Intercompany payable (receivable)			269,507	447,475
Net cash provided by (used in) continuing operations				136,223
Net cash provided by discontinued operations				0
Net cash provided by operating activities			119,195	136,223
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			493	(421,157)
Purchases of property, plant and equipment			(3,783)	(7,514)
Proceeds from sale of property, plant and equipment			92	0
Cash received from (used in) disposition, net of cash divested			(1,337)	593,066
Cash paid for business acquisitions, net of cash acquired			0	(60,135)
Cash received from (paid for) sales of marketable securities			0	0
Cash received from equity method investments			3,357	2,205
Cash paid for investments			(184)
Proceeds from sale of equity investments			38,157
(Increase) decrease in other assets			(50)	368
Net cash provided by continuing operations				106,833
Net cash used in discontinued operations				0
Net cash provided by investing activities			36,745	106,833
Cash Flows from Financing Activities:
Cash paid for financing costs			(29,186)	(15,836)
Cash paid for contingent purchase price consideration			0	(13,640)
Cash paid for dividends			(15,969)	(15,970)
Proceeds from issuance of common stock, net of issuance costs			13,923	76,457
Proceeds from issuance of long-term debt			0	2,119,125
Payments on short-term debt			0	0
Payments on long-term debt			(186,879)	(2,128,625)
Net proceeds (payments) under revolving credit facilities			125,000	(127,000)
Excess tax benefits on exercised stock options				3,264
Principal payments on capital lease obligations			0	0
Net cash used in continuing operations				(102,225)
Net cash used in discontinued operations				0
Net cash used in financing activities			(93,111)	(102,225)
Foreign exchange effect on cash and cash equivalents			0	16
Net increase (decrease) in cash and cash equivalents			62,829	140,847
Cash and cash equivalents, beginning of period - continuing operations			139,153	2,149
Cash and cash equivalents, beginning of period - discontinued operations				0
Cash and cash equivalents of continuing operations, end of period	201,982	142,996	201,982	142,996
Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income	(33,645)	66,069	40,298	108,164
Income (loss) from discontinued operations, net of tax				(1,912)
Income (loss) from continuing operations		66,069		110,076
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			9	19
Depreciation and amortization			133,532	128,363
Non-cash stock-based compensation expense			7,595	4,251
Impairment of inventory			0	133
Impairment of long-lived assets			548	64
Loss on disposition of fixed assets			4,530	2,768
Equity earnings of unconsolidated entities, net of tax	0	0	0	0
Deferred income taxes			(300)	(27,430)
(Gain) loss related to impairment and net loss on dispositions			0	(8,804)
Loss on extinguishment of debt				0
Other non-cash items			(1,824)	(1,054)
Non-cash change in fair value of contingent purchase price consideration			(14,323)	16,616
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			2,502	(9,213)
Inventories, net			(34,902)	(31,708)
Prepaid expenses and other current assets			(8,417)	(28,016)
Accounts payable			2,517	777
Accrued expenses and other current liabilities			15,149	72,936
Other non-current liabilities			(2,170)	740
Cash paid for contingent consideration			0	0
Intercompany payable (receivable)			(143,767)	(282,519)
Net cash provided by (used in) continuing operations				(52,001)
Net cash provided by discontinued operations				318
Net cash provided by operating activities			977	(51,683)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			0	0
Purchases of property, plant and equipment			(20,325)	(25,915)
Proceeds from sale of property, plant and equipment			367	846
Cash received from (used in) disposition, net of cash divested			0	(8,722)
Cash paid for business acquisitions, net of cash acquired			0	0
Cash received from (paid for) sales of marketable securities			88	103
Cash received from equity method investments			0	0
Cash paid for investments			0
Proceeds from sale of equity investments			0
(Increase) decrease in other assets			(104)	497
Net cash provided by continuing operations				(33,191)
Net cash used in discontinued operations				(209)
Net cash provided by investing activities			(19,974)	(33,400)
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			0	0
Cash paid for dividends				0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of long-term debt			0	0
Payments on short-term debt			0	0
Payments on long-term debt			0	0
Net proceeds (payments) under revolving credit facilities			0	0
Excess tax benefits on exercised stock options				2,531
Principal payments on capital lease obligations			(1,782)	(1,876)
Net cash used in continuing operations				655
Net cash used in discontinued operations				(76)
Net cash used in financing activities			(1,782)	579
Foreign exchange effect on cash and cash equivalents			174	(301)
Net increase (decrease) in cash and cash equivalents			(20,605)	(84,805)
Cash and cash equivalents, beginning of period - continuing operations			21,150	69,154
Cash and cash equivalents, beginning of period - discontinued operations				23,300
Cash and cash equivalents of continuing operations, end of period	545	7,649	545	7,649
Non-Guarantor Subsidiaries [Member]
Cash Flows from Operating Activities:
Net income	(54,447)	91,589	48,861	250,044
Income (loss) from discontinued operations, net of tax				0
Income (loss) from continuing operations		91,589		250,044
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	0	0	0	0
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			110	66
Depreciation and amortization			72,848	97,390
Non-cash stock-based compensation expense			7,173	4,745
Impairment of inventory			915	68
Impairment of long-lived assets			86	314
Loss on disposition of fixed assets			887	505
Equity earnings of unconsolidated entities, net of tax	(6,677)	(5,348)	(12,815)	(9,340)
Deferred income taxes			(18,550)	(7,794)
(Gain) loss related to impairment and net loss on dispositions			(3,810)	(29,924)
Loss on extinguishment of debt				0
Other non-cash items			8,684	(3,358)
Non-cash change in fair value of contingent purchase price consideration			(167)	(34,860)
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			19,549	6,052
Inventories, net			1,666	(26,651)
Prepaid expenses and other current assets			(14,876)	4,917
Accounts payable			(9,507)	(9,342)
Accrued expenses and other current liabilities			60,896	(27,203)
Other non-current liabilities			(3,137)	5,389
Cash paid for contingent consideration			(3)	(13)
Intercompany payable (receivable)			(132,020)	(167,580)
Net cash provided by (used in) continuing operations				53,425
Net cash provided by discontinued operations				0
Net cash provided by operating activities			26,790	53,425
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			(294)	(17,608)
Purchases of property, plant and equipment			(27,529)	(36,093)
Proceeds from sale of property, plant and equipment			2,333	1,554
Cash received from (used in) disposition, net of cash divested			22,807	2,281
Cash paid for business acquisitions, net of cash acquired			(5,958)	0
Cash received from (paid for) sales of marketable securities			0	(4)
Cash received from equity method investments			0	12,092
Cash paid for investments			0
Proceeds from sale of equity investments			2,594
(Increase) decrease in other assets			614	(219)
Net cash provided by continuing operations				(37,997)
Net cash used in discontinued operations				0
Net cash provided by investing activities			(5,433)	(37,997)
Cash Flows from Financing Activities:
Cash paid for financing costs			0	(217)
Cash paid for contingent purchase price consideration			(575)	(439)
Cash paid for dividends				0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of long-term debt			462	42,897
Payments on short-term debt			(1,722)	(25,584)
Payments on long-term debt			(938)	(540)
Net proceeds (payments) under revolving credit facilities			(124)	397
Excess tax benefits on exercised stock options				307
Principal payments on capital lease obligations			(1,321)	(2,463)
Net cash used in continuing operations				14,358
Net cash used in discontinued operations				0
Net cash used in financing activities			(4,218)	14,358
Foreign exchange effect on cash and cash equivalents			4,650	(8,208)
Net increase (decrease) in cash and cash equivalents			21,789	21,578
Cash and cash equivalents, beginning of period - continuing operations			341,897	307,158
Cash and cash equivalents, beginning of period - discontinued operations				0
Cash and cash equivalents of continuing operations, end of period	363,686	328,736	363,686	328,736
Eliminations [Member]
Cash Flows from Operating Activities:
Net income	88,092	(157,658)	(89,159)	(358,208)
Income (loss) from discontinued operations, net of tax				0
Income (loss) from continuing operations				(358,208)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Equity in earnings of subsidiaries, net of tax	(88,559)	155,764	86,943	357,024
Non-cash interest expense, including amortization of original issue discounts and deferred financing costs			0	0
Depreciation and amortization			978	7
Non-cash stock-based compensation expense			0	0
Impairment of inventory			0	0
Impairment of long-lived assets			0	0
Loss on disposition of fixed assets			0	0
Equity earnings of unconsolidated entities, net of tax	(591)	(16)	(340)	2
Deferred income taxes			0	439
(Gain) loss related to impairment and net loss on dispositions			0	0
Loss on extinguishment of debt				0
Other non-cash items			(7)	3
Non-cash change in fair value of contingent purchase price consideration			0	0
Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net			0	0
Inventories, net			1,576	207
Prepaid expenses and other current assets			116	5,048
Accounts payable			0	0
Accrued expenses and other current liabilities			(6,387)	(9,306)
Other non-current liabilities			0	1,445
Cash paid for contingent consideration			0	0
Intercompany payable (receivable)			6,280	2,624
Net cash provided by (used in) continuing operations				(715)
Net cash provided by discontinued operations				0
Net cash provided by operating activities			0	(715)
Cash Flows from Investing Activities:
(Increase) decrease in restricted cash			0	0
Purchases of property, plant and equipment			1,642	1,575
Proceeds from sale of property, plant and equipment			(1,642)	(914)
Cash received from (used in) disposition, net of cash divested			0	0
Cash paid for business acquisitions, net of cash acquired			0	0
Cash received from (paid for) sales of marketable securities			0	0
Cash received from equity method investments			0	0
Cash paid for investments			0
Proceeds from sale of equity investments			0
(Increase) decrease in other assets			0	235
Net cash provided by continuing operations				896
Net cash used in discontinued operations				0
Net cash provided by investing activities			0	896
Cash Flows from Financing Activities:
Cash paid for financing costs			0	0
Cash paid for contingent purchase price consideration			0	0
Cash paid for dividends				0
Proceeds from issuance of common stock, net of issuance costs			0	0
Proceeds from issuance of long-term debt			0	0
Payments on short-term debt			0	0
Payments on long-term debt			0	0
Net proceeds (payments) under revolving credit facilities			0	0
Principal payments on capital lease obligations			0	0
Net cash used in discontinued operations				0
Net cash used in financing activities			0
Foreign exchange effect on cash and cash equivalents			0	(181)
Net increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents, beginning of period - continuing operations			0	0
Cash and cash equivalents, beginning of period - discontinued operations				0
Cash and cash equivalents of continuing operations, end of period	$ 0	$ 0	$ 0	$ 0

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Thousands	Oct. 12, 2016Patient	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)
Subsequent Event [Line Items]
Aggregate revenue | $		$ 579,874	$ 600,469	$ 1,763,909	$ 1,826,340
Arriva Medical LLC [Member]
Subsequent Event [Line Items]
Aggregate revenue | $				$ 88,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of reimbursement claims allegedly submitted | Patient	211
Number of allegedly submitted reimbursement claims the CMS letter identifies | Patient	47